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Abstract 
 
Background: South African guidelines recommend that HIV-positive pregnant women immediately 
initiate antiretroviral therapy (efavirenz, emtricitabine, and tenofovir), regardless of trimester. Efavirenz 
causes central nervous system neuropathy and has been linked to birth defects such as encephalocoele. 
Cohort studies of HIV-uninfected children exposed to antiretroviral treatment in utero report minor 
learning delays but are inconclusive. 
Non-transformed human derived neuroepithelial stem (NES) represent a unique pre-clinical model in 
which to investigate the effects of efavirenz on the developing neural system. Efavirenz-induced global 
cellular molecular changes may be characterised using mass spectrometry (MS). 
Aims: To optimise an MS-based efavirenz extraction and detection assay, and to investigate efavirenz- 
induced NES proteomic responses. 
Methods: A TSQ Vantage triple quadrupole mass spectrometer was employed to optimise targeted 
detection of efavirenz extracted from cultured cells and supernatant. Cells were cultured for 72 hours, 
incorporating a 24-hourly efavirenz treatment. Efavirenz concentration dynamics were assessed over 
this period, and cells were harvested every 24 hours for discovery proteomic analysis using a Q-Exactive 
quadrupole-Orbitrap mass spectrometer. 
Results: Drug extraction with acetonitrile was selected as the optimal extraction and detection 
technique. In cell culture, efavirenz concentration increased after 24 hours and decreased after 48 
hours.  A total of 1663 protein groups were identified, with 26, 39, and 80 protein groups differentially 
expressed 24, 48, and 72 hours respectively post EFV treatment. The most significantly enriched 
deregulated pathways included cholesterol biosynthesis, mRNA splicing, and JAK/STAT and Wnt 
signalling. 
Conclusions: Efavirenz-altered protein expression reflects functional pathway perturbations, which may 
contribute to clinically-observed neurological effects. Orthoganal and in vivo confirmation is required.
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Chapter 1: Literature review 
 
1.1 Introduction 
 
The human immunodeficiency virus (HIV) epidemic in South Africa is the largest worldwide, with an 
estimated  13%  of  the  population  infected  in  2018.1   HIV  is  classified  as  a  lentivirus,  a  subset  of 
retroviruses consisting of RNA instead of DNA, which infect humans and animals and cause a slow 
progressing chronic disorder.2 HIV differs from animal lentiviruses as it causes major immunodeficiency, 
whereas animal lentiviruses cause slightly impaired immune responses.2 
 
Once HIV enters the host, it targets and depletes host CD4+ T-cells via apoptosis and pyroptosis.3  This 
causes a major inflammatory response, which attracts and activates more T-cells, ultimately resulting in 
a cycle of inflammation and immune cell destruction.4 A CD4+ cell count below 200 cells/mm3 and a high 
viral load is indicative of immunodeficiency that results in vulnerability to secondary infections.5  Most 
commonly, tuberculosis (TB) and the development of certain types of cancer are seen in patients that 
progress to acquired immunodeficiency syndrome (AIDS). Left untreated, HIV infection will usually result 
in progression to AIDS, and subsequently, death within 11 years.6  AIDS can be a debilitating disease, 
causing major financial strain and emotional trauma within families. With the introduction of anti- 
retroviral (ARV) drugs, the implementation of various sustainable intervention strategies within affected 
communities, and general education, there has been a steady decline in HIV infection rates, as well as 
morbidity and mortality rates.7,8 
 
As a result of ARV medication, HIV has become a chronic disease, necessitating life-long treatment that 
allows those infected to live longer and healthier lives. Another major success of ARV treatment has 
resulted in HIV-infected women being able to give birth to uninfected children. The benefit of ARV 
treatment in protecting the foetus from HIV is undeniable, although concerns have been raised about 
the side effects of certain ARV drugs that the foetus may experience during development, both pre- and 
post-natally. In adults, the side effects of ARV treatment are well documented, while a limited amount 
of information on the effects of ARV exposure in utero exists. Thus as the use of ARVs become more 
wide-spread, it is pertinent to obtain a deeper understanding of the effects of ARV usage during 
pregnancy.
18 
 
 
1.2 Aetiology and pathogenesis of HIV 
Since the identification of HIV 1981, many studies have been conducted to better  understand the origin, 
transmission, and pathogenicity of the virus.9   ARV drugs need to target processes that are vital to viral 
replication, while causing minimal side effects to the host. Therefore, in order to develop effective ARV 
treatment, an understanding of the viral life cycle and mechanisms essential for infection is needed. 
 
Transmission of HIV can occur via bodily fluids such as blood, semen, or breast milk, among others. Most 
commonly, HIV is transmitted through unprotected sexual intercourse with an infected person. Once the 
virus enters the blood stream of an uninfected person, usually via a mucous membrane in the genital 
tract, it attacks the host immune cells. HIV is an enveloped virus and therefore needs to fuse with the 
host cell membrane in order to insert the viral core particles into the host cells.   The viral envelope 
protein gp120 targets the host cell CD4+ receptor and a co-receptor (either CCR5 or CXCR4) in order to 
successfully bind to the cell.10   Gp41 of the viral envelope protein then initiates fusion between the host 
and viral membranes and the viral core particle enters the host cell where viral RNA is transcribed to 
double stranded viral DNA by reverse transcriptase.11–13     The viral DNA enters the host cell nucleus 
where integrase removes the 3’ ends from the viral DNA and, via transesterification, joins it to the 5’ end 
of the host DNA.14,15 Protease enzymes then cleave polyprotein precursors for gag and gag-pol, both of 
which are essential for maturation and infectivity of the virus.16–18 The newly transcribed viral proteins 
and viral RNA assemble at the surface of the host cell and bud from the cell as a mature virus. HIV 
hijacks many host cell proteins, but reverse transcriptase, integrase, and protease are all exclusively 
virally transcribed, making them extremely attractive as targets for ARV treatment of HIV infection.10,14,18
19 
 
 
1.3 Classes of ARV treatments and their mechanisms 
There are several classes of ARVs, each targeting a different vital part of the viral life cycle, including cell 
recognition and  entry, DNA  transcription, DNA  integration,  and cleavage of essential viral  proteins 
(Figure 1.1). 
Entry/fusion inhibitors prevent the virus from fusing with the host cell membrane, either acting as a 
CCR5 antagonist, or by targeting CXCR4 co-receptors.10    For example, maraviroc is a CCR5 antagonist 
that blocks gp120 from associating with the receptor.19  Enfuvirtide is a synthetic peptide that mimics 
part of the viral membrane protein gp41 and inhibits fusion with the host cell membrane.10,20 
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTI/NtRTI respectively) were the first class of 
ARV drugs to be developed. NRTIs are phosphorylated intracellularly, and are incorporated into the 
lengthening viral DNA strand. The NRTI either lacks a 3’-OH group or contains a modified group that 
prevents  subsequent  addition  of  nucleotides  to  the  strand,  thus  preventing  all  downstream  viral 
action.13   NRTIs  are  widely  used  in  treatment  cocktails,  as  they  are  effective  and  generally  well 
tolerated.20  Some of the more common NRTIs used regularly to treat of HIV infection are tenofovir 
(TFV), emtricitabine (FTC), zidovudine (ZDV) and abacavir (ABC). 
Non-nucleoside reverse transcriptase inhibitors (NNRTI), the third class of ARV drugs produced, inhibit 
viral reverse transcriptase by specific binding to a non-substrate binding site of the enzyme, allosterically 
inhibiting DNA polymerisation by changing the conformation of the enzyme at its active site.13,20,21 
Efavirenz (EFV) and neviraprine (NVP) are two commonly used NNRTIs. 
Integrase  inhibitors,  such as  raltegravir  and dolutagravir,  are the most  recent  class  of  ARVs  to  be 
developed.19  These drugs bind to the enzyme and mimic the DNA substrate/integrase interaction.14 
Integrase inhibitors are attractive as an ARV treatment as there are no equivalent enzymes found in the 
host cell, limiting possible side effects.14 
Protease inhibitors block the viral enzyme by acting as competitive peptidomic inhibitors, mimicking the 
transition state of the protease catalysis and blocking the binding of viral proteins.16,18 This class consists 
of drugs including saquinavir, ritonavir, and lopinavir.
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Figure 1.1: Schematic representation of the key points in the life cycle of HIV and the main drug 
classes that interfere with viral infection and replication. The class of drug as well as specific 
examples are in red text. The point of disruption is indicated by a red line. Schematic adapted from 
Encyclopaedia Britannica.22
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1.3.1 Current ARV treatment recommendations 
 
In 1987 the first NRTI drug, ZDV, was used in monotherapy with great and rapid benefit to patients. It 
soon became apparent that the virus was developing resistance to the drug, causing virologic failure.23 
Subsequently, other drugs, such as didanosine and zalcitabine, were used as sequential monotherapies, 
and  eventually  as  dual  NRTI  therapies.19    Although  dual  therapy  was  a  vast  improvement  on 
monotherapy, the timeframe for success was limited. Almost 20 years after the introduction of ARV 
monotherapy,  triple  drug therapy  regimens  were developed,  known  as  highly  active  anti-retroviral 
therapy (HAART) or combination therapy.19    HAART treatment usually consists of one NNRTI and two 
NRTIs, and is more effective than mono or dual therapy as it targets multiple points of the viral life cycle. 
HAART decreased the viral load significantly, leading to stalled development of resistance, as well as a 
drastic increase in survival expectation across all ages.24–27 
 
 
1.3.1.1 Treatment regimen development for low income settings 
 
With strict adherence to a HAART regimen, the viral load can remain undetectable, known as virologic 
control. An adherence level below 80% leads to virologic failure in up to 87% of patients, and is a major 
factor contributing to the development of ARV resistant strains of HIV.28  Combination therapy such as 
HAART has an increased  risk of non-adherence, which is associated with the increased dose frequency 
and pill count.29  The risk of non-adherence is also compounded by limited accessibility to health care 
facilities and resources in low-income settings.29,30 
In  order  to  minimize  side  effects  and  maximize  adherence  and  viral  suppression,  a  fixed  dose 
combination (FDC) pill has been prescribed as a first line treatment in South Africa. This is a single tablet 
taken once a day, as opposed to multiple tablets taken multiple times in the day. The drugs used in any 
fixed dose pill have to be carefully selected so as to provide the highest potency and the lowest side 
effect profile possible. The components of the FDC must be carefully selected as ARV drugs interact not 
only with other ARVs, but also with anti-tubercular drugs.31,32 This is particularly pertinent in the South 
African context as it is  estimated that over 60% of HIV infected patients are co-infected with TB, which 
is the primary cause of death in those with HIV.33
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1.3.1.2 The constituents of the current first line FDC treatment in South Africa 
 
The South African Department of Health implemented roll-out of an FDC consisting of EFV (600mg), FTC 
(200 mg), and tenofovir disoproxil fumarate ([TDF] 300 mg), the latter metabolised in the gut into its 
active form, TFV.34–36 The combination of these three drugs is the preferred first line treatment currently 
in use in South Africa.37 
EFV is a NNRTI that inhibits HIV replication by binding specifically to a non-substrate binding site of the 
HIV reverse transcriptase.21,38  EFV has a plasma half-life of roughly 46 hours, and reaches steady state 
within ten days.39 In adults, EFV has most commonly been associated with central nervous system (CNS) 
neuropathy  including  dizziness,  headaches,  confusion,  stupor,  impaired  concentration,  agitation, 
amnesia, depersonalization, hallucinations, insomnia, and abnormal or vivid dreams, all of which are 
generally resolved within a month after treatment commencement.39–42   Gastrointestinal effects such as 
nausea, diarrhoea, and vomiting have also been reported.39 Clinical manifestations of EFV toxicity have 
been well documented in adults in relatively short term studies, and in recent years there has been 
more focus on the cellular and molecular effects of EFV. 
FTC is an NRTI analogue of the nucleoside cytidine. When the analogue enters the nucleus, it is 
phosphorylated and incorporated by the viral reverse transcriptase. Once incorporated, elongation is 
prohibited as the analogues lack a 3’-OH group and/or contain a modified sugar moiety, both of which 
block the addition of another nucleotide.13,43 FTC has a serum half-life of roughly ten hours, although its 
intracellular half-life can be as long as 39 hours.42 Toxicity from FTC is uncommon and it is generally well 
tolerated. Side effects include hyperpigmentation, headaches, rash, and gastrointestinal upset.42 
TFV is an acyclic nucleotide diester analogue of deoxyadenosine 5'-monophosphate, lacking the 3’-OH 
group, preventing phosphodiester linkage that is essential for DNA chain elongation.13,42  TFV has a 
serum half-life of roughly 15 hours and a low toxicity profile, with side effects such as gastrointestinal 
upset, nausea, abdominal pain, and dizziness.42 TFV is recommended as treatment for patients who are 
co-infected with hepatitis B virus and HIV, and the combination of FTC and TFV is recommended as a 
preventative prophylaxis treatment for HIV.38,44
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1.3.1.3 ARV drug interactions 
 
When drugs are used in combination, there are three potential interaction effects. The non-interaction 
of drugs (as described by the Bliss independence model45) is known as an additive effect, whereby each 
drug achieves the individual pharmacological effect, without influencing the other. Non-interaction can 
be likened to the null hypothesis or the baseline of the drugs interaction. A deviation from the baseline, 
where  the  combined  effect  of  two  drugs  results  in  a  reduced  response  than  that  of  each  drug 
individually, is known as an antagonistic effect.45  This can either be in terms of the desired response, 
such as pathogen death, or an undesired response such as a  negative side effect for the patient. 
Antagonistic drugs can be useful to minimise negative side effects, as long as other drugs are used to 
maintain the desired responses such as pathogen death. When two drugs result in a greater response 
than that of each individual drug, it is known as a synergistic effect. This is highly desirable in many drug 
treatments as it allows for a lower dosage of drugs to be administered while still achieving high efficacy. 
At the same time, lower doses of drugs may result in fewer adverse side effects. Drug interactions 
influence the selection of the constituents of ARV FDC regimens. 
NRTIs, such as ZDV or FTC, are transported across the host cell membrane and phosphorylated to 
become metabolically active nucleotides lacking a 3’-OH group, thus causing termination of elongation 
by the viral reverse transcriptase. Viral resistance to NRTIs occurs when the reverse transcriptase 
catalyses ATP  to act as a nucleophile that is able to remove chain terminating analogues, thus allowing 
transcription to continue.46    NNRTIs such as EFV, which bind allosterically to reverse transcriptase, are 
able to inhibit ATP catalysis of nucleotide analogue removal, thus decreasing the rate of acquiring 
resistance.46      Based on  this  synergistic  action, NRTIs  and NNRTIs are  recommended  to  be  used in 
combination.  The first line FDC regimen in South Africa contains one NNRTI (EFV), one NRTI (FTC), and 
one NtRTI (TFV). In combination, both FTC and TFV increase in intracellular concentration. This may be 
as a result of a decrease in the efflux of the drugs via the ABCC transporters, as ABC transporter 
functionality decreases in the presence of all three drugs.47  EFV concentration is not affected by the 
combined administration, possibly due to the ability of EFV to induce its own metabolism, minimising 
the effect of the ABCC decrease in functionality.47,48 According to most opinions, the FDC regimen is safe 
for use by HIV infected adults. The side effects caused by FTC and TFV are minimal, although there have 
been reports of up to 50% of patients on EFV containing regimens developing CNS-related side effects.49–
51
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1.4 ARVs and the CNS 
During  HIV  infection  the  CNS,  specifically  the  brain,  is  the  second most  frequently  infected organ 
following the lungs, and is thought to be a primary infection site of the HI-virus.52,53  The virus infects 
microglia and astrocytes and can remain within these cells in a latent state, acting as a reservoir of 
infection, unaffected by many current ARVs in use. 53–56    Infection of the CNS can result in a range of 
neurological complications classified as HIV associated neurocognitive disorder (HAND) that includes 
asymptomatic   neurocognitive   impairment   (ANI),   mild   neurocognitive   disorder   (MND),   and   HIV 
associated dementia (HAD).57 
While the introduction of ARVs has resulted in a 40-50% decline in the incidence of severe HAD cases, 
there has been little to no improvement in the reported incidence of milder forms of HAND, indicating 
that new patients are still presenting with HIV related CNS disease, even with treatment and virologic 
control.57,58 Low level viral replication in the CNS or immune activation triggered by HIV infection may be 
responsible for continual HAND emergence, necessitating ARVs with a higher CNS penetrance.59  ARVs 
themselves may contribute to the mild forms of HAND, as the nature of HAND has somewhat changed in 
the ARV era. For example, although HAD is much less frequently diagnosed, it is now observed in 
patients with less severe immunosuppression than previously seen, as well as in patients with lower viral 
loads.60  Before the ARV treatment era, HAND affected mostly motor skills, cognitive speed, and verbal 
fluency. Post ARV era, memory, learning skills, and executive function are the most noticeably impaired 
neurocognitive areas.61 The subtle change in the nature of HAND and the change in relevant biomarkers 
for HAND has brought the safety profiles of certain ARV drugs into question.61    ARV treatment greatly 
decreases the risk of HAD, but it is important to investigate the long-term side effects of the drugs as the 
lifespan of those living with HIV, and thus lifetime usage of the drugs, increases. 
The  three  constituents  of  the  FDC  (EFV,  FTC,  and  TFV)  are  able  to  cross  into  the  CNS  to  some 
extent.34,62,63 EFV is strongly recommended for use in first-line treatment by the World Health 
Organisation (WHO) due to its high potency and ability to cross the blood brain barrier (BBB).64 Reaching 
approximately 1% of the plasma concentration in the cerebrospinal fluid (CSF), it is still well above the 
50% inhibitory concentration of EFV on the wild type virus.62,65   EFV is therefore a useful agent in 
reducing the viral load in the CNS in order to prevent the development of HAD, as well as reducing the 
risk of a latent reservoir of HIV forming in the CNS. Aside from the necessary benefits of EFV with 
regards to systemic viral suppression and CNS viral suppression, EFV is notorious for having strong CNS- 
related side effects. Despite neurocognitive side effects presenting in up to 50% of those administered 
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EFV as a constituent of HAART,51  the FDC containing EFV is still recommended as a first line treatment 
for all patients, including pregnant women. In order to minimise the risk of mother to child transmission 
(MTCT) of HIV, pregnant, HIV-positive women receive priority treatment regardless of their CD4+ cell 
count and stage of pregnancy. The treatment with this often toxic drug during critical stages of foetal 
development necessitates investigation into the effects of EFV during pregnancy, and specifically during 
foetal neurogenesis.
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1.5 ARV treatment in vulnerable populations: pregnant mothers and 
foetuses 
 
The chance of MTCT of HIV is between 25-35%, which can be lowered to approximately 2% with ARV 
treatment.66  With an estimated 30% of women of child-bearing age infected with HIV in South Africa, 
pregnant women infected with HIV are considered priority patients in the roll out of the FDC, regardless 
of their CD4+ cell count, clinical staging, or the gestational age of pregnancy.1,67,68 Children who contract 
HIV through vertical transmission, either during pregnancy, childbirth, or breastfeeding, have a very low 
survival rate, with close to 50% mortality in the first two years of life.69  It is therefore imperative to 
minimise vertical transmission with ARV treatment. 
Due to pregnant women and children generally being excluded from drug trials, animal models were 
used to create an initial preclinical safety profile for treatment with ARV drugs. The generalizability of 
these models to human populations is questionable,70 and thus there is still a need for deeper insights 
into the effects of the FDC drugs on during the development and neurogenesis of foetuses. 
 
 
1.5.1 The safety profile of the FDC during pregnancy 
The three constituents of the FDC are able to cross the placenta, which has the desirable effect of 
reducing viral load in the mother and the foetus, allowing the infant to be born HIV-negative.35,71–74 
Literature regarding the effects of these drugs on infants exposed in utero is limited, but in recent years 
there have been increasing numbers of retrospective and prospective studies investigating the effects of 
in utero exposure to ARVs, and whether exposure increases the risk of birth defects. Findings are mixed 
and generally not definitive regarding the safety of the drugs during pregnancy and each study highlights 
the need for larger cohorts, longer follow up periods, and standardized testing. In infant populations 
exposed in utero, the FDC consisting of TFV, FTC, and EFV has the lowest risk for birth defects when 
compared to other drug combinations,75 although the risk of pre-term birth and stillbirth is significantly 
higher in infants exposed to the FDC compared to unexposed infants.76
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1.5.2 The safety profile of EFV during pregnancy 
 
Of the three FDC drugs, EFV has the most thoroughly documented and severe side effects in adults. EFV 
is classified as a category D drug for use in pregnancy, which indicates positive evidence of risk to the 
foetus.77 Case studies have reported increased risks of myelomeningocele and encephalocoele after EFV 
exposure in the first trimester,78–81 but the benefit of the drug outweighs the potential risk, and for this 
reason, EFV was initially recommended for pregnant women only after the first trimester as a foetus is 
most vulnerable to teratogens during organogenesis at this time. NVP was initially used as the first 
trimester NNRTI instead of EFV, but it was found that women on NVP had consistently higher viral loads 
and that NVP interacts with rifampicin, a first line treatment for TB.82  Women treated with EFV and 
unaware of the pregnancy for the first six weeks did not have a significantly increased risk of birth 
defects, and as a result, in 2012 pregnant women in lower income countries such as South Africa were 
recommended  to  take  EFV  as  a  first  line  treatment,  regardless  of  the  stage  of  pregnancy.64,82 
Subsequently, there were multiple reports of first trimester exposure to EFV causing an increase in 
negative pregnancy outcomes, including neurological defects.81,83,84 The risk was further elevated when 
including elective termination of pregnancy due to observed neurological defects.85 Foetuses exposed to 
EFV were also found to have elevated lactate levels, indicating mitochondrial dysfunction, which has 
been linked to neuropathy.58,86–89 
The use of EFV during pregnancy remains controversial, as the increased risk is often small, and there 
are too few cohort studies of adequate size to draw any concrete conclusions. Neurological defects in 
the general population are rare, and therefore larger sample sizes are needed to detect increased risk in 
EFV exposed populations. For this reason, a small increase in observed neurological defects in EFV- 
exposed populations, even if insignificant, is still noteworthy.  The safety of EFV during pregnancy and 
the neurological risk it poses can therefore neither be confirmed nor refuted currently.90–92 
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1.5.3 The conflicting evidence regarding long term effects of in utero EFV 
exposure 
 
The great success of the WHO in decreasing MTCT has been invaluable to the millions of children born to 
HIV-positive mothers.66 As a result, there are many children who have been exposed to both the HI-virus 
and ARV drugs in utero, as well as HIV prophylaxis treatment post-partum. This increasing population 
therefore needs to be better understood as they face many challenges, such as living with HIV positive 
caregivers,  increased risk of illness, and potential risk of exposure to both the virus and the drugs during 
foetal and postnatal development.93  The first 1000 days of neural development, from conception to 
approximately two years old, are vital. Exposure to toxic stress can affect different areas of the brain, 
depending on which point during development the exposure occurred.94  During the critical periods of 
development, damage in a particular area may be irreversible, while exposure during the sensitive 
period may not be deterministic.94 The impact of toxic drugs might only manifest later in life, when the 
exposed children begin to participate in more complex tasks relating to cognitive function such  as 
reading, concept learning, critical thinking, and problem solving.95,96 
With the increasing population of HIV exposed, uninfected (HEU) children there is a need to gain a 
deeper understanding of the long term effects of in utero exposure to both the virus and the ARV drugs. 
The majority of the literature focusses on congenital abnormalities, with some emphasis on neurological 
defects. When investigating the long term effects of exposure, there are conflicting results, with some 
studies indicating no increased risk of any long term neurological deficit, while others show an increased 
risk. Due to the recent introduction of the FDC as a first line treatment for treating HIV in pregnant 
women, the majority of long-term studies include drugs such as ZDV, lamivudine (3TC), and NVP, with 
few studies including EFV. 
 
 
1.5.3.1 The HEU child 
Upon investigation of the long-term effects of ARV exposure  in utero, multiple studies found that 
children exposed to ARV drugs in utero experienced neurological deficits when compared to peers that 
were not exposed. Although these deficits were correlated to ARV exposure after sensitivity analysis, 
there was generally no link to any specific drug.97–99 HEU children had deficits in language-related tasks 
such as delayed language emergence or lower scores in reading skills. 86,96,99–102  HEU children also had 
motor developmental delays95,103  as well as scores in cognitive ability,98,104  executive function levels,105 
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and mathematical ability106 slightly below those of their unexposed peers. Elevated lactate levels, 
indicative  of  mitochondrial  dysfunction  and    linked  to  in  utero  ARV  exposure,97,103,107   have  been 
associated with neurological dysfunctions including behavioural problems.97,107 The deficits in 
neurocognitive function caused by mitochondrial dysfunction can be supported by findings in a primate 
model, which found that primates exposed to an NRTI regimen in utero and for an additional six weeks 
postnatally had accumulative mitochondrial damage in the brain cortex when assessed at one year after 
birth.10 In contrast to the aforementioned findings, there are reports that claim that there is no 
correlation between in utero ARV exposure and long term neurodevelopmental risks. The biochemical 
profile and gross structure of the brains of HEU children and their non-exposed peers were the same 
between the ages of five and ten years old, indicating that HEU children have typical brain 
development.109 This study only included HEU children who had no CNS-related disorders or dysmorphic 
syndromes, excluding the population  of  HEU  children  suffering  from  CNS  disorders  potentially  
caused  by  ARV  exposure.  In America, the majority of drug regimens in longitudinal studies contained 
ZDV or 3TC, and there was no statistically significant difference between HEU and their unexposed peers 
in neurological development.98,110  These studies were all performed in high income countries and 
lacked appropriate control groups. Often the HEU group was from lower income communities and thus 
lower cognitive scores or mental health problems were attributed to socioeconomic background and 
caregiver health.111 
When compared to similar studies performed in Africa, it was found that the HEU children had poorer 
outcomes than those predicted for HEU children in high income settings.95 The distinction in long term 
exposure effects between high and low income settings highlights the need for early intervention to 
mitigate potential negative effects of in utero ARV exposure, as early intervention has been shown to 
improve cognitive functioning of affected children.112 
Although there has been an increase in interest in HEU children specifically in Africa, there are many 
contradictory findings and methodological shortcomings. A study performed in Zambia reported no 
difference in language and cognitive development in HEU and unexposed children.113  In this study, 
children up to two years of age were assessed, excluding detection of developmental deficits that would 
only become apparent at a later age when performing more complex tasks. The standardized Capute 
Scales Clinical Adaptive Test/Clinical Linguistic and Auditory Milestone Scale testing that was used in this 
study is unable to detect specific cognitive or language delays in children and as a result the study was 
unable to rule out the possibility of cognitive or language delays in HEU children.113     In South Africa 
similar results indicated that HEU children had no cognitive developmental deficits when compared to 
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their unexposed peers. This study had major confounding factors, whereby the control group was 
mostly comprised of children from Afrikaans population groups, while the HEU group was mostly 
Xhosa.114    The  control  group  surprisingly  had  a  higher  rate  of  maternal  substance  abuse,  and 
subsequently, a higher rate of growth stunting, which has been  shown to delay neurodevelopment.115 
It is possible that the control group was not representative of a population mean, confounding the 
results. In contrast to these findings, in the Democratic Republic of Congo, HEU children were found to 
have lower cognitive scores than the control group, although this was attributed to HIV-positive status 
of the caregivers as well as poor living conditions.116 
Most longitudinal studies are unable to either confirm or deny the safety of ARV usage in pregnancy due 
to confounding factors. Even more concerning is the lack of data regarding the use of EFV in pregnancy, 
as it is a first line treatment in South Africa. The question remains whether the potential increased risk 
of  aberrant  neurodevelopment  in  HEU  children  is  as  a  result  of  exposure  to  ARVs  in  utero,  and 
specifically EFV, which is known to cause seizures, aggressive behaviour, ataxia, tremors, and cerebellar 
dysfunction in children,117,118  and other CNS symptoms in adults. In order to create early interventions 
for the growing population of HEU children, a deeper understanding of the mechanisms by which EFV 
can  affect the  developing  neural  system  needs to be  attained. Seemingly  minor  alterations  in the 
neurocognitive functions on an individual level can have a large impact on public health, indicating a 
need to address the potential long term side effects of in utero EFV exposure. The present study aims to 
investigate the biochemical effects of EFV at a cellular level, using human derived foetal neuroepithelial 
stem (NES) cells as a model for EFV exposure during early development. Understanding the effects of 
EFV at the molecular level may provide compelling pre-clinical evidence to emphasize the importance of 
further research in order to provide optimal protection for both the mother and the foetus from HIV, as 
well as for the long-term health and development of the neural system.
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1.6 Cell culture as a means to investigate molecular effects of EFV on 
developing neurons 
Several  studies  attempting  to  elucidate  the  effects  of  ARVs  on  the  CNS  have  used  methodologies 
including cohort studies, animal models, and cell culture models. In most cases, cohort studies contain 
many confounding factors which limit the ability to draw conclusions. Animal models allow for more 
controlled studies, although their applicability to human settings has been questioned as there are 
reports of only 2-3% of animal teratogens having the same effect in humans.70,119 Cell culture models are 
the easiest to control and offer insights into the molecular mechanisms of ARVs and their side effects. By 
building a solid foundation of understanding at the cellular level, further studies can be more targeted 
and precise. Previous cell culture models attempting to elucidate the effects of ARVs on the neural 
system have used either animal neural cells, or human non-neural cell lines.120–122 Transformed human 
neural cell lines such as neuroblastoma (SHSY-5Y) have been used, but are also not necessarily 
representative of the functioning of primary neuronal tissue. 
Non-transformed, human-derived NES cells have been isolated from the hind brain of a five week old 
foetus and successfully passaged up to 100 times while maintaining genetic stability.123  These 
proliferating neuroepithelial cells spontaneously form rosettes that are responsive to patterning signals 
and are the sole cell type found in developing neural tubes.124 Upon removal of various growth factors 
such  as  EGF  and  FGF,  the  NES  cells  are  able  to  spontaneously  differentiate  into  an  almost  pure 
population of synaptically active neurons in vitro, forming elaborate neural networks within four weeks 
from growth factor removal.123,125 The NES cell line can act as a model that represents early neural tube 
development, the neurogenesis process, and a pure population of neurons in vitro.123,124  The NES cells 
thus provide a model that allows for a deeper insight into the molecular effects of EFV on the developing 
neural system. This model can be used to assess global cellular molecular changes during early neural 
development, as well as in mature neuronal populations. The effects of EFV at the molecular level can 
be used in conjunction with cohort and animal studies to further the understanding of the effects of EFV 
on the developing neural system in this growing population of infants exposed to ARVs in utero.
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1.6.1 Using proteomics to investigate global cellular changes 
Traditionally, biological research followed a reductionist approach, where one component of a system 
was  examined  and  its  function  described. This  approach  lacks  the  ability  to  describe  the  complex 
pluralistic nature of cause and effect in a biological system. Systems biology offers a more holistic 
approach, by observing the system and its interactions as a whole. The term “omics” is often used to 
describe the network under observation. Genomics, the most well-known approach to systems biology, 
is considered to be the blueprint of an organism and offers many insights to the makeup of different 
organisms. Proteins can be likened to the building blocks or the functional aspect of the genome. Genes 
are translated into proteins which can then be modified to suit the immediate needs of the organism or 
cell, thus the snapshot in time provided by observing cell wide protein changes, known as the proteome, 
gives a clearer indication of the cellular response to the environment. 
 
 
1.7 Mass spectrometry for proteome analysis 
Mass spectrometry (MS) has been a cornerstone in the advancement of proteomics, allowing thousands 
of proteins to be identified in a single experiment.  Experiments can be approached in a top-down or 
bottom-up workflow, which involves the analysis of whole, intact proteins, or digested peptides, 
respectively.   Smaller peptides are preferred for MS analysis over whole proteins, as peptides have a 
higher ionisation and fragmentation efficiency than the larger proteins.126,127 In order to prepare peptide 
samples for MS analysis, proteins from cell lysate or tissues are precipitated and digested, and the 
peptides  are  suspended  in  an  organic  solvent  such  as  an  acetonitrile  (ACN)/water  mixture.  The 
acquisition of MS data from the peptide mixture can then be performed in discovery or targeted mode. 
Discovery,  or  shotgun,  proteomics  is  a  hypothesis  generating  investigation  which  identifies  and 
quantifies several thousand proteins from a complex mixture of proteins. Targeted experiments can be 
used to validate hypotheses generated from discovery data or to search for a predetermined list of 
proteins by setting the MS experiment to detect peptides of specified retention times or masses. MS 
experiments can be performed on various instruments, each with advantages and disadvantages, and 
commonly used instruments or techniques will be discussed in more detail. A typical MS workflow for 
cell culture shotgun proteomics is illustrated below (Figure 1.2).
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Figure  1.2:  Schematic representation of  a  typical  MS  workflow. 1)  A  treatment and  control  
condition  are prepared. 2) Cells are harvested, frozen with liquid nitrogen, and stored until needed for 
further processing. 3) Cell pellets are lysed, and proteins are extracted via protein precipitation 
methods. 4) Proteins are digested over night with trypsin. 5) The peptides are desalted and suspended 
in 2% ACN. 6) The peptide mixture is separated by liquid chromatography (LC) based on hydrophobicity. 
As the peptides reach the charged emitter tip they are ionised by electrospray ionisation  (ESI).  7)  
Ionised  peptides  flow  through  the  MS  into  the  first  quadrupole where  the precursor ions are 
selected, generally by data dependent “top 10”   precursor selection. 8) In a precursor scan (MS1), 
precursor ions are transferred to the C-trap, and then analysed on the Orbitrap. In a product ion 
scan (MS2), selected precursor ions travel via the C-trap into a collision cell where fragmentation of the 
ions occurs. 9) The Orbitrap mass analyser uses an electrostatic field and the frequency of the ion 
oscillation to determine the mass to charge ratio. 10) An MS1 chromatogram is generated by the 
detection of precursor ions. 11) An MS2 chromatogram is generated by the detection of fragmented 
product ions. 12) Statistical analysis is performed with software such as R, Perseus, and Excel to 
determine significance of differences observed in the data. 13) Enrichment and  pathway analysis is  
performed in  order  to  assess the  relevance of  the  observed proteome differences.
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1.7.1 Liquid chromatography 
 
Prior to analysis by MS, the complexity of the peptide mixture is reduced to ensure the detection of the 
majority of the peptides. The pre-fractionation of peptide samples results in fewer peptides reaching the 
ion source of the MS at any given time. This prevents competition for charge that results in the lower 
abundance peptides being masked by the highly abundant peptides. MS instruments have limited 
dynamic  range,  and  thus  by  decreasing  sample  complexity  with  liquid  chromatography  (LC),  the 
sensitivity of the experiment  is  increased  and very low  abundance  peptides are more likely to  be 
detected. 
 
High performance LC (HPLC) is commonly used in proteomics and offers higher resolution than regular 
LC. A hydrophobic  stationary phase (reverse phase) consisting of c18 silica beads is packed into a 
column, and a mobile phase containing water, an ion pairing agent (usually formic acid [FA]), and 
organic solvent is able to flow through the column. Strongly hydrophobic peptides adsorb to the 
stationary phase, while less hydrophobic peptides are eluted. An increasing   gradient of non-polar 
solvent, generally ACN or methanol, causes increasingly hydrophobic peptides to elute into the ion 
source.126,128 
 
 
1.7.2 Ion Sources 
 
Typically, an MS instrument consists of an ion source, a mass analyser, and a detector. To be detected 
by the mass analyser, analytes are first ionised by the ion source. The development of soft ionisation 
techniques enabled the ionisation of non-volatile and thermolabile compounds, such as peptides (or 
biological macromolecules), with minimal fragmentation. Matrix assisted laser desorption/ionisation 
(MALDI) and electrospray ionisation (ESI) are most commonly used as ionisation techniques for MS and 
can both be coupled to LC systems. 
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1.7.2.1 MALDI 
Samples are co-crystallised in a matrix made up of small organic molecules, which serve to absorb 
energy from a laser pulse, as well as ionise the analyte in question. MALDI is especially useful for simple 
samples, mass fingerprinting, and analysis of proteins in situ, as whole tissue sections can be coated with 
matrix, which allows for spatial distribution within a sample to be maintained.129,130  MALDI generally 
produces singly charged peptides, which results in fewer fragmented ions than ESI.126 
 
1.7.2.2 ESI 
Peptides in solution are passed through a charged metal capillary tip, where positive and negative 
charges are separated, forming a charged Taylor cone which extends into a liquid filament.  The filament 
is unstable and breaks off into charged droplets - the charge depending on the ionisation mode of the 
capillary. A neutral gas, such as nitrogen, can be continually pumped around the capillary, causing 
solvent  evaporation.  As  the  solvent  evaporates,  the  surface  area  of  the  droplet  shrinks,  and  the 
Columbic repulsion between charges eventually overcomes the surface tension cohesive force (the 
Rayleigh limit), causing Columbic fission and the formation of smaller droplets.131,132 This process repeats 
until a single gas phase ion is produced.   The exact mechanism by which this happens is unknown, 
although three models have been proposed.133 The ion evaporation model suggests that the decreasing 
size of the droplet and the increasing field strength causes the charged ion to be ejected into the gas 
phase. The charge residue model suggests that eventually, each droplet contains a single charged ion, 
and once the solvent completely evaporates, the charged ion remains in the gas phase.131,134 The chain 
ejection  model  suggests  that  in  solution,  polymer  chains  may  become  disordered,  with  more 
hydrophobic sections becoming exposed to the solvent. This in turn causes ejection from the solvent 
droplet, as the interior of the droplet is unfavourable for hydrophobic polypeptide chains.133  Once the 
ion is in the gas phase, it is detected by the mass analyser. 
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1.7.3 Mass analysers 
 
There are four mass analysers currently used in proteomics. Time of flight (TOF) analysers simply record 
the amount of time taken for the analyte to travel across the flight tube. An analyte with a larger mass 
to charge ratio (m/z) will take longer to traverse the flight tube. TOF instruments are often coupled to a 
MALDI  ion source,  and  can  be  placed  in tandem with  a  collision  cell  between  them.135,136   Fourier 
transform ion cyclotron resonance (FT-ICR) analysers trap ions with magnetic fields and use cyclotron 
resonance to detect the ions.135 Quadrupole mass analysers consist of four metal rods which create an 
electric field by means of radio frequency and direct current which alters the flight of the ions through 
the quadrupole. Quadrupoles can be placed in tandem, with the first acting as a mass filter, the second 
acting as a collision cell, and the third acting as another mass filter.137   An ion trap, such as the Orbitrap, 
uses static electrostatic fields to trap ions. The ions oscillate around the central electrode of the Orbitrap 
at a frequency related to the m/z value of each ion. A Fourier transform algorithm is used to accurately 
convert the time/domain signal into the m/z value.138,139  The Orbitrap comes with a large trapping 
volume, high mass accuracy, a large dynamic range, and a high m/z range. The Orbitrap is both a mass 
analyser and a detector, while other mass analysers will be coupled to detectors such as electron 
multipliers to increase the signal detected. 
 
1.7.3.1 Tandem MS 
As the peptide mixture elutes and flows through the MS, charged ions (subsequently referred to as 
precursor ions) are detected by the mass analyser. The m/z values of each precursor ion are plotted on a 
chromatogram (MS1). The intensity value on the y-axis represents the relative quantity of the peptide 
eluting at a specific retention time. All plotted MS1 scans make up a total ion chromatogram (TIC). The 
Q-Exactive instrument contains a C-trap in which precursor ions are stored and subsequently transferred 
and analysed in the Orbitrap, creating the MS1 chromatogram.   In discovery MS, ten or 20 of the 
precursor ions with the highest intensity are transferred via the C-trap and enter a collision chamber 
where they interact with a gas, often nitrogen, which causes collision induced dissociation (CID). The 
resultant ions are referred to as product ions, which are then transferred back into the C-trap, followed 
by analysis in the Orbitrap.140,141  Higher energy collisional dissociation (HCD) is common in Obritrap 
instruments, and results in a wide range of fragmentation patterns and high quality product ion spectra 
(MS2).138,142 In order to prevent the same highly abundant precursor ions from being fragmented 
constantly, dynamic exclusion essentially ignores already seen parent ions for a small window in time. 
Fragmentation along the peptide backbone occurs and the dissociated product ions are detected by the 
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mass analyser, creating the MS2 spectra.143  When fragmented, the charge either remains on the N- 
terminus (b-ion) or on the C-terminus (y-ion). Adjacent fragments differ by the mass of an amino acid 
and can thus be used to identify the peptide sequence.135,143 
 
1.7.4 Protein quantitation with MS analysis 
 
In addition to protein identification, MS is an indispensable tool for protein quantitation. Relative or 
absolute quantitation can be assessed depending on the experimental design and sample preparation. 
 
1.7.4.1 Isotope labelling 
Stable isotope labelling is considered the gold standard for protein quantitation, with many different 
types of labels, each with their own advantages and disadvantages.144,145 There are two broad categories 
for isotope labelling, namely, pre- and post-harvest. 
Pre-harvest labelling occurs when metabolically active cells incorporate isotopic labels during protein 
synthesis. This allows the samples to be mixed together once they have been harvested, eliminating 
much of the variation due to sample processing. Stable isotope labelling by amino acids in cell culture 
(SILAC) uses media containing either heavy or light amino acids that become incorporated into each new 
synthesised protein. The heavy amino acids cause a mass shift,  allowing for relative quantitation of the 
two conditions.145,146 Major drawbacks of SILAC are that it cannot be used to label primary tissues and 
few conditions can be studied at one time. Post-harvest tagging, such as isobaric tagging, overcomes 
these issues and can be used to tag tissue samples, as well as multiplexing the number of samples 
analysed. Isobaric tags for absolute and relative quantification (iTRAQ) react with peptides via a peptide 
reactive group.147  The tag consists of a reporter and a balancer group, which ensures that the relative 
mass increase for each peptide is equivalent, and thus differentially tagged peptides appear initially as a 
single peak, reducing complexity. In MS2, the relative abundance of the reporter ion is proportional to 
the relative abundance of the peptide in each sample, allowing for relative quantitation between 
samples. iTRAQ is a reliable method for relative protein quantitation, although it is limited to only eight 
different tags.145 
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1.7.4.2 Label free quantitation 
With recent advances in MS and LC performance, such as nano-electrospray, label free quantitation 
(LFQ) has become an increasingly popular method of quantitation.148,149  Higher mass resolution and 
peptide identification rates increase the number of data points available for   pairing corresponding 
peptides across samples, improving the quality of LFQ.150   By using LFQ, it is possible to obtain an 
unlimited number of “snapshots” of the proteome, making LFQ attractive for time course analyses or 
characterisation of an entire proteome, as the number of samples is not limited to the number of 
tags.151  LFQ is the most economical and simple method used for MS analysis and is able to achieve 
quantitation equivalent to SILAC labelling.150  LQF uses either spectral counting or peak intensity to 
quantify peptides. If a peptide is more abundant, there will be more MS2 spectra detected, which allows 
for simultaneous protein identification and quantitation by MS2 data collection. The more highly 
abundant peptides in a sample are thus favoured in spectral counting. Another drawback of spectral 
counting is that poor quality data can lead to inaccurate protein identification and thus inaccurate 
quantitation.151 
Extracted ion chromatograms (XICs) are another means of performing LFQ, and use the area under the 
curve (AUC) of the peak corresponding to the peptide as a surrogate for peptide quantity, as peak 
intensity increases linearly with peptide abundance.152 Intensity measurements can distinguish between 
peptides  with  a  similar  mass  but  a  different  amino  acid  sequence,  which minimises  false  positive 
identification, thus improving accurate protein quantitation.151  Quantitation by XICs has also shown 
superior performance to spectral counting, especially in the case of low abundance peptides.150
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1.8 Data analysis 
 
1.8.1 MaxQuant 
 
A shotgun MS experiment typically generates large amounts of raw data, presenting a challenge for data 
analysis.  Software  packages  such as  MaxQuant  have  been specifically  developed  for  high accuracy 
quantitation and identification of shotgun MS data.153,154  MS1 spectra consist of information regarding 
the peptide mass and the intensity, while the MS2 spectra are used to identify the peptide by matching 
the  fragment  spectrum  against  a  database.  Andromeda,  the  search  engine  integrated  into  the 
MaxQuant workflow, scores peptide-spectrum matches (PSM) based on probability calculations.155 Each 
PSM is tested against a decoy database and assigned with a posterior error probability (PEP) score that 
represents the probability of error for that particular PSM. The false discovery rate (FDR) determines the 
error rate associated with the collection of all PSMs. The PEP and FDR scores ensure that false positive 
PSMs  are  minimised.156   The  MaxQuant  workflow was  originally  designed  for  analysis of  SILAC  raw 
data,153  but with the recent increase in the number of LFQ experiments, a MaxQuantLFQ algorithm 
specifically designed to handle LFQ data has been integrated into the workflow and is recommended for 
use in comparative shotgun proteomics.150,157 
 
 
1.8.2 Skyline 
 
Skyline is software that can be used to develop and analyse targeted MS experiments.158,159     During 
method development, peptides belonging to proteins of interest can be empirically detected via a 
shotgun experiment, or can be created in silico by Skyline. Collision energy (CE) ramping is integrated 
into the Skyline method development pipeline to ensure target peptides with the highest intensity are 
detected.158   Raw data are imported back into Skyline for processing, whereby each product ion  is 
grouped with the precursor ion and stored graphically.159 The best peak for each peptide will be picked 
by Skyline based on various parameters, such as log intensity, identified count, library intensity score, 
co-elution count, shape score, and weighted co-elution.158 Quantitation is assessed by the AUC for each 
product ion, and the total area is related to the precursor ion. The intensity and the interference for 
each product ion can be individually inspected in Skyline.158–160
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1.8.3 Statistical analysis and biological inference 
 
Outputs from MaxQuant and Skyline can be easily exported to R, Perseus, or Microsoft Excel software 
for further statistical analysis. The intensity values are used as a proxy for the relative abundance of 
each peptide and statistical testing can then be performed to evaluate the relative protein expression 
between samples.152 In differential proteomics, a Student’s t-test is considered the best test for 
significance when there are three or more replicates per group.150,161 
Peptides are assigned to protein groups rather than individual proteins, as this takes protein isoforms as 
well as peptide redundancy in certain proteins into account. Thus further analysis is based on protein 
groups that are identified by a set or subset of peptides as opposed to specific individual proteins. A list 
of statistically significant differentially expressed protein groups can then be interrogated further using 
various bioinformatics workflows available. Data bases such as Panther, StringDB, Reactome, and GSEA 
are curated protein function databases that can be used to infer interactions between differentially 
expressed protein groups, which can result in a deeper understanding of the biological significance of 
the condition tested.
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1.9 Aims and objectives 
 
Due to the severity of the HIV epidemic, the approval of ARV drugs was initially accelerated, without full 
knowledge of the long term side effects.162,163 CNS side effects caused by EFV in adults are well 
documented but due to pregnant women and children generally being excluded from clinical trials, 
there remains a gap in the knowledge of how EFV exposure affects the developing neural system of 
children exposed in utero. This study aims to characterise the proteomic cell wide changes caused by 
EFV in proliferating NES cells at biologically relevant concentrations. Based on the literature reviewed, it 
seems reasonable to hypothesise that EFV may cause perturbations in the proteome of neural stem cells 
in vitro, ultimately affecting neural differentiation and development in vivo.  
 
Aim 1: Understand the movement and degradation of EFV in cell culture using 
small molecule targeted MS. 
 
Objectives 1: 
a)   Optimise the detection of EFV on the Vantage Triple-Stage quadrupole (TSQ) with different 
solvents such as ACN, methanol and dimethyl sulphoxide (DMSO). 
b)   Develop a targeted MS experiment to detect EFV, optimising gradient elution, CE, and ensuring 
reproducible results. 
c)    Optimise the extraction of EFV from cell suspension and supernatant using protein precipitation. 
d)   Assess whether EFV is able to enter NES cells at detectable levels. 
e)   Assess the degradation of EFV in NES cell culture. 
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Aim 2: Characterise the global cellular changes in NES cells caused by EFV 
treatment 
 
Objectives 2: 
a)   Design a treatment schedule over 72 hours for NES cells based on EFV concentrations over 72 
hours as elucidated in aim 1. 
b)   Investigate cytotoxic effect of EFV in cells using cell counting and cell viability assays. 
c)    Create a time-course proteomic profile over 72 hours for NES cells treated with EFV using a 
discovery MS workflow with LFQ on the Q-Exactive.
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Chapter 2: Optimisation of the detection of EFV using targeted MS. 
 
2.1 Introduction 
Small  molecules  have  a  wide  range  of  functions,  serving  as  pharmaceutical  drugs,  secondary 
metabolites, pesticides, and signalling molecules. Assays are needed to determine the amount of the 
small molecule present in a system, their activity, and their cellular location. Most biochemical assays 
used to detect or quantify small molecules are unable to directly measure the molecule, instead 
measuring either enzymes or proteins which interact with the molecules, such as immunological or 
colorimetric assays.164–166 The small molecule in question may bind to an antibody, an aptamer, or may 
act in a biochemical reaction, all of which result in a measurable signal that acts as a proxy for the 
presence  and  quantity  of the  small molecule.  Immunological and colorimetric assays are generally 
simple and fast, and minimal training is required. There is no need for specialised, expensive equipment 
or training to perform these assays, although in some cases, antibodies may be costly for a single 
experiment.167  Immunological assays are useful for studies in which the outcome is predicted, but are 
blind to unexpected biological events.144 
MS  is  another  way  to  detect  and  quantify  small  molecules  by  measuring  the  m/z  of  the  ionized 
molecule. It is generally accepted that MS has lower limits of detection than immunological assays, and 
lends  itself  to  high  throughput  experiments.168   Another  appealing  aspect  of  using  MS  is  that  the 
molecule is being directly measured, as opposed to quantification occurring via a proxy. MS experiments 
also allows for performance of multiplexed experiments, whereby multiple small molecules can be 
detected in one experiment at no extra cost, as opposed to needing multiple antibodies and multiple 
tests.167  LC coupled to MS separates complex mixtures and allows for higher sensitivity by minimizing 
interference, which is particularly important in biological samples. Initial method development for drug 
detection assays can be lengthy and costly, but ultimately allow for automated, high throughput 
experiments. 
Selected reaction monitoring (SRM) is a targeted MS method that is often used in drug detection assays. 
A triple quadrupole instrument is considered the gold standard for SRM quantitative analysis as it 
maintains high selectivity in complex samples. The first quadrupole acts as a mass filter, selecting 
analytes of a specific m/z value from a target list. The second quadrupole acts as a collision cell, 
fragmenting the selected analytes. The third quadrupole acts as the second mass filter, once again 
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selecting ions of a pre-specified m/z value.137 By having two levels of mass filtering within a narrow mass 
window, high selectivity is achieved as co-eluting ions are effectively filtered out.137,169 
This chapter describes various optimisation steps taken to confidently identify EFV by SRM analysis. 
Factors such as drying and reconstitution of EFV, as well as multiple instrument parameters were 
optimized to ensure high quality data.
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2.2 Materials and methods 
 
2.2.1 Optimisation of instrument parameters and detection of EFV by direct 
infusion. 
 
EFV (99.4% purity) was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH. 
EFV powder (10 µg) was reconstituted in 50% DMSO (Sigma Aldrich) and diluted by a factor of 100 and 
1000 in 2% ACN (HPLC grade, Sigma Aldrich), 0.1% formic acid (FA, Sigma Aldrich). At low concentrations 
DMSO has been found to improve ionization, specifically for hydrophobic compunds170,171 such as 
EFV.13,172   EFV  powder  was  also  reconstituted  in  100%  ACN,  100%  methanol,  50%  ACN,  and  50% 
methanol. Each sample was infused directly into the TSQ Vantage Triple-Stage quadrupole (Thermo 
Scientific) at 2 µl/min with a Hamilton syringe. Source parameters were optimized according to the 
heated electrospray ionization (HESI) probe manual.173  The capillary and vaporizer temperatures were 
set  to  360⁰C  and  350⁰C,  respectively.  The  sheath  gas  and  auxiliary  gas  were  set  to  40  and  15, 
respectively. The spray voltage was set to 3000 V. 
 
2.2.2 Optimisation of EFV ionisation and detection 
 
Sample was loaded onto a 10 cm reverse phase monolithic column (C18 silica-based, pore size 130 Å, 
Phenomenex) using the Accela 600 auto sampler (Thermo Scientific). The sample was separated over 20 
minutes using a standard gradient optimised for separation of peptides in complex mixtures. The mobile 
phase consisted of solvent A (0.1% FA in HPLC grade water, Sigma Aldrich) and solvent B (0.1% FA in 
ACN). Solvent B was increased from 2% to 60% over nine minutes, increased to 80% in one minute, 
followed by a hold at 80% for six minutes. Solvent B was then decreased to 2% in one minute, and held 
for four minutes to equilibrate the column before the next sample. Ionisation occurred via a heated 
electrospray ionisation (HESI) probe (HESI-II, Thermo Scientific). 
To optimize detection in complex mixtures, a full scan, or parent ion scan, was performed in positive 
and negative ionization mode.174–176 Different ionisation modes cause the fragmentation pattern of the 
molecule to differ, resulting in different product ions, which can improve the sensitivity when identifying 
the molecule in complex mixture.177  Changing the ionisation mode could also decrease interference by 
co-eluting molecules that ionise in one mode only. The TSQ was operated in full scan mode across a scan 
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range of 10-1500 m/z over 1.5 seconds. EFV in 100% ACN or methanol and in 50% ACN or methanol was 
injected and analysed with a full scan in both positive and negative mode. 
 
 
2.2.3 Developing a reliable drug detection assay using SRM 
 
Subsequent to detection of EFV in MS1, as well as the selection of solvent and gradient optimisation, a 
more selective and sensitive method was created using SRM to improve detection of EFV in complex 
samples. A product ion scan was performed and the resultant product ions were then verified using 
known and predicted tandem mass spectrometry (LC-MS/MS) EFV spectra from the human metabolome 
data base (HMDB).178 Subsequently, the raw files were imported into Skyline159 to obtain a product ion 
target list, which was achieved by selecting the highest ranking ions. Transitions are evaluated by Skyline 
according to signal intensity and interference.160 High ranking transitions have high signal intensity and 
low interference values. Transitions that were ranked poorly or had less than 1 Da mass difference to 
previously selected transitions were discarded. Once this list was completed, it was exported to the 
Xcalibur software (Thermo Scientific v2.2) and an SRM method was created to target the selected 
product ions. In order to increase overall peak area and sensitivity of detection, CE was optimised for 
each product ion by performing a manual ramping of CE ranging from 10 to 40 volts (V) in increments of 
10 V.179,180 Once the CE for each transition was optimized, a final transition list was generated for future 
detection assays. 
 
2.2.4 Standard curve of EFV in ACN 
 
Increasing concentrations of EFV from 3.9 ng to 2000 ng was reconstituted in 100% ACN in triplicate. 
Samples were analysed on the TSQ vantage using the optimised SRM assay in order to assess if the 
intensity of EFV increased linearly with the concentration. Raw data was imported into Skyline, and total 
peak area values were exported into GraphPad Prism (v7 for Windows) for statistical analysis and 
visualisation. Intensity values and concentration values were log2 transformed for ease of visualisation 
and a linear regression line was fitted to the graph. 
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2.3 Results 
 
2.3.1 Optimisation of instrument parameters and detection of EFV by direct 
infusion. 
 
EFV powder (99.4% purity) was reconstituted in 50% DMSO 10 µg/µl. Stocks were stored at -20⁰C until 
needed. When infused onto the TSQ, a 1:100 dilution of 1 µg EFV stock (10 µg/µl) in 2% ACN, 0.1% FA 
was not detected in positive or negative mode. Polyethylene glycol (PEG), characterised by 44 m/z 
repeating peaks, was detected in diluted DMSO samples. EFV was detected by infusion when 
reconstituted in 50% and 100% methanol or ACN. Detection optimisation was subsequently performed 
using 50% and 100% methanol or ACN (Figure 2.1). 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Optimisation of EFV detection in organic solvents. Neat EFV was solubilised in a) DMSO (50%), diluted in 2% ACN, and 0.1% FA. b) Methanol 
(50%), c) ACN (50%), and d) ACN (100%). The upper panel represents the total ion count from the infusion. The lower panel represents the mass spectrum, 
indicating the m/z value of the peaks in the total ion count. The repetitive peaks in a) are Polyethylene glycol (PEG) peaks. EFV was detected in 50% 
methanol, 100% methanol (not shown), 50% ACN, and 100% ACN. 
  
a) 
d) c) 
b) 
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2.3.2 Optimisation of EFV ionisation and detection 
 
When ionised, a molecule is either protonated (positive mode) or deprotonated (negative mode). The 
difference in charge results in a mass difference of 2 Da. Neutral EFV has a molecular mass of 315 g/mol, 
and was detected in negative mode with a m/z value of 314, as expected, as it becomes deprotonated. 
No EFV peak of 316 m/z was detected in positive mode when solubilised in either concentration of 
methanol or ACN (Figure 2.2). In negative mode, the intensity of the EFV peak did not differ significantly 
when reconstituted in 100% or 50% methanol or ACN. The average intensity value of the EFV peak in 
50% methanol was 8.19 x108 and 1.24 x109 in 50% ACN, although the ACN samples had a slightly higher 
average intensity the difference was not statistically significant (p = 0.061) (Figure 2.3). 
 
 
  
Figure  2.2:  Optimisation of  EFV  detection in  positive  and  negative ionisation mode.  The  upper  panels  (a) represent the TIC, and the lower 
panels (b) represent the respective extracted chromatogram (XIC). The XIC corresponding to the positive mode TIC shows a molecule with an m/z value of 
272. The XIC corresponding to the negative mode TIC shows a molecule with an m/z value of 314. EFV is expected to have an m/z value of 316 in positive 
mode and 314 in negative mode. The three smaller peaks in negative mode represent the isotopes of EFV.  
b) 
a) 
  
 
 
 
Figure 2.3: EFV detection in full scan mode when solubilised in 50% ACN and 50% methanol. EFV was detected when solubilised in ACN and in 
methanol (100% and 50%). ACN (upper panel, a) signal of1.31 x109 was slightly higher than the signal of 8.63 x108 in methanol (lower panel, b) although this 
was not significantly different (p = 0.061).  
  
b) 
a) 
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2.3.3 Developing a reliable drug detection assay using SRM 
 
CE ramping was performed to optimise the fragmentation of each transition. All of the product ions 
fragmented optimally at 20 V apart from the 69.01 ion that had the highest ranking at 30 V (Figure 2.4). Table 
2.1 shows the final list as imported into Xcalibur. The completed transition list consisted of five distinct and 
high ranking product ions for the parent molecule of EFV. The parent ion of EFV was 314 m/z, and the 
product ions were 69.01; 215.67; 242.13; 243.88 and 249.83 m/z.
  
Figure 2.4: CE optimisation for the EFV SRM assay. The collision energy (CE) for the five top ranking product ions was optimised with manual CE 
ramping. Each red peak in the upper panels represents the parent ion detection. The black peaks in the panels directly below represent the product ions. 
The collision energy measured in volts (V) causes different fragmentation of the product ions. The collision energy with the highest intensity product ions 
was selected for the final SRM list. In this figure, the product ion 69.01 was optimally detected at 30V, indicated by a red arrow. 
20 V) 
30 V) 
40 V) 
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Table 2.1: SRM transition list for EFV detection 
 Parent Product SRM Collision 
Energy 
Start Time Stop 
Time 
Polarity Trigger Reference Name 
1 314.019 69.014 30 0.00 30.00 - 0 No Efavirenz 
2 314.019 215.675 20 0.00 30.00 - 0 No Efavirenz 
3 314.019 242.137 20 0.00 30.00 - 0 No Efavirenz 
4 314.019 243.887 20 0.00 30.00 - 0 No Efavirenz 
5 314.019 249.837 20 0.00 30.00 - 0 No Efavirenz 
 
 
2.3.4 Standard curve of EFV in ACN 
 
The log2 transformed intensities of EFV peaks were found to increase linearly with increasing EFV 
concentration. The coefficient of determination (R2 value) was 0.9915. 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Standard curve for EFV. Neat EFV was solubilised in 100% ACN. The relationship between 
EFV concentration and intensity was linear between 3.9 ng and 2000 ng.
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2.4 Discussion 
To detect EFV in complex samples, a method was created using an EFV standard (99.4% purity). The 
reconstitution  solvent,  gradient,  and SRM method were optimised to  ensure  sensitive and reliable 
detection of EFV. 
 
2.4.1 Optimisation of instrument parameters and detection of EFV by direct 
infusion. 
In this work, the vehicle used for EFV was DMSO. DMSO has been suggested to improve ionization, 
especially in hydrophobic compounds, such as EFV,13,170–172  which was considered as an advantage for 
EFV  detection.   EFV  solubilised  in  DMSO  and  diluted  1:100  in  ACN  and  FA  resulted  in  large  PEG 
contamination peaks (Figure 2.1). This may have been due to the DMSO washing off contaminants stuck 
to the column , but considering the high concentration of EFV initially used(10 µg), it is possible that the 
contaminants were causing ionisation suppression of EFV, thus making EFV undetectable. DMSO is also 
known to leach plastic, and may have stripped the plastic lines, causing PEG contamination.181,182 
 
2.4.2 Optimisation of ionisation of EFV 
For further analysis, 50% ACN was used to reconstitute EFV, as the solvent is already used within the MS 
system,  and  ACN  peak  intensities  were  10-fold  higher  than  methanol  (Figure  2.3).  There  were 
insignificant differences found between 100% and 50% ACN reconstitution, although 50% reconstitution 
resulted in slightly higher peak intensities. The EFV peak of 314 m/z was not detected in positive mode 
when reconstituted with either ACN or methanol, indicating that EFV was unable to ionise in these 
conditions (Figure 2.2). All subsequent runs were performed in negative mode. 
 
2.4.3 Developing a reliable drug detection assay using SRM 
A total of five transitions were selected for the identification of EFV. For accurate detection of the 
molecule in question, it is recommended that there be no less than 12 data points acquired over the 
elution time of the molecule.169 EFV was found to elute over 25 seconds at 80% ACN. The cycle time was 
set to one second, resulting in a scan time for each transition of 0.2 seconds. This resulted in a total of 
25 data points for each transition over the elution of EFV, which is well above the minimum 
recommendation of 12 data points.
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2.4.4 Standard curve of EFV in ACN 
 
The standard curve for EFV in ACN indicated that the concentration and intensity values increased 
linearly. The R2  value of 0.9915 indicated that the linear regression was an accurate fit to the data 
(Figure 2.5). This confirmed that intensity could be used as a proxy for the relative concentration of EFV 
in further experiments. 
 
 
2.5 Conclusion 
Targeted MS using SRM can be used for drug detection assays. Optimisation for the detection of the 
analyte EFV was performed and ACN was selected as the solvent for reconstitution of EFV as it resulted 
in higher intensity values when compared to DMSO and methanol. EFV was detected in negative 
ionisation mode but not in positive ionisation mode. An SRM assay was created, resulting in five high 
quality transitions with optimised CE values for further analysis. Using the SRM assay, a standard curve 
for  EFV in ACN  was  analysed,  and indicated  that signal  intensity  and EFV concentration increased 
linearly. This allowed for further experiments to be performed using signal intensity as a proxy for 
concentration. All further work was performed using the optimised parameters specified in this chapter.
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Chapter 3: Optimisation of EFV extraction from cell culture media and cell 
suspension 
 
3.1 Introduction 
Pharmacokinetics is an investigation into the fate of a drug once administered, leading to information 
pertaining to its degradation or metabolism. The efficient extraction of a drug from a biological system is 
an integral part of a study aiming to describe the relationship between the two components. A biological 
system in this respect ranges from cell culture to human tissue. There are various extraction procedures 
such as solid-phase extraction, whereby sample is loaded onto a cartridge of silca beads and eluted with 
organic solvent .174,183 Liquid-liquid extraction partitions solutes based on their relative solubility in two 
immiscible liquids.175,184 Protein precipitation is performed with miscible organics solvents, which cause 
proteins to aggregate, leaving small molecules in the solvent.185–187 Proteins can also be depleted from 
the sample by use of proteinase K.185,188 
 
When using MS for drug detection, complex samples such as cell supernatant or cell lysates compete 
with the analyte  for charge, resulting in ion suppression and reducing the sensitivity of detection. 
Simplifying  the  sample  also  improves  the  sensitivity  and  specificity  of  the  experiment  as  an  MS 
instrument has a limited dynamic range. By reducing sample complexity, accurate detection of a low 
abundance target is more likely. Ostensibly, protein precipitation is the fastest and most cost-effective 
method of small molecule extraction, and requires very little method development,185,189 and as such, it 
was the starting point for drug extraction optimization. Organic solvents such as ACN, methanol, and 
chloroform among others can be used to extract small molecules such as EFV by precipitating the 
protein and retaining the supernatant.185,190,191    Although all methods lead to the majority of proteins 
being precipitated, the detection of the small molecule by MS is dependent on the solvent used for 
extraction as well as the properties of the small molecule.185 
 
EFV is soluble in ACN, methanol, and chloroform, all of which have been routinely used for protein 
precipitation in various drug extraction techniques with plasma samples.184,185,187,188,191–193 ACN and 
chloroform-methanol (CM) were used as the solvents for drug extraction optimisation.
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3.2 Materials and methods 
3.2.1 Drug extraction optimisation using protein precipitation methods 
 
Fresh DMEM: Hams F12 media (Invitrogen, Gibco) was spiked with 1 µg of EFV per 1 ml of media. 
Untreated cells were pelleted and resuspended in 1 ml fresh media, as the phenol red component of the 
media was needed for subsequent steps during method development. The cell suspension was then 
spiked with 1 µg of EFV. All protein precipitation was performed in 400 µl flat bottomed glass vials 
(Separations) so as to avoid leaching of plastic by the organic solvents. The optimisation was performed 
with three experimental replicates for each extraction method applied to both the cell suspension and 
supernatant. The organic solvents had a dual purpose of lysing the cells and precipitating the proteins. 
 
3.2.1.1 CM protein precipitation 
A CM (both HPLC grade, Sigma Aldrich) solution (2:1) was added to 100 µl of the supernatant or cell 
suspension fractions (4:1). The samples were shaken on vortex for 20 seconds, incubated at room 
temperature for 40 minutes, then transferred to 1.5 ml polypropylene high-quality reaction tubes 
(Eppendorf), and centrifuged at 15 000 g for five minutes at 23°C (LabNet Z233MK2 Microcentrifuge). 
EFV is a polar molecule and was therefore retained in the methanol-water phase (upper phase) which 
was isolated for further processing.194 The middle and lower phases contained chloroform and non-polar 
molecules and were discarded. 
 
3.2.1.2 Acetonitrile precipitation 
ACN (100%, HPLC grade, Sigma Aldrich) was added to spiked media and cell suspension fractions in a 3:1 
ratio.  Samples  were  vortexed  for  20  seconds,  incubated  at  room  temperature  for  40  minutes, 
transferred to high quality reaction tubes, and centrifuged at 15 000 g for five minutes at 23°C. The 
supernatant was retained and the pellet containing the protein was discarded. Retained supernatants 
from both precipitation methods were then transferred into 400 µl flat bottom glass inserts and dried at 
30⁰C in an SPD SpeedVac (ThermoSavant) for approximately one hour. Dried samples were then 
resuspended in 50 µl 50% ACN, transferred into auto sampler vials with 100 µl tapered glass inserts 
(Separations) and analysed on the TSQ Vantage in full scan and SRM mode (section 2.3.3).
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3.2.2 Assessment of inter- and intra- daily sample variation 
 
The relative drug concentration in cell culture was to be measured over the course of 72 hours, which 
required supernatant and cell suspension samples to be harvested on three subsequent days.  It was 
therefore necessary to ensure the accuracy of the standard curve to predict concentrations, as well as 
the consistency over time of the chromatogram intensity as a predictor of drug concentration. The 
volume of  sample  for extraction as well as  the effect of  sample  processing on different  days  was 
assessed. On three consecutive days EFV extraction was performed on three replicates, each containing 
1 ml of media spiked with 1 µg of EFV. The drug was extracted from 100 µl of each replicate using the 
ACN method (section 3.2.1.2). A further three 100 µl extractions were performed from one replicate, to 
assess whether the 100 µl volume was sufficient for reproducibility (triplicate extraction). This resulted 
in three experimental replicates and a subset of three technical replicates for each day. In order to 
assess whether day to day variability was caused by processing on different days, 100 µl from each 
replicate was stored in glass auto sampler vials (Separations) at -20°C in 75% ACN. Once three samples 
were collected from three consecutive days and stored at -20°C for at least 24 hours, samples were 
processed according to the ACN method (section 3.2.1.2). The workflow is represented in figure 3.1. The 
batch-to-batch variability was quantified by calculating the percentage coefficient of variation (CV), with 
a lower value indicating higher precision. A value of <20% was considered to be an acceptable level of 
precision as indicated by the Food and Drug Administration (FDA) guidelines for method validation.195
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Figure 3.1: Workflow to assess daily variability of sample processing. Representation of day 1 of 
EFV extraction with ACN protein precipitation. Fresh media was spiked with 1 µg of EFV per 1 ml of 
media. Samples were either processed immediately on sequential days or stored at -20⁰C for at least 24 
hours, until all samples were collected over three days. A set of triplicates was processed from one of 
the replicates and processed immediately on sequential days. This work flow was followed over three 
sequential days.
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3.2.3 Decreasing inter- and intra- daily sample variation 
 
3.2.3.1 Assessment of plastic leaching with ACN in high quality reaction tubes during protein 
precipitation. 
High quality reaction tubes were needed for protein precipitation in order to obtain a protein pellet via 
centrifugation. PEG is a common contaminant in MS which causes ion suppression, specifically in ESI-MS, 
and a resulting decrease in resolution and sensitivity.132,196 The binding of PEG to the column also limits 
peptides binding to the column,197 causing poor chromatography of the peptide mixture. Polypropylene 
tubes (Eppendorf) have been specifically enhanced to resist damage by various chemicals, and are 
resistant to ACN for up to 24 hours.198 In order to ensure that plastic leaching did not occur in MS 
detectable amounts, protein precipitation was performed for 20, 40, and 60 minutes. Full scans were 
performed in positive and negative mode. Equivalent glass and plastic EFV extractions were compared 
on the TSQ in full scan and SRM mode (section 2.3.3) to observe any effect on the detection caused by 
method of extraction. After pelleting the protein, the supernatant was transferred to a glass tube and 
dried down. Due to the higher extraction volume, a larger pellet remained and resolubilisation with 50% 
ACN was increased from 50 to 200 µl. 
 
3.2.3.2 Increasing the number of replicates and the starting volume of extraction 
To mitigate the high degree of observed variability the number of experimental replicates was increased 
to four, as variation decreased when a higher number of replicates were processed (data not shown). 
Extractions were performed with the whole 1ml of media spiked with 1 µg EFV over three days, as 
opposed to 100 µl from 1 ml (section 3.2.2).  As the volume for extraction was increased, larger reaction 
tubes were needed for the protein precipitation step. High quality reaction tubes were used as an 
alternative to glass tubes as the latter required a specialised centrifuge to obtain high enough speeds to 
pellet the proteins. Plastic leaching tests indicated that protein precipitation could be performed for up 
to 60 minutes with no PEG contamination. 
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3.2.3.3 Extraction of EFV from the organic phase 
A phase separation was observed when the volume of 50% ACN for pellet solubilisation was increased to 
200 µl, which consisted of water and ACN fractions. The separation was highlighted by the presence of 
phenol red in the water fraction. The resolubilised EFV/phenol red solution (200 µl) was transferred into a 
400 µl glass auto sampler insert (Separations) and centrifuged at 2000 g for one minute in a reaction tube 
to maximise the phase separation. The upper ACN layer was carefully removed using a micropoint 200  µl  
gel  loading  pipette  tip  (Corning),  ensuring  that  the  entire  fraction  was  removed.  Any contamination 
by the aqueous fraction quickly migrated to the bottom of the glass insert and was carefully removed with 
the micropoint tip. Both the aqueous and organic fractions were analysed on the TSQ Vantage in positive, 
negative, full scan, and SRM mode (methods described in chapter 2). The needle height from the 
bottom of the vial was also increased to 3 mm, and the syringe speed was decreased to 0.8 µl/second in 
order to prevent contamination by any residual phenol red left at the bottom of the vial. 
 
3.2.4 Comparing gradient elution and isocratic elution for detection 
optimisation 
 
To minimize analysis time, an isocratic elution that held at 75% solvent B for four minutes was assessed. 
The sensitivity of the isocratic elution was compared to the 20-minute gradient elution using the 
optimised SRM method (section 2.3.3). The equilibration time at the end of the gradient was 
subsequently extended to 15 minutes. 
 
 
3.2.5 Data analysis for SRM in Skyline 
 
Raw SRM data was imported into Skyline which contained the transition list from the optimization steps 
as described in section 2.2.3. In Skyline, the raw data was processed and generated an output file. The 
area under the curve for each transition or product ion was summed to obtain the total intensity of EFV 
in each sample. Each product ion was measured 25 times during the elution of the molecule over 25 
seconds. The total area values were exported to GraphPad Prism for statistical analysis and graphical 
representation.  Daily  variability  was  assessed  with  CV  values  and  a  one-way  analysis  of  variance 
(ANOVA) test.
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3.3 Results 
 
3.3.1 Drug extraction optimisation using protein precipitation methods 
 
Samples from ACN and CM drug extraction methods were analysed on the TSQ in both full scan and SRM 
mode. Full scan analysis showed the EFV peak (m/z = 314) was detected with the ACN extraction but not 
with the CM extraction (Figure 3.2, upper panels). Using the SRM method, EFV was detected in both 
conditions (Figure 3.2, lower panels). The CM method resulted in less smooth peaks with lower intensity 
and higher background noise than the ACN method (Figure 3.3). The average intensity for the CM 
method was 1.17x105   and the average intensity for the ACN method was 1.57x107, two orders of 
magnitude higher than that of the CM method (CV = 9.6% and 4%, respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Detection of EFV after protein precipitation extraction. EFV was extracted by a) chloroform- methanol (CM) or b) ACN protein precipitation. 
The upper panels (black peaks) represent the full scan (MS1). The lower panel (red peaks) shows the detection of EFV by SRM (MS2). EFV is not detected in 
the CM precipitation full scan, but is detected in the SRM. EFV is detected in both the full scan and SRM mode with ACN protein precipitation. EFV in the ACN 
extraction full scan is indicated by a red arrow. This peak was not present in the CM extraction full scan 
b) 
a) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Transition peaks of EFV after protein precipitation extraction. The average peak intensity was two orders of magnitude lower with a) 
chloroform-methanol (CM) extraction compared to b) ACN extraction. The smooth peaks in the ACN extraction are due to higher signal intensity and less 
background noise, indicating a more efficient extraction. The intensity of the SRM peak was 1.17x105 for the CM method, and 1.57x107 for the ACN method. 
a) 
b) 
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3.3.2 Assessment of inter- and intra- daily sample variation 
 
The CV of each set  of replicates in both conditions over three days was assessed. When samples 
containing 1 µg/ml of EFV were processed on sequential days, none of the three sets had acceptable CV 
values (CV > 20%). Samples processed on the same day after storage at -20⁰C only had one of three sets 
with acceptable CV values. The triplicate extraction to assess whether the volume of extraction was 
sufficient for reproducibility had two of three sets with acceptable CV values (Table 3.1). A one-way 
ANOVA test performed on replicates processed on sequential days indicated that the intensities of EFV 
measured on each day were significantly different (p < 0.005) from each other. Samples stored at -20⁰C 
and processed on the same day were also found to be significantly different from each other (p < 0.005). 
 
 
Table 3.1: CV values for EFV extraction to assess inter- and intra-daily variation 
Processed on 
sequential days 
Processed on same day 
(freezer) 
Processed on same day 
(triplicate) 
Four replicates, 1 ml 
starting volume 
Day 1      0.479 0.230 0.315 0.174 
Day 2      0.253 0.173 0.147 0.372 
Day 3      0.485 0.515 0.163 0.254 
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3.3.3 Decreasing inter- and intra- daily sample variation 
 
 
3.3.3.1 Assessment of plastic leaching with ACN in high quality reaction tubes during protein 
precipitation 
High quality reaction tubes with 75% ACN were used to assess plastic leaching. No PEG was detected in 
any samples when incubated at room temperature for up to 60 minutes in positive or negative mode full 
scans (data not shown). Drug extraction in glass vials or plastic reaction tubes did not differ significantly 
based on EFV intensity values (data not shown) 
 
 
3.3.3.2 Increasing the number of replicates and the starting volume of extraction 
Processing the whole 1 ml of four replicates on sequential days resulted in a decrease in CV values when 
compared to processing 100 µl from three replicates on sequential days, but not when compared to 
stored samples processed on the same day (Table 3.1). A one-way ANOVA showed that there was no 
significant  difference  between  EFV intensities  detected on different  days when  four  samples were 
processed with a 1 ml starting volume (p > 0.05). 
 
 
3.3.3.3 Extraction of EFV from the organic phase 
Performing the extraction on the full 1 ml resulted in organic and aqueous phases containing EFV and 
phenol red respectively. EFV was not detected by the full scan in the aqueous fraction, but was detected 
by a full scan in the organic fraction (Figure 3.4 a and 3.5 a). EFV was detected by SRM with intensity 
6.46 x103  and 3.39 x105  in the aqueous and organic fractions respectively (Figure 3.4 and 3.5). The 
blank sample after the water fraction showed a large phenolic acid contaminant peak that was not 
present after the ACN fraction (Figure 3.6).
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: EFV extraction from the aqueous phase. A phase separation resulted in an organic and aqueous phase. The upper panel (a) represents the TIC 
from the aqueous fraction. The peak at 15.96 represents a molecule of 354 m/z, the mass of phenol red, indicated by a red arrow. The lower panel (b), 
shows the SRM chromatogram, whereby EFV was detected. The lack of smooth lines indicates low intensity of the detected analyte. 
 
 
 
 
a) 
b) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: EFV extraction from the organic phase. The upper panel (a) represents the TIC from the organic phase. EFV was detected at 18.51 in the full scan 
(indicated by a blue arrow), as well as phenol red at 15.93 (indicated by a red arrow). The lower panel (b) shows the SRM chromatogram, the smooth lines indicate 
high signal intensity and low background noise 
 
a) 
b) 
  
 
Figure 3.6: Blank runs after aqueous and organic phase EFV extraction. The upper panel (a) shows the blank run directly after an aqueous phase EFV 
sample. The large contamination peak was identified as phenolic acid. The lower panel (b) shows a blank sample run directly after an organic phase EFV 
sample. The TIC shows the gradient and is typical of a blank sample with no contamination..
b) 
a) 
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3.3.4 Comparing gradient elution and isocratic elution for detection optimisation 
 
The gradient elution resulted in much narrower peak widths as well as higher intensity values when 
compared to the isocratic gradient. The average intensity value for isocratic elution was 1.36x104, which 
was 24-fold lower than the gradient elution with an average intensity of 3.24x105 (Figure 3.7). There was 
a shift in retention time of EFV over multiple sample analyses (Figure 3.8). The extension of post- 
gradient equilibration time resulted in a reproducible elution of the analyte over multiple consecutive 
analyses (data not shown).
  
Figure 3.7: Comparison of isocratic and gradient methods. The upper panel (a) shows the isocratic elution of EFV. The analyte elutes at 3.01 on a 7 
minute run with an intensity of 7.97 x103. The lower panel (b) shows the gradient method, with the analyte eluting at 18.53 on a 30 minute run with the 
intensity of 1.08 x106.
a) 
b) 
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3.4 Discussion 
Protein precipitation was performed with organic solvents ACN and CM to optimise extraction of EFV 
from media and the cell lysate. Optimisation steps were performed to improve reproducibility between 
days, as well as the chromatographic gradient. 
 
3.4.1 Drug extraction optimisation using protein precipitation methods 
 
The signal intensity of EFV in ACN was shown to increase linearly with increasing concentration, 
indicating that intensity could be used as a proxy for analyte amount (Chapter 2, section 2.3.4). For 
assessment of extraction efficiency, higher signal intensity indicates a higher relative abundance, and 
thus a more efficient extraction method. EFV intensity was 1.57x107 and 1.17x105 for ACN and CM 
extraction respectively, indicating that ACN was ~100 times more efficient at extracting EFV from spiked 
media and lysate than the CM method (Figure 3.2 and 3.3). It is interesting to note the inefficiency of 
CM extraction as EFV is soluble in and was detected in methanol (Chapter 2, section 2.3.1). Methanol is 
often a preferred solvent for drug extraction, although its efficiency depends on the properties of the 
small molecule being extracted.185 Photolysis of EFV (the decomposition or separation of the molecule 
by the action of light) is affected by the solvent in which it was reconstituted in.199 A bathochromic shift 
indicates a change in the absorption of light by the molecule, caused by photolysis. EFV solubilised in 
chloroform showed a larger bathochromic shift than methanol, and the smallest effect was that of 
ACN.199 This may be caused by stabilization of the polarized imidic acid phototautomer of EFV, which 
occurred with chloroform and methanol, as they both have strong hydrogen bond donor ability, as 
opposed to ACN which has no hydrogen bonding ability.199 It is possible that the lower efficiency of the 
CM method to extract EFV was due to the solvents enabling photolysis during the sample preparation. 
Another explanation for the lower efficiency of the CM extraction method could be that the EFV fraction 
was contaminated by proteins and lipids, caused by the inability to discern the phase separation, which 
may have resulted in ion suppression and thus lower detection efficiency. It is also plausible that the CM 
method, often selected for top-down proteomics as it does not fully denature proteins during the 
precipitation process, resulted in EFV remaining bound to non-denatured precipitated proteins.200
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3.4.2 Assessment of inter- and intra- daily sample variation 
 
Inter- and intra- daily variation between samples was assessed in three ways. Samples processed on 
sequential days were all significantly different from each other and had high CV values. Samples 
processed on the same day after storage were also significantly different from each other and had high 
CV values. The triplicate extractions from a single replicate had two CV values < 20% and one triplicate 
with  CV  >  20%.  The  outlier  triplicate  set  from  the  first  day  of  processing  had  significantly  lower 
intensities than the two following days. This trend was also observed in the first day replicates of 
samples processed on sequential days, as well as those stored at -20⁰C and processed on the same day, 
which suggests that the low intensity was due to an error either in the initial spiking of EFV into the 
media, or due to pipetting error during the 100 µl extraction for processing and/or storage steps (Table 
3.1). These results indicated that the inter- and intra- daily variation was too high to use this assay as a 
semi-quantitative method for detection of EFV within cell culture. It was hypothesised that higher 
starting amounts for processing and thus a higher final concentration of EFV would ensure that the 
lower limit of EFV detection was not reached, as well as preventing pipetting error when removing a 
small volume for processing. 
 
 
3.4.3 Decreasing inter- and intra- daily sample variation 
3.4.3.1 Assessment of plastic leaching with ACN in high quality reaction tubes during protein 
precipitation 
Intra- and inter-daily variation posed a problem for determining relative concentration of the drug over 
three days. In order to increase the initial volume of extraction, high quality reaction tubes were first 
tested for resistance to ACN, in order to avoid damage to the LC column or PEG contamination due to 
plastic leaching. Although the manufacturer assures resistance to ACN for up to 24 hours incubation in 
polypropylene products,198,201 the reaction tubes were tested for resistance before proceeding. No PEG 
was detected  for up  to  60  minutes of  incubation (data  not shown).  Protein precipitation was not 
affected by incubation in plastic reaction tubes as opposed to glass vials, which indicated that further 
work could be performed without risk of contamination or decreased efficiency in the larger plastic 
reaction tubes. 
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3.4.3.2 Increasing the number of replicates and the starting volume of extraction 
Increasing the starting volume for extraction to 1 ml and the number of processed replicates to four 
ensured that there was no significant difference between the intensity values between each day, and 
slightly improved CV values (Table 3.1). This may have been simply due to lower pipetting error at higher 
volumes. Alternatively, extracting 1 µg of EFV in 1 ml as opposed to 100 ng in 100 µl may have mitigated 
variation caused by MS accuracy at the lower end of the limit of detection.  Increasing the number of 
experimental replicates to four allowed for the detection and potential removal of outliers while still 
maintaining three replicates for statistical validity. Outliers and variation between samples may be as a 
result of the manual extraction procedure. As the number of steps required during a procedure 
(operational complexity) increases, the possibility of variation due to error increases.202  Automation of 
procedures often minimises operational complexity, as well as “hands-on time”, resulting in lower %CV 
values  between  replicates.202,203   Processing  four  replicates  on  sequential  days  did  not  significantly 
reduce the %CV values when compared to the samples processed after -20⁰C. Due to processing the 
samples manually, the stored four experimental replicates per condition over three days would have 
had to be processed in daily batches to reduce the operational complexity. It was therefore decided to 
process the samples daily without freezing. 
 
 
3.4.3.3 Extraction of EFV from the organic phase 
ACN is miscible in water, but when a larger volume of 50% ACN was used to reconstitute the EFV pellet 
after extraction, a phase separation was visible. Phase separation of miscible organic solvents and water 
due to “salting-out” has been well documented.204,205  The extraction of organic solutes can also be 
performed with ACN and water, with or without salt.206 The phase separation observed was likely to be 
as a result of the phenol red, a polar organic molecule used in tissue culture.206 EFV is relatively insoluble 
in water (0.093 mg/L) ,194 and thus was expected to be present mostly in the organic ACN phase. Phenol 
red (354 g/mol) separated mostly in to the aqueous phase, but was still present in the organic phase as 
it is soluble in both water and ACN. The peak at 15.96 in the full scan in both the aqueous and organic 
fractions had an m/z of 353, identifying it as phenol red ionised in negative mode (Figure 3.4 and 3.5). 
A full scan only detected EFV in the organic phase, indicating a higher concentration than the aqueous 
phase.  The SRM assay confirmed this, as the EFV intensity was ~100 fold higher in the organic phase 
than in the aqueous phase. In addition, a large contaminant of 352 m/z was present in the blank sample 
(2% ACN) following the water fraction, identified as a phenolic acid.207   Therefore only the organic 
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fraction was analysed in further experiments, as the blank samples following the organic phase samples 
did not contain the contaminant, indicating that the organic phase samples were also somewhat less 
complex (Figure 3.4 and 3.5). 
 
3.4.4 Comparing gradient elution and isocratic elution for detection 
optimisation 
 
An isocratic elution is preferable for analysis of simple samples, or samples that occupy 20 – 40% of the 
separation space in a scouting gradient run.208 Other studies have found that a gradient elution is faster, 
more selective, and has a higher resolution even in samples that are specifically suited to an isocratic 
elution.209    Sensitivity and resolution were both increased when using the gradient elution, with an 
average intensity of 3.24x105 compared to 1.36x104 for the isocratic elution, resulting in a sharper peak 
with a higher intensity (Figure 3.6). A gradient elution separates molecules within a complex mixture, 
causing them to elute at different times based on their hydrophobicity. Control over the elution of an 
analyte in a complex mix allows for simplification and optimisation of the detection of the analyte of 
interest. 
As fewer molecules elute at a time, ion suppression is less likely to occur. Ion suppression is most 
commonly caused by endogenous organic or inorganic molecules that are present in the samples to be 
analysed after extraction.210  Highly polar molecules such as phenol red or organic molecules such as 
lipids and peptides are ion suppressor agents. Exogenous molecules such as PEG are also considered ion 
suppressor agents.210,211 The presence of these non-volatile or less volatile molecules can cause a 
decrease the evaporation efficiency of the droplet, causing fewer analytes to reach the gas phase.210,211 
Another cause of ion suppression is due to competition of compounds for the maximum ionisation 
efficiency.210  Molecules of higher mass and more abundant molecules are more likely to supress lower 
mass and less abundant molecules.211 As fewer analytes are ionised, the signal is decreased, which leads 
to a decreased detection ability or inability to detect the analyte. In order to minimise the unpredictable 
effects of ion suppression it is therefore preferable to use the gradient method over the isocratic elution 
for further experiments. Phenol red, lipids, and other molecules remain in the organic phase after 
extraction with ACN, as this protein precipitation method does not remove these molecules. The 
increased sensitivity and specificity of the gradient method was also advantageous for detection of EFV 
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in the lysate with low cell numbers, when the total volumetric space available and thus the total 
concentration of EFV would be lower. 
Over several runs, the retention time of the EFV peak of the gradient method drifted from elution at 
14.46 to 19.93 minutes (data not shown). This drift indicated that the equilibration of the column 
may not have been sufficient prior to sample introduction. Equilibration of the column ensures that 
the entire column is covered uniformly with 2% solvent B. Incomplete equilibration results in areas 
of the column containing a higher percentage of solvent B, which would change the binding of the 
analytes to the column, thus causing drifting retention times between samples. Subsequent to the 
increase of equilibration time, the retention time remained stable (data not shown). For adequate 
equilibration, it is recommended to be between two and ten column volumes.209 At a flow rate of 
300 µl/minute, the five minute equilibration time amounted to approximately two column volumes. 
The extended 15 minute equilibration amounted to six column volumes.
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3.5 Conclusion 
 
Optimisation of EFV extraction, sample processing, and the elution gradient was performed. ACN 
precipitation was selected over CM precipitation for EFV due to higher extraction efficiency. Inter- and 
intra- sample variation was deemed too high for semi-quantitative analysis when processing 100 µl from 
three replicates, necessitating a higher starting volume and more replicates. In order to prevent damage 
to the LC column and a decrease in analyte detection sensitivity, the extraction method in high quality 
reaction tubes was tested for PEG contaminants prior to increasing the starting volume for processing. 
PEG was not found as a contaminant for up to 60 minutes incubation and detection by SRM was not 
decreased by this method. The inter- and intra- daily variation between samples was decreased when 1 
ml of four replicates was processed. EFV detection was further improved by extraction of the organic 
phase containing the majority of EFV, as well as the use of a gradient elution as opposed to an isocratic 
elution. The equilibration time at the end of the gradient was also increased to prevent retention time 
drift over an extended period of time. The optimised methods for EFV extraction were used for all 
further analysis.
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Chapter 4: Relative EFV concentration in neuronal cell culture over three 
days 
 
4.1 Introduction 
EFV  is  a  small  lipophilic  molecule  that  diffuses  passively  across  most  cell  membranes,  with  a  low 
solubility and a high permeability.212  It is highly bound to plasma proteins (99.5%) and is only able to 
pass through the BBB in its unbound form. Entry into CNS is by passive diffusion with no active transport 
back into the systemic circulation.65,213 Although only a small amount of EFV is able to pass through the 
BBB into the CNS, it is still estimated to be 26 times higher than the IC50 for wild type HIV-1.65  CSF 
measurements are considered to be an acceptable estimate of the brain tissue drug concentration, and 
are more safely obtained from patients.214,215 
During HIV treatment with ARV drugs, it is vital to ensure that the drug plasma concentration always 
remains above a certain level in order to achieve systemic viral suppression, and below a certain level in 
order to minimise toxicity.216 Once the elimination of the drug is balanced by the administration of the 
drug - when the average concentration of the drug remains the same over time - it is said to have 
reached a steady state. EFV reaches its steady state within 6-10 days after initiation of dosing. The half- 
life is between 40-55 hours, although this varies greatly depending on the metabolism of the drug in 
individuals, which can be altered by genetic polymorphism.217–219 
A challenging factor in modelling the effect of EFV on the development of proliferating NES cells is 
adequately imitating the in vivo pharmacokinetics of EFV in vitro. In order to gain deeper understanding 
of the chemical stability of the drug, as well as the mechanism of degradation, forced degradation 
studies have been previously performed using a range of pH values in various buffer formulations.220–223 
EFV degradation follows first order kinetics in buffers ranging from pH 0.6 – 12.8 at 60°C, whereby the 
drug is eliminated at a rate proportional to the drug concentration. 
The stability of EFV in solution was optimal at a neutral pH and did not degrade when exposed to 
temperatures up to 70°C, even after 30 days of exposure.222  In a more acidic solution of pH4, EFV was 
stable in solution up to 60°C. In basic solutions, EFV tended to degrade more rapidly.220–222 
NES cells are grown in serum free media supplemented with growth factors. The pH of the media ranges 
from pH 6-8 over three days when kept at 37°C and 5% CO2. It is therefore important to understand the 
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degradation profile of EFV in these specific cell culture conditions to properly model the treatment- 
elimination profile.  
In vivo, EFV is metabolised primarily by the cytochrome p450 CYP2B6, mostly in the liver. EFV regulates 
its own metabolism by activating the constitutive androstane receptor that induces CYP2B6 
transcription.48 Mutations of CYP2B6 have been linked to elevated EFV concentrations in plasma, as well 
as various CNS side effects  associated with EFV treatment and early discontinuation of 
treatment.117,224,225  CYP2B6 is found in the liver and in the CNS parenchyma, including neuronal, glial, 
and epithelial cells. CYP2A6 and CYP3A4, secondary metabolisers of EFV, are not found in any CNS tissue 
(Human Protein Atlas available from www.proteinatlas.org).226  CYP2B6 follows atypical kinetics in the 
liver, and its activity in the CNS tissue differs from that in the liver.227–229  Over an extended treatment 
period in mice, CYP2B6 expression increases dramatically after an initial delay with the onset of 
treatment. This may indicate that CYP2B6 induction only occurs once a steady-state is reached or higher 
levels  of  EFV  begin  to  accumulate  and  that  a  higher  rate  of  metabolism  occurs  with  extended 
exposure.229 
This chapter aims to establish a dosage regimen that mimics the in vivo EFV exposure in a developing 
neural system. First, the movement of EFV in cell culture was assessed in order to clarify whether EFV 
crosses the membrane of the NES cells. Next, the degradation of EFV in cell culture conditions was 
assessed in order to gain insight into whether the components of the media at 37°C and 5% CO2 would 
affect the stability of the drug. Assessing the degradation of EFV through relative concentration studies 
would also indicate whether EFV is metabolised by the NES cells. 
By  analysing  the  movement  and  degradation  patterns  of  EFV  within  these  culture  conditions,  a 
treatment schedule can be designed in order to attempt to approximate the exposure of NES cells to 
EFV in vivo. EFV in the form of an FDC is administered once every 24 hours, reaching a steady state 
within approximately ten days.39,218 This work aims to assess EFV in NES cell culture over three days, with 
dosing at estimated biologically relevant concentrations every 24 hours.62,71,72,230
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4.2 Materials and methods 
 
4.2.1 Cell culture preparation 
 
This study used human-derived non-transformed NES cells which were kindly donated by the Austin- 
Smith group at the Cambridge Stem Cell Institute. The cell line was derived from 5-6 week old foetal 
hindbrains (Carnegie stage 15–17),123 and were maintained in culture as follows: Adherent dishes were 
coated with proteins to provide an environment conducive to NES cell adherence and growth.231 Plates 
were coated with Poly-L-Ornithine (100 µg/ml in phosphate buffered saline (PBS) (Invitrogen Gibco) and 
incubated for 30 minutes at 37˚C. The plates were then washed with PBS and coated with laminin (2 
µg/ml in PBS) for 8-12 hours at 37˚C. The laminin was washed off with PBS and could either be stored at 
4˚C for up to three weeks or used immediately. 
 
 
4.2.2 Media and supplements used for tissue culture 
 
The minimal amount (5 ml) of DMEM: Hams F12 medium (Invitrogen Gibco), supplemented with 
penicillin/streptomycin (1:100 v/v, Lonza), N2 supplement (1:100 v/v, Invitrogen Gibco), B27 supplement 
(1:1000  v/v,  Invitrogen  Gibco),  epidermal  growth  factor  (EGF,  0.01  ng/µl,  Invitrogen  Gibco)  and 
fibroblast growth factor 2 (FGF2-b, 0.01 ng/µl, Invitrogen Gibco) was added to pre-coated plates. Cells 
were seeded onto adherent cell culture plates (TPP) by spotting onto plates containing pre-warmed 
media. The plates were rapidly slid back and forth to ensure even distribution of the cells and incubated 
at 37°C, 95% humidity and 5% carbon dioxide (CO2). Once confluence was reached (roughly every three 
days), cells were lifted using Tryp-LE (Gibco), and transferred onto a larger plate, ensuring cell density 
remained at minimum between 3-4x104   cells/cm2, as cell to cell contact is necessary for optimal 
maintenance of the culture.123 Media was changed every 24 hours. 
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4.2.3 Standard curve 
 
A standard curve was created to assess the relationship between signal intensity and EFV concentration 
in both the supernatant and lysate. Fresh media (1 ml) with and without cells was spiked with 1, 0.5, 
0.25, 0.125, 0.0625, 0.03125 µg/ml of EFV; extracted as described in chapter 3, section 3.2.1.2; and 
analysed on the TSQ according to the method described in chapter 2 section 2.2.3. All data analysis was 
performed as described in chapter 3, section 3.2.5. The intensity and concentration values were log2 
transformed for ease of interpretation. 
 
 
4.2.4 DMSO viability assay 
 
The vehicle for drug delivery used in this work was DMSO. Previous work in the Blackburn Laboratory has 
shown that up to 0.5% DMSO does not affect the viability of SHSY-5Y cells. To ensure that the same was 
true for NES cells, a DMSO dose response was performed with a doubling concentration from 0.125 to 
2%. The proposed treatment vehicle concentration (0.05%) was also tested. Cell viability was assessed 
using 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT). At each time point the media 
was removed, cells were gently washed with warmed PBS to remove dead cells, and 0.5 mg/ml of MTT in 
base media was added to each well (1 ml). The cells were then incubated for 30 minutes. The media was 
then aspirated and 200 µl DMSO (100%) was added to solubilise the formazan crystals. This was followed 
by gentle agitation for 10 minutes at room temperature. The formation of purple formazan crystals is 
used as an indicator of cell viability. Absorbance values were recorded by the iMark microplate reader 
(Biorad) at 595 nm and analysed in the Microplate Manager software. Viability was measured as a 
percentage of the control (100% viability), and a t-test was performed to confirm significance. 
 
 
4.2.5 Drug internalization by cells 
 
Once  EFV  was  successfully  spiked  into  and  extracted  from  media  and  cell  lysate  fractions,  it  was 
necessary to determine whether EFV was able to enter the NES cells as well as whether the ACN drug 
extraction followed by MS analysis was sufficient to detect the potentially low levels of EFV within the 
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cells. Based on a review of the literature, the estimated foetal plasma as - opposed to the foetal CNS 
concentration - of 1.05 µg/ml was  used as the treatment concentration as there are currently mixed 
reviews estimating that the gestational age of BBB formation ranges from eight weeks to mid-gestation 
in non-human primates.232–234  Cells were seeded, left to settle overnight, and then treated with 0.525 
(half of the estimated concentration), 1.05, and 2.1 (double the estimated concentration) µg/ml of EFV. 
After 24 hours the supernatant was collected, and the cells harvested. Both fractions were subjected to 
ACN protein precipitation and analysed on the TSQ. Statistical analysis and visualization were performed 
with Skyline, Excel, and Prism (methods described in chapter 3, section 3.2.1.2 and 3.2.5). 
 
 
4.2.6 Relative concentration of EFV over three days 
 
EFV  was  administered  to  NES  cells  every  24  hours  to  approximate  the  current  therapeutic  dosing 
schedule of  EFV.218   The  relative  concentration was measured by MS every 24 hours to  assess the 
accumulation or degradation of EFV. 
Adherent six-well plates were seeded with NES cells and allowed to settle overnight (12 hours) after 
which fresh media containing 1.05 µg/ml EFV was added to each well (T0). From this point, the two 
conditions being tested were as follows: 
Condition 1 – every 24 hours, media containing EFV was removed and the cells were washed with pre- 
warmed PBS. The old media was replaced with fresh media containing 1.05 µg/ml EFV (re-treatment). 
Condition 2 – every 24 hours, media containing EFV was removed and cells were washed with pre- 
warmed PBS. Fresh media only was added (single treatment). 
After  treatment  at  24  hours,  48  hours,  and  72  hours,  four  replicates  from  each  condition  were 
harvested. The media (supernatant) was removed and retained. The cells were then washed with pre- 
warmed PBS to remove dead cells and any residual EFV, lifted, and pelleted in fresh tubes. The cell pellet 
was then resuspended in 1 ml fresh media. EFV was extracted with the ACN precipitation technique, 
which caused cell lysis and protein precipitation.   The samples were analysed on the TSQ using the 
optimised SRM target list. Every 24 hours, four T0 replicates of fresh media spiked with 1.05 µg/ml EFV 
were processed concurrently. Treatment conditions 1 and 2 were repeated with cell free samples. 
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4.2.7 Normalizing with cell count and cell viability assays. 
 
The mean cell count was normalised to the cell viability to take into account apoptotic cells with intact 
membranes but not metabolically active.235 The EFV intensity signal of the lysate was then normalised to 
the viable cell count, assumed to be representative of the viable cell population. This would indicate the 
amount of EFV per viable cell. T-tests were performed to assess if there was a significant difference in 
the EFV signal every 24 hours. 
 
 
4.2.7.1 Cell counting 
Preliminary data showed that EFV was found inside the NES cells after treatment (Figure 4.3). NES cells 
have a doubling time of ~24 hours, making it necessary to normalize to the cell count over 72 hours.123 A 
higher cell number could also impact the amount of drug detected in the lysate fraction, as more cells 
would result in higher total intracellular volume. Cells were seeded onto six-well plates and following 
overnight adherence, were treated with EFV, repeating conditions 1 and 2 (section 4.2.6). Cells were 
counted manually at 24 hours, 48 hours, and 72 hours in triplicate using the Trypan Blue cell viability 
assay (Sigma Aldrich). Each condition consisted of three biological replicates which were seeded from 
three separate plates in triplicate. This resulted in a total of nine replicates in each condition in order to 
control for variation due to seeding density. 
A t-test was performed between the re-treat and single treatment condition to assess whether the 
treatment schedule had an effect on the cell count.  The mean values of each technical replicate were 
used for normalisation to cell viability, resulting in three replicates at each time point in each condition. 
 
4.2.7.2 Cell viability 
Following seeding onto six-well plates and overnight adherence, cells were treated with the predicted 
foetal plasma concentration (1.05 µg/ml) of EFV.62,71,72,230  A control and vehicle control (0.05% DMSO) 
were prepared. Viability was assessed using an MTT assay for the re-treat and single treatment 
conditions. T-tests were performed between the treatment conditions to assess whether the schedule 
has an effect on the  cell  viability.  The cell  viability  was  then  reported  as a  percentage of  the  
control condition absorbance value (100% viability).
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4.3 Results 
 
4.3.1 Standard curve 
 
Standard curves were created to ascertain whether a linear relationship between the signal intensity 
and EFV concentration exists. Supernatant and lysate fractious were spiked with known EFV 
concentrations. The final estimated injection amount ranged from 9.7 pg – 40 ng. Intensity and 
concentration values were logged to more easily visualise the results. Both lysate and media extraction 
curves  showed  linearity  over  the  range  of  EFV  amount  injected  (Figure  4.1)  with  an  average  raw 
intensity of 1.14 x103 at the lower end.  This indicated that intensities as low as 1.14 x103 could still be 
used to assess relative concentration when EFV was extracted in the presence of total cellular protein. 
The highest raw intensity detected that was still in the linear range was 2.3 x107. 
 
 
 
Figure 4.1: Standard curve of EFV extracted from spiked lysate and supernatant. EFV was spiked 
in a range of concentrations from 1 to 0.03125 µg/ml with a final injected amount estimated to be 
between 9.7 pg – 40 ng. Raw intensity values and concentration values were log2 transformed for ease 
of visualisation. The EFV concentration range displayed a linear relationship with signal intensity.
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4.3.2 DMSO viability assay 
 
The control condition absorbance value was set as 100% cell viability. NES cells showed statistically 
significant sensitivity to DMSO from 0.25%. Cell viability was not affected at 0.05% (Figure 4.2). 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: DMSO dose response in NES cells. NES cells were treated with DMSO at varying 
concentrations. Cell viability showed a slight but insignificant decrease at 0.125% DMSO. At 2% DMSO, 
there was 30% decrease in cell viability. The * indicates a significant (p < 0.05) decrease in the cell viability 
compared to the control after 24 hours.  The final concentration of DMSO used during EFV treatment 
(0.05%) did not have a significant effect on cell viability.
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4.3.3 Internalisation of EFV by NES cells over 24 hours 
 
NES  cells  were  treated  with  0.525,  1.05,  and  2.1  µg/ml  of  EFV  to  determine  whether  EFV  was 
internalized by the NES cells after 24 hours. In all cases, EFV was detected in both the supernatant and 
cell lysate fractions. When treated with 0.525 µg/ml, the lysate to supernatant ratio was 0.18. The 
lysates to supernatant ratios of the higher treatment concentrations of 1.05 and 2.1 µg/ml were 0.12 
and 0.11, respectively (Figure 4.3 and table 4.1). 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.3:  Assessment  of  internalisation  of  EFV  by  NES  cells.  NES  cells  were  treated  with  
increasing concentrations of EFV. Detection of EFV in the lysate indicated that EFV was potentially able 
to cross the cell membrane. *** indicate significant values of p < 0.0001. 
 
 
 
 
 
 
 
Table 4.1 Lysate to supernatant ratio of EFV 
EFV concentration (μg/ml) Lysate to supernatant ratio 
0.0525 0.18 
1.05 0.12 
2.1 0.11 
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4.3.4 Relative concentration of EFV over three days 
 
EFV was extracted at 24, 48, and 72 hours from both the cell lysate and the media supernatant. EFV was 
also extracted from a cell free control. Each day, a T0 sample was created as a control for extraction and 
detection efficiency. All replicates had acceptable CV values (CV < 20%) as suggested by the FDA.195 
 
 
4.3.4.1 Cell free control 
 
Re-treatment: The signal intensity increased significantly with each subsequent treatment. From 24 to 48 
hours there was a 1.8-fold change (p = 0.005) and from 48 to 72 hours there was a 2.7-fold change (p = 
0.001). 
Single treatment:  There was a -0.19-fold change in signal intensity between 24 and 48 hours (p = 0.0002), 
and a -0.2-fold change between 48 and 72 hours (p = 0.0006). 
T0: The T0 samples were not significantly different between 24 and 48 hours, and between 48 and 72 
hours. Between the samples prepared at 24 and 72 hours, there was -0.5 fold change (p = 0.023). 
 
The first set of samples processed at 24 hours contained two conditions that had been treated 24 hours 
before, and one condition that had been spiked with an equivalent amount immediately before 
processing (T0). The signal intensity between these three conditions was not found to be significantly 
different (Figure 4.4).
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Figure 4.4: Relative intensity of EFV over 72 hours in cell free media. Cell free samples were treated 
according to the treatment schedules. In the re-treat condition, EFV concentration increased significantly 
with each successive treatment as EFV degradation was not caused by the media or cell culture conditions. 
In the single treatment condition EFV concentration decreased significantly with each successive media 
change. Each successive T0 was not significantly different from the previous T0 sample. * indicates p < 0.01, 
** indicates p < 0.001, *** indicates p < 0.0001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
90 
 
 
4.3.4.2 Supernatant: 
After 24 hours the supernatant for the two conditions (re-treatment and single treatment) had EFV 
signal intensity values that were not significantly different from each other (p > 0.05), as expected. 
When compared to the T0 sample prepared at 24 hours, the signal intensity was not significantly different. In 
the re-treatment condition there was a 1.3-fold change in the relative intensity of EFV between 24 and 48 
hours (p = 0.01), and a -0.6-fold change between 48 and 72 hours (p = 0.0001). After 72 hours, the signal 
intensity was 0.66-fold lower than the T0 samples (p = 0.01). The single treatment condition showed a -0.13-
fold change in relative EFV intensity between 24 and 48 hours (p=0.0007), and a -0.22-fold change between 
48 and 72 hours (p = 0.0029) (Figure 4.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: EFV relative intensity over 72 hours in the supernatant. Cells were plated and 
treated according to the treatment schedules.  In the re-treat condition, EFV intensity significantly 
increased and subsequently decreased significantly  by  72  hours.  In  the  single  treatment  
condition  the  EFV  relative  intensity  decreased  with  each successive media change. T0 replicates 
were not found to be significantly different from each other. The signal intensity at T0 was not 
found to be significantly different to the signal intensity measured at 24 hours in both conditions. * 
indicates p < 0.01, ** indicates p < 0.001, *** indicates p < 0.0001.  
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4.3.5 Normalizing intensity data 
 
4.3.5.1 Cell counting 
As cell counting is variable by nature, a total of nine replicates were used to estimate an average 
cell count each day in both treatment conditions. There was no significant difference in the growth 
between the re-treatment and single treatment conditions (Supplementary Figure S1). 
 
4.3.5.2 Viability assays 
Treatment with the predicted foetal plasma concentration resulted in a slight decrease (9%) in cell viability 
although this was not statistically significant. In all four conditions, conversion of the MTT reagent 
into formazan crystals (indicating viability) increased after 48 hours, and then decreased after 72 hours 
(Figure 4.6). This trend was observed in repeat experiments (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Cell viability assay. Viability of NES cells was assessed by an MTT assay when exposed to the 
estimated biologically relevant concentration of EFV (1.05 µg/m) over 72 hours. The DMSO condition 
contained 0.05% DMSO (vehicle control). There was no significant difference between the four conditions. 
In all conditions, there was a significant increase in cell viability (inferred by metabolism) at 48 hours, and 
a subsequent significant decrease at 72 hours. 
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4.5.5.3 Viable cell count 
Once normalised, the viable cell count between the two treatment conditions were not significantly 
different (Figure 4.7). 
 
 
Figure 4.7: Cell count normalised to cell viability data. When the cell count was normalised to the 
cell viability data, there was no significant difference in the viable cell count between the two treatment 
schedules. 
 
 
4.3.6 Normalised lysate intensity values 
 
The cell lysate intensity values were normalised to the viable cell count. This value represents the 
relative concentration of EFV per cell (figure 4.8). 
Re-treatment: When normalized to viable cell count, there was a 2-fold increase in the signal intensity of 
the cell lysate of re-treatment condition between 24 and 48 hours (p = 0.014), and then decreased -2- fold 
between 48 and 72 hours (p = 0.0017). The relative EFV concentrations at 24 and 72 hours were not 
significantly different from each other (p = 0.504). 
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Time                Lysate to supernatant ratio in NES cell                  Tissue to plasma ratio in vivo 
culture 
24 hours                                 0.0064                                                   Macaque                       3.7 (172) 
48 hours                                 0.0116                                                       Rodent                       9.5 (236) 
72 hours                                 0.0204                                                   Macaque                      12.7 (172) 
 
Single treatment:  After normalisation, intensity values decreased -0.3-fold between 24 and 48 hours (p = 
0.0051), and then a further -0.5-fold decrease from 48 to 72 hours (p = 0.025). Lysate to supernatant ratios of 
EFV increased roughly 2-fold every 24 hours. An accumulation of EFV was detected in vivo over a period of 
eight days or five weeks (Table 4.2). 
 
      Table 4.2: Comparison of in vitro lysate to supernatant ratio to in vivo tissue to plasma ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: EFV relative intensity over 72 hours in the cell lysate. Signal intensity values were 
normalised to the viable cell count. The EFV signal intensity in the re-treatment condition increased 
significantly between 24 and 48 hours, and subsequently decreased significantly between 48 and 72 
hours. The signal intensity decreased significantly with each subsequent media change in the single 
treatment condition. * indicates p < 0.01, ** indicates p < 0.001, *** indicates p < 0.0001.
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4.4 Discussion 
 
4.4.1 Standard curves 
 
To create a treatment schedule of EFV in the in vitro NES cell culture model, an understanding of the 
movement and degradation of the drug both in media and when exposed to cells was required. In this 
work, it was adequate to measure the relative quantity of EFV between days. SRM assays are highly 
sensitive, and can quantify purified analytes at amounts as low as 0.2-2 fmol.237 The TSQ Vantage has a 
linear dynamic range in excess of four orders of magnitude, making it a useful tool for drug detection 
assays in more complex mixtures.238    The standard curves for both media and lysate spiked with EFV 
showed linearity when measuring intensity over spiked drug amount from 9.7 pg to 40 ng. Observing 
linearity at the lower end was important as is improved the chance of the measured values falling within 
the linear range. It was hypothesised the concentration of EFV within the cells would be on the lower 
end, as the cell density and small intracellular volume would not sequester a large fraction of the EFV 
(assuming passive diffusion into the cells). Linearity at the lower end would therefore allow the relative 
concentration to be inferred even in cell lysates with very low concentrations of EFV. 
 
 
4.4.2 DMSO viability assay 
 
Contrary to findings in SHSY-5Y cell lines, DMSO appeared to cause a decrease in NES cell viability in 
concentrations below 0.5%. SHSY-5Y is an immortalised cell line derived from a tumorigenic 
neuroblastoma, which may alter the response to various insults. The NES cells used in this work are non- 
immortalised human foetal derived cells. Their origin may make them more susceptible to DMSO 
compared to tumour derived cell lines. 
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4.4.3 Drug internalisation 
 
Prior to treatment it was necessary to establish if EFV was able to enter the cells, as lack of detectable 
intracellular  EFV  would  suggest  active  excretion,  effective  metabolism,  or  inability  to  enter  this 
particular cell type.  With increasing concentrations of EFV, the ratio of EFV found in the cell lysate when 
compared to the supernatant decreased (Figure 4.3, table 4.1). In a study modelling the movement and 
transportation of EFV in plasma using the “inverse” Michaelis-Menton equation, it was suggested that 
EFV transport diffusion movement was mostly passive.239   The model also predicted that when the 
concentration increased in a volumetric space, the collective movement of the particles would initially 
increase and then decrease when approaching equilibrium, as passive transport is dependent on a 
concentration gradient.212 According to these findings, EFV may move mostly via passive diffusion in the 
CNS, with higher concentrations moving into the CNS and neural tissue immediately after the initial 
treatments which may account for rapid CNS side effects.240 
 
 
4.4.4 Relative concentrations of EFV over three days 
 
The raw intensity values of both the lysate and supernatant were found to fall within the linear range of 
the standard curve. This indicated that an increase in the intensity value was proportional to an increase 
in the concentration, allowing for inferences about the concentration to be made from the signal 
intensity. 
 
 
4.4.4.1 Supernatant 
 
Re-treatment: The relative concentration in the re-treat and the single treatment conditions were 
equivalent 24 hours post treatment, which is expected as at this point the conditions were exactly the 
same. When compared to the T0 sample that was spiked with EFV immediately before processing, there 
was no significant difference in the intensity values. This also occurred in the cell free control. This 
indicates that after 24 hours in NES culture media EFV is not significantly degraded by the culture 
conditions (Figure 4.4). It also indicates that EFV is not significantly metabolised by the cells after 24 
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hours  (Figure  4.5).  The  T0  sample  prepared  at  72  hours  was  significantly  lower  than  the  samples 
prepared at 24 hours. Over the 72 hours the signal intensity of T0 followed a downward trend. This was 
not seen in repeat experiments and in subsequent MS analysis indicating that it was not a MS technical 
variation. It was therefore attributed to experimenter error. 
After 48 hours, the EFV relative concentration increased, and subsequently decreased significantly after 
72 hours. The relative concentration at 72 hours was lower than the T0 sample, indicating that 
degradation of EFV had occurred. In order to determine whether this was due to degradation caused by 
culture  conditions  or  degradation  due  to  metabolism,  the  relative  concentration  trend  of  the 
supernatant was compared to that of the cell-free re-treatment condition. When there were no cells 
present, the relative EFV concentration increased every 24 hours with re-treatment. When cells were 
present, the relative intensity followed the same increasing trend for the first 48 hours, and then 
decreased significantly (Figure 4.4 and 4.5). EFV  is  known  to  activate  the  transcription  of  the  
cytochrome  CYP2B6,  thus  inducing  its  own metabolism.48  EFV is most likely being metabolised by 
CYPB26, as the secondary cytochromes that metabolise EFV have not been found in neuronal cells, 
whereas CYP2B6 has.226 The significant decrease observed at 72 hours may be due to the accumulation 
of EFV and the subsequent up-regulation of its metabolism. In mice, CYP2B6 activation increased 4-fold 
during extended treatment compared to short term treatment indicating that as EFV levels increase, a 
concurrent increase of CYP2B6 occurs and the metabolism of EFV increases.229 
 
Single treatment: EFV was detected in the supernatant up to 72 hours post treatment, subsequent to 
two drug free media changes. Passive diffusion of EFV from within the cells could not account for the 
relatively high concentration remaining in the supernatant. Rather, upon inspection of the cell free 
single treatment control, a similar trend is observed leading to the following hypothesis: 
EFV is a highly lipophilic molecule, allowing it to diffuse easily into the brain tissue which is made up of 
roughly 60% fatty acids.241  High CNS penetrance of ARVs is a desired characteristic as it is associated 
with improved viral suppression in the CSF.242 In order to maintain cell adhesion in culture, the growth 
surface of disposable polystyrene plates are treated to become more hydrophilic.243 The sides walls of 
the dish are not treated for cell growth, thus it is possible that the lipophilic EFV molecule would be 
strongly attracted to the hydrophobic areas of the plastic, creating a large reservoir of EFV which diffuses 
back into fresh drug free media even after two instances of complete media removal and PBS washes. A 
 97 
 
reservoir of EFV as seen in the single treatment condition may also contribute to the accumulation of 
EFV in the cell free re-treat condition. 
4.4.4.2 Normalisation of lysate signal intensity to viable cell count 
Cell counting: In biological systems, contact inhibition is the means by which cells stop growing or 
proliferating when they come into contact with other cells. This process is important for organ 
development as well as general tissue and muscle health. Aberrations in  this process lead to cancer or 
tumorigenesis.244  In neuronal cell culture, contact inhibition regulates mitosis in non-transformed cell 
lines, inhibiting proliferation and initiating apoptosis. Dead cells were found to inhibit further 
proliferation, and removal of dead cells resulted in an increase in proliferation.245  Pavel et al. (2018)244 
found that high density cell culture resulted in a decrease in autophagy and an increase in apoptosis, 
leading to a reduction in overall cell viability. During apoptosis, the cell membrane stays intact while the 
organelles begin to disintegrate.235  The mitochondria become compromised through the intrinsic or 
mitochondrial pathway, which is a main process in apoptosis.235   In cell culture macrophages or microglia 
are often not present, meaning that apoptotic cells are not engulfed and can remain within the 
population of live cells. In this work cell counting was performed by using a dye exclusion method, 
whereby the dye used is unable cross an intact cell membrane.   Apoptotic cells maintain an intact 
membrane, which may have given false inflated readings for live cell count.246 
 
Cell viability: An MTT assay assesses the viability of the cells based on mitochondrial function. As cell 
density increases, apoptosis increases, and mitochondria begin to disintegrate, leading to decreasing 
viability.235,244 Due to the cell membrane staying intact, the cell count does not decrease proportionally 
to the viability reading of the culture. When testing multiple treatment concentrations as well as control 
and vehicle control conditions, the same trend was observed whereby the viability initially increased 
between 24 and 48 hours, and then decreased between 48 and 72 hours. This supports the idea that at 
high density, regardless of the treatment conditions, there was a decrease in viability which was likely 
caused by apoptosis.244 
By normalising the cell count data to the cell viability, an estimate of the number of viable cells can be 
attained. This normalised count is referred to as the viable cell count. Supernatant values were not 
normalised to the viable cell count, as the intracellular volume was not considered likely to affect the 
supernatant volume. Although the volume of the NES cells has not been established, based on the 
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average volume of fibroblasts and osteoblasts (2-4 pL respectively), even after 72 hours, the cell count 
would not be high enough for the intracellular volume to significantly impact supernatant volume. 
 
4.4.4.3 Lysate: 
Re-treatment: When normalised to the viable cell count, the relative concentration of EFV followed the 
same trend as  observed  in the  supernatant  whereby  there was  an initial  increase  after 48  hours, 
followed by a significant decrease after 72 hours. The hypothesis that an accumulation of EFV resulted in 
an increased metabolism of the drug between 48 and 72 hours can also be applied based on the trend of 
cell lysate relative concentration. 
When normalising to the viable cell count, the relative concentration of EFV decreases after 48 hours, 
indicating that there is less EFV present per cell after 72 hours (Figure 4.8). Based on diffusion and 
transport studies, EFV is transported passively across a concentration gradient.212  If CYP2B6 activity is 
induced by EFV accumulation, then the rate of metabolism of EFV would increase, resulting in a lower 
intracellular concentration (Figure 4.5). 
This work aims to model the exposure of NES cells to EFV. Although somewhat simplistic, one can 
compare the tissue to  plasma ratio to the lysate to supernatant ratio of EFV. EFV is predicted to 
accumulate in vivo due to its high lipophilicity. This was confirmed in rat and macaque studies, whereby 
the tissue to plasma ratio ranged from 3.7 – 12.7.172 
Similarly, when re-treated with EFV over 72 hours, the lysate to supernatant ratio essentially doubles 
with each re-treatment (Table 4.2). More data would be needed in order to determine whether EFV 
accumulates in the cells in a time dependent manner or simply a concentration dependent manner, but 
at first sight, the data presented here would support the hypothesis that passive transport across the 
cell membrane is rate limiting and that true equilibrium may not have been achieved in a 24 hour 
period. 
Based on these findings, it appears that once EFV accumulates, it induces its own metabolism. It is 
important to note that this only occurs more than 48 hours post treatment. This indicates that in order 
to understand the more global cellular response to EFV, data needs to be collected prior to and 
subsequent to the initiation of the metabolism of the drug. Short term studies investigating the effects 
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of  EFV  over  24  hours  or  less  may  not  determine  a  true  biological  response  to  EFV  over  time  as 
metabolism has not been initiated at that point.120,121 
 
Single treatment: Relative EFV concentration in the cell lysate followed the same trend before and after 
normalisation. In both cases, EFV concentration showed a significant decrease after the first media 
change and decreased again after the second media change. EFV was still detected in the lysate even 
after two washes, supporting the hypothesis of the culture vessel plastic acting as an EFV reservoir. The 
trend observed in the single-treatment lysate and supernatant followed the same trend as the cell free 
control. It is possible that at such low concentrations, the number of viable cells present did not affect 
the passive diffusion of EFV. Modelling of EFV transport found that at concentrations lower than 0.97 
µg/ml, EFV passive movement is increased, and the drug can move in and out of the system with ease.212 
Based  on  this,  it  is  possible  that  EFV  is  still  detected  even  with  extremely  low  supernatant 
concentrations due to increased passive diffusion into the cells.
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4.5 Conclusion 
 
The  aim  of  this  chapter was  to  assess  the  movement  and degradation of EFV in  NES  cell  culture 
conditions. Establishing whether EFV was being degraded by the conditions and/or metabolised by the 
cells was necessary to attempt to mimic the in vivo conditions of exposure in a developing neural 
system. The plastic cell culture dishes appeared to act as a reservoir of EFV which, although assumed to 
be fairly consistent across conditions, may have caused the model to be less biologically relevant.  EFV 
was able to enter the NES cells, most probably by passive diffusion.212,239  The stability of EFV was not 
significantly affected in cell-free cell culture conditions, indicating that the media did not cause 
degradation of the cells. A decrease in the relative EFV concentration in cell containing conditions was 
therefore most probably due to EFV inducing its own metabolism by CYP2B6 in the NES cells once 
reaching a threshold concentration.224,226,228,247  Interestingly, the ratio of lysate to supernatant (as a 
rudimentary proxy for tissue to plasma ratio) was found to increase over time but not with an increasing 
concentration at a single time point. In vivo, EFV does indeed accumulate in the CNS tissue over time 
and is potentially underestimated when using CSF concentration as an approximation.172,236 
This chapter indicated that a 24 hour re-treatment schedule was sufficient to use as an initial model for 
foetal neural exposure to EFV, as the drug was metabolised by the cells and not degraded by the cell 
culture conditions. Metabolism of EFV appeared to be initiated at least 48 hours post EFV treatment, 
indicating the necessity for longer term studies. 
These data implied that there was a biologically relevant interaction between the cells and the drug, as 
opposed to the cells being exposed to an un-metabolised form of EFV, increasing every 24 hours.
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4.6 Summary 
The preceding three chapters aimed to develop a biologically relevant treatment schedule of EFV in NES 
cell culture in order to approximate the exposure of foetal neural progenitor cells to EFV in utero. 
Human derived NES cells were used in this work, which require specialised stem cell culture techniques. 
This cell type has also not been extensively researched. It was therefore important to assess the 
movement and degradation of EFV in these specific cell culture conditions. Prior to working with EFV in 
cell culture, a method of EFV detection using targeted MS was created. The optimal detection of neat 
EFV (99.4% purity) was in 50% ACN, in negative ionisation mode. A targeted SRM assay was developed, 
resulting in a target list containing five transitions, each optimised for collision energy. Once the assay 
was established, a standard curve was created for neat EFV in ACN in order to confirm that signal 
intensity and concentration showed a linear relationship over a concentration range. 
Following detection optimisation, a method for EFV extraction from the cell culture was optimised. This 
was performed for both the lysate and the media fractions. ACN protein precipitation was selected as 
the extraction technique for subsequent experiments. The extraction method was further optimised in 
order to decrease variation between inter-sample and inter-day processing. Various other optimisation 
steps were performed to improve the detection of EFV, including gradient optimisation and sample 
concentration prior to MS analysis. 
Once the detection and extraction of EFV was optimised, a standard curve was created using lysate and 
supernatant fractions spiked with EFV. This determined that the concentration and intensity has a linear 
relationship over a concentration range when EFV was extracted from a complex mixture. Further 
experiments were then performed to gain insight into the behaviour of EFV within the cell culture 
conditions. From this it was determined that EFV was able to enter NES cells, that it was metabolised by 
the cells, and that it was not degraded by the cell culture conditions. The estimated biologically relevant 
concentration of EFV and the concentration of the drug delivery vehicle did not cause a significant 
decrease in the cell count or the cell viability. 
Based on the overall findings of these method development chapters, future experiments modelling the 
exposure of NES cells to EFV in utero were conducted as follows: After adhering to tissue culture plates 
overnight, NES cells were treated with 1.05 µg/ml of EFV in 0.05% DMSO. Every 24 hours, the media was 
removed and replaced with new media containing freshly spiked EFV (1.05 µg/ml).
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4.5.1 Future work and limitations 
The limitations acknowledged in this work indicate the necessary steps to further optimise the drug 
detection assay as well as to better model neural progenitor exposure to EFV in utero. 
 
4.5.1.2 Decreasing variability between samples 
Multiple attempts were made to decrease the inter-sample and inter-day variability. Although this was 
somewhat achieved, future work should include an internal standard that can be used to normalise 
intensity values. Larger sample starting volume and more replicates would serve to decrease variation. 
 
4.5.1.3 Improvement of processing techniques 
Variability between samples may have also been due to the manual processing of multiple samples per 
day, as well as the unavoidable multiple transfer steps during processing. An automated drug extraction 
technique or one that can be performed with fewer transfer steps would ensure more reliable and 
accurate results, mitigating human error and differential sample loss during processing. 
 
4.5.1.4 Assessing the effect of the EFV reservoir 
Based on this work it appears that EFV is absorbed into the untreated sides of the plastic cell culture 
dishes. With appropriate controls this may not have affected the comparative ability of the assay within 
these particular conditions, although it may cause the assay to be less biologically relevant. Future work 
could further elucidate whether the resultant reservoir of EFV diffusing into the media and cells affects 
the biological inference. This may necessitate optimisation of the cell culture conditions in order to 
mitigate the effect of the plastic absorption of EFV. 
 
4.5.1.5 Detection of metabolites to validate assumptions 
Based on the literature and the findings in this work, it is assumed that EFV activates its metabolism by 
the cytochrome CYP2B6. MS analysis can be used to detect various metabolites of EFV, which can clarify 
if EFV is indeed being metabolised by the cells. Metabolite analysis can also give insight into whether 
EFV is only metabolised by CYP2B6 in neural cells, or whether other secondary cytochromes also play a 
role in the CNS metabolism of EFV.
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Chapter 5: Proteomic analysis of the effects of EFV in NES cells over 72 
hours.  
 
5.1 Introduction 
 
The FDC consisting of EFV, FTC, and TFV is prescribed to pregnant, HIV-positive women in South Africa 
regardless of their CD4+ cell count and stage of pregnancy.37,248 EFV is classified as a category D drug 
(positive evidence of foetal risk); case studies and animal studies suggest that EFV exposure may cause 
CNS malformations including incomplete neural tube closure (encephalocoele), myelomeningocele, 
craniofacial malformations such as cleft palate, and increased risk of spontaneous abortion.76,78–81,249 
Despite these findings, based on the small number of case studies and few small cohort studies, EFV 
exposure during pregnancy is not considered to be associated with an increased risk for CNS 
malformations or neurologic deficits, and is therefore used as a first line treatment for HIV-positive 
pregnant women.91,250,251 
The protection that the ARV treatment affords a child born to an HIV-positive mother is invaluable, 
allowing the child to live a healthy, HIV-free life. Recently there have been reports of HEU children 
showing subtle neurological deficits, although not potentially fatal or as debilitating as the malformations 
such as encephalocoele or myelomeningocele, neurological deficits can affect HEU children throughout 
their lives, from school age to adulthood. Deficits in areas such as mental cognition, mathematic ability, 
verbal IQ, full scale IQ, memory, and language expression have been noted in cohort studies that follow 
HEU children longitudinally as opposed to a single assessment for malformations at birth.99,106,116,252 
Assessment of the effects of EFV during development is important as some skills only develop as the child 
ages. Some neurocognitive deficits, for example those due to early brain injury in pre-term births, can be 
diminished over time due to plasticity, or can only be detected at old age due to a vulnerability to 
neurodegeneration (the sleeper effect).253 Exposure to toxic compounds such as EFV during early 
neurodevelopment may cause deficits that are not detectable upon birth, but rather emerge at a later 
stage affecting plasticity or causing a vulnerability to insult.253 Thus, the potential effects of EFV on HEU 
children is an important public health issue that needs to be addressed. Currently, the neurocognitive 
deficits seen in HEU children are attributed to perinatal HIV exposure,97 perinatal  ARV exposure,85,254 poor 
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maternal health,113,114 or poor socioeconomic background.113,114 In adults, the effects of EFV are well 
documented at a systemic level and in the CNS as a whole, but not on a molecular level. Characterization 
of the effects of EFV on foetal neural development is also lacking. The present study aims to elucidate the 
effect of EFV on developing neurons by treating human foetal- derived NES cells with estimated 
biologically relevant concentrations of EFV. Animal models are time consuming and expensive, making cell 
models appealing for initial discovery work. The human-derived NES cells used in this work offer a more 
biologically relevant model than cell lines with a tumorigenic background.255 
Changes in the proteome caused by EFV treatment in NES cells can be characterised with MS. By using 
discovery proteomics, one can create a systematic snapshot in time of all the proteins within a biological 
network. Discovery proteomics aims to identify all the proteins within the system, post-translational 
modifications, protein localisation, protein interactions, and protein turnover.127   The proteome is used to 
characterise the global molecular effects of EFV on NES cells when treated at an estimated biologically 
relevant concentration of 1.05 µg/mL. The treatment schedule for this experiment was determined by 
previous empirical evidence (Chapters 2-4). In an HIV-free experimental system, the potential effects of 
EFV on neurocognitive function during foetal neural development and in the postnatal CNS can be 
determined. This could lead to a broader understanding of HEU children and highlight the need for further 
studies and early intervention strategies. Characterising the molecular effects of EFV in neural cells may 
also be used to direct future research regarding adults suffering from persistent HAND or CNS side effects 
while on ARV treatment containing EFV. As a recommended first line constituent of combination 
treatment prescribed to HIV-positive patients in South Africa, gaining insights into the global cell-wide 
changes in the CNS may indicate a direction for future investigations into the safety profile of EFV.
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5.2 Materials and methods 
5.2.1 Sample preparation for MS 
 
5.2.1.1 Cell culture and treatment of NES cells 
NES cells were cultured according to the method described in chapter 4, section 4.2.1 and 4.2.2 in 6 cm 
dishes (TPP). Prior to plating, cells were counted using Trypan blue in order to ensure consistent seeding 
numbers across replicates. Cells were seeded with 4x104 cells/cm2 and allowed to adhere to the plates 
overnight (12 hours), followed by treatment with 0.05% DMSO (vehicle only control) or 1.05 µg/mL EFV 
in 0.05% DMSO (EFV treatment). Media was changed every 24 hours and replaced with fresh media 
either containing DMSO only (0.05%) for the control or EFV (1.05 µg/mL) for the treated condition, 
according to the treatment schedule determined in chapter 4. 
 
5.2.1.2 Cell harvesting and lysis 
After overnight adherence, five replicates were harvested (T0). Following the initiation of treatment, five 
replicates from the control and treated conditions were harvested every 24 hours, up to 72 hours. Cell 
pellets were snap-frozen in liquid nitrogen and stored at -80⁰C. The sample lysis and digestion was 
performed following the method described in Jersie-Christensen, Abida, and Jesper (2016) with minor 
alterations.256 Lysis buffer made up of 6 M guanidinium hydrochloride (GuHCl, Sigma Aldrich) in 100 mM 
Tris–HCl (pH 8.5, Sigma Aldrich) was heated to 90⁰C before the addition of 200 µl to each replicate. 
Samples were heated to 90⁰C for 20 minutes followed by sonication for 20 minutes. Heating and 
sonication was repeated for five rounds or until the lysate was clarified. 
 
5.2.1.3 Protein quantitation 
To ensure equivalent loading of peptide onto the column for MS analysis, the protein quantity was 
determined using the bicinchoninic acid assay (BCA) with the Pierce BCA Protein Assay Kit (Thermo 
Scientific). A standard curve using bovine serum albumin in lysis buffer was made in flat-bottomed 96 
well plates (Greiner). The standard curve and the samples were prepared in triplicate. The absorbance 
values were read by the iMark microplate reader (Biorad) at 565 nm and analysed by the Microplate 
Manager software. 
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5.2.1.4 Digest and clean up 
The remaining sample lysates (190 µl) were reduced and alkylated with 5 mM tris(2- 
carboxyethyl)phosphine (TCEP, Sigma Aldrich) and 10 mM iodoacetamide (IAA, Sigma Aldrich), followed 
by incubation at room temperature for one hour. Samples were then pre-digested with LysC at an 
enzyme to protein ratio of 1:100 for one hour at room temperature with gentle rotation, followed by 
dilution to a final volume of 1 M GuHCl with 25 mM Tris–HCl pH 8.5. Trypsin was added at an enzyme to 
protein ratio of 1:50 and incubated for 18 hours in a wet chamber at 37⁰C. Samples were acidified post 
digestion with FA to a final concentration of 1% (pH 2-3) and then spun at 15 000 x g for five minutes to 
pellet insoluble material. 
The peptide solutions were desalted following the stop and go extraction method.257 Tips were packed 
in-house with c18 discs (Empore SPE Disks,C18, 47 mm) and equilibrated with 80% ACN, 0.1% FA 
(solvent B). The tips were loaded with 10 µg of peptide and washed with 2% ACN, 0.1% FA (solvent A). 
The peptide solution was eluted into clean tapered glass auto sampler inserts with 60% ACN, 0.1% FA 
(solvent C) and dried in the SpeedyVac vacuum concentrator (no heat). The dried peptides were 
resuspended in solvent A to a final concentration of 250 and 500 ng/µl for MS analysis. 
 
5.2.2 Instrument parameters 
 
Protein quantitation ideally ensures that the protein amount is constant in all the samples, although it is 
possible that protein loss occurs during subsequent preparation steps. A short gradient pilot sample was 
injected onto a Q-Exactive Orbitrap-quadrupole hybrid coupled to a Dionex UltiMate 3500 RSLC Nano-LC 
system (both Thermo Scientific) to determine the correct concentration and volume necessary to achieve 
a TIC intensity of 4 – 5 x109. The sample injection volume and sample concentration was adjusted equally 
across all samples as they were processed in parallel and assumed to have incurred similar loss due to 
processing. In order to achieve an optimal TIC, 5 µl of 500 ng/µl (a total of 2.5 µg peptide) was loaded 
onto a 2 cm trap column (5 µm Luna c18 beads, 100 µm ID, pore size 100 Å, Phenomenex, packed in-
house) in 98% solvent A and 2% solvent B. Peptide was then eluted onto a 30 cm reverse phase analytical 
column (3.6 µm Aeris c18 beads, 75 µm ID, pore size 100 Å, Phenomenex, packed in-house). Peptides 
eluted over a 120 minute slope gradient, whereby solvent B increased from 6 – 40% between 10 – 80 
minutes (curve of gradient = 3), and then from 40 – 80% between 80 - 85 minutes (curve of gradient = 7). 
This was followed by an 80% washout for 15 minutes before equilibration at 2% for 20 minutes. A 60-
minute wash was performed after each analysis of three consecutive samples. Samples were analysed in 
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a randomized order to mitigate any technical bias introduced by instrument performance over time. The 
data acquisition was performed in positive mode. MS1 spectra collection settings were as follows: 
resolution: 70 000, range: 300-1750 m/z, automatic gain control (AGC): 3 x105, maximum injection time: 
250 milliseconds (ms). Precursor ions were selected for fragmentation by a Top10 data dependent 
selection method. The MS2 spectra collection settings were as follows: resolution: 17 500, range: 200 –
2000 m/z, AGC: 1 x105, maximum injection time: 80 ms, isolation window: 2 m/z, dynamic exclusion: 30 
seconds, and normalized collision energy: 28. 
 
 
5.2.3 Data analysis 
 
5.2.3.1 Statistical analysis 
Raw MS data were imported into MaxQuant (v. 1.5.3.12) for peak identification and quantitation. The 
default settings were used with the following alterations. “Match between runs” was selected to identify 
unsequenced or unidentified peptides based on their mass and retention time;150 LFQ was selected; the 
UniProt Human proteome protein sequence FASTA file was uploaded for the Andromeda database 
search (downloaded 2018/02/07); LysC and trypsin were selected as the digestion mode; and the FDR 
rate was set to 0.01. Summary statistics of the MS data were performed by an R script developed by 
Karsten Krug (Proteome Center Tuebingen, University of Tuebingen, Germany). 
The protein groups text output from MaxQuant was imported into Perseus software258 for visualisation of 
the data. The data was filtered by removal of contaminants, reverse hits, and protein groups with less 
than one unique peptide. LFQ intensity values were log2 transformed to aid visualisation, and protein 
groups with peptides detected in less than three replicates out of five per condition were removed. 
Perseus software was used to assess the protein expression profiles between conditions and visualized 
with heat maps. 
LFQ values were normalised to T0 in both the control and treated conditions. A Student’s t-test was 
performed to assess significant differences between control and treated groups at each time point. A 
one way ANOVA was used to assess a difference in expression over time, within either treatment 
condition.
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5.2.3.2 Biological inference 
Biological inference was performed in a series of steps to narrow the list of proteins of interest from broad 
interaction networks to specific pathways. Protein groups were converted to their gene identifiers using 
the UniProt database.259 Through the CRUNCH environment (developed by Shaun Garnett, University of 
Cape Town), a STRING-db interaction network was generated for significantly differently regulated genes 
in each time point. STRING-db provides functional association networks and is a useful scaffold for the 
initial visualisation of the dataset.260 The significantly deregulated genes were imported into Reactome to 
further interrogate the data. Reactome provides mechanistic detail of the protein interactions and uses 
over-representation analysis to rate the enrichment of super pathways and sub pathways in the 
dataset.261 The list of user input proteins is assessed for over-representation by comparing whether there 
is more annotation matched to a pathway than would be expected by chance. The number of proteins in 
the set, the number of proteins annotated to the pathway, and the number of proteins annotated from 
the whole Reactome database are used to create the over-representation probability score.261 Pathway 
navigation can be visualized through whole tissue diagrams as well as at a protein-to-protein level. The 
genes contained within the top five most significantly enriched pathways were identified in the STRING-db 
interaction pathway, and the interaction partners were investigated in order to obtain a broader view of 
the significantly differentially regulated genes at each time point.
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5.3 Results 
 
5.3.1 MS runs 
 
A 2 µl injection of both low (250 ng/µl) and high (500 ng/µl) concentration samples was assessed. Based 
on the TIC, the high concentration samples were used for MS analysis. A total of 2.5 µg peptide (5 µl) 
was injected and eluted over 90 minutes on a 120-minute gradient (Figure 5.1). The steep drop towards 
the end of the gradient was found to be a common feature when using GuHCl lysis and protein 
precipitation (Blackburn Laboratory, unpublished). Of the 35 samples that were analysed, the 
chromatograms of two indicated low peptide levels (Figure 5.2, a). These samples were re-analysed with 
a higher injection volume, but the TIC was still sub-optimal (Figure 5.2, b) and were subsequently 
discarded. The TIC should be comparable between samples to decrease variation due to technical 
reasons (lack of detection due to low peptide levels as opposed to not being present in the sample). 
During the sample analysis, the chromatography spray was disrupted. Before and after the analysis of 
the experimental samples, reference samples of SH-SY5Y were analysed for quality control purposes. 
Figure 5.3 shows that the chromatography spray had improved subsequent to the loss and repair of the 
spray. This can be seen by sharper less “fuzzy” lines. Unfortunately, due to time limitations, the samples 
analysed before the spray was repaired were not re-analysed. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Optimisation of sample concentration and injection volume. a) The MS1 spectrum on a short, 70- minute gradient to determine the optimal 
injection volume. The TIC was 3.96 x109 with a 2 µl (1 µg) injection of the 500 ng/µl samples. b) The MS2 spectrum on the 70-minute gradient. c) The MS1 of 
an extended 120-minute gradient ensured optimal chromatography. The TIC was 4.74 x109 with a 5 µl (2.5 µg) injection of the 500 ng/µl samples. d) The MS2 
spectrum on the 120-minute gradient 
a) 
b) 
c) 
d) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Samples assessed for re-analysis. a) Low amount of peptide resulted in the chromatogram appearing low and flat, with limited MS2 
detection compared to other samples. The TIC was 3.33 x108 due to the large peak at the end of the gradient. A similar peak was observed during wash 
samples and coincides with the high concentration of solvent B. Samples with low TIC were reanalysed. b) Samples were re-analysed with a 6 µl injection (3 
µg). The flat TIC in MS1 (b) and in MS2 (c) indicates that there were very low levels of peptides left in the sample. These samples were subsequently 
discarded.
a) 
b) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: SH-SY5Y reference samples: a) Reference sample was analysed directly before the experimental samples. The spray at this point was considered 
acceptable. b) Reference sample analysed directly after the experimental samples (subsequent to repairing the spray). When comparing the two reference 
samples, the final reference sample had a sharper TIC than the initial reference, indicating an improved, stable spray. The TIC values of 3.12 x109 and 3.61 x109 
respectively were similar between the two references 
a) 
b) 
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5.3.2 MaxQuant – data quality 
 
A total of 286924 MS1 spectra and 1019253 MS2 spectra were detected across 35 samples. The 
Andromeda database search identified 1663 protein groups and 5844 peptides by MS2 spectrum to 
peptide matching. The digestion efficiency was indicated by the percentage of missed cleavages, 63.6% 
peptides with no missed cleavages, 29.7% with one, and 6.7% with two (Supplementary Figure S3). The 
MS2 identification for all samples was over 20%, which is considered acceptable (Supplementary Figure 
S4). The mass error was 0.8 +- 0.05 ppm in all samples analysed (Supplementary Figure S5). 
 
5.3.3 Statistical analysis 
 
5.3.3.1 Data visualisation 
The protein groups text file was imported into Perseus for data visualisation. A total of 1663 protein 
groups were identified. After the data was filtered, 1332 protein groups remained. Scatter plots were 
used to assess the variation between samples, which was low (Pearson’s correlation score > 0.95). The 
linearity indicates that proteomes were generally similar within treatment groups and between 
treatment groups (Supplementary Figure S6). 
Hierarchical clustering showed very weak clustering between treatment groups. The clustering was not 
correlated to the order in which samples were run (data not shown). Hierarchical clustering performed 
with each treatment group separately tended to contain a mixture of T24 and T48 or T48 and T72. These 
results indicate that between control and treated groups the majority of the proteome remained 
unaltered at the time points analysed. Clustering of the replicates in the individual treatment groups 
indicated that the proteome changes were largely unaltered between 24 and 48 hours, and between 48 
and 72 hours. However, the proteomes at 24 and 72 hours were distinct from each other (Figure 5.4). 
When comparing the variation between the replicates in each treatment condition, the standard 
deviation between the control samples increased at each time point and was more varied than the 
treated group. The variation between replicates of the treated samples decreased over time (Figure 5.5). 
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(a) 
 
 
 
(b)                                                                                                                    (c) 
 
 
Figure 5.4: Hierarchical clustering of EFV treated NES samples over 72 hours. a) When analysed 
together, samples across both treatment conditions showed weak clustering. Treatment condition did 
not seem to have an appreciable effect on the proteome of the NES cells. The order of MS analysis was 
not correlated to the cluster groups, although there appeared to be weak clustering by time point and 
when hierarchical clustering was performed within the treatment group. In the control (b) and treated (c) 
conditions T24 and T48 clustered together and T48 and T72, but not T24 and T72.
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(a)                                                                 (b) (c)
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Boxplots representing the standard deviation between replicates within each 
condition group. a) At T24, control and treated samples had a similar spread of standard deviation 
within each group. The treatment group had a higher mean standard deviation. b) At T48, the standard 
deviation of the control group was higher and has more variation than the treated group. c) At T72, the 
mean standard deviation in the control group was higher than the treated group and the data points 
had a larger distribution. The variation of standard deviation increased in the control over time, with 
T72 having the most variation between replicates.
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5.3.3.2 Differential statistics 
Of the 1332 protein groups remaining after filtering, 131 were found to be significantly differentially 
regulated (p < 0.05) across all three time points following the Student’s t-test. Protein group names were 
imported into Uniprot259 and converted to their gene identifier, to which they will be referred to in the 
following sections. After 24, 48, and 72 hours of EFV treatment, 26, 39, and 80 protein groups were 
differentially regulated, respectively. The total protein groups identified and significant protein groups at 
each time point are listed in table 5.1. All significantly differentially regulated protein groups across all time 
points are listed by gene name in supplementary table S4. 
 
  Table 5.1: Protein groups identified and significantly differentially regulated by EFV treatment. 
Hours post-treatment Total protein groups identified Total significant protein groups 
24 1488 26 
48 1442 39 
72 1487 80 
 
5.3.3.3 Time course analysis 
The change in expression of genes that were significantly differentiated at each time point was also 
analysed over the entire time course. T-tests were used to determine differential regulation between 
conditions, and ANOVA was used to detect differential regulation within conditions between time points 
(significance indicated with green shading for down-regulation and red shading for up-regulation). Genes 
of interest were selected based on Reactome pathway enrichment as well as STRING-db network 
interactions. The time course data of the expression of genes of interest are represented and described 
here. Section 5.4.5 further discusses of the specific genes and the enriched pathways 
The trend for squalene synthase (FDFT1) in the treatment condition was opposite to that of the control 
over 72 hours and was significantly different to the control across all time points. 
Hydroxymethylglutaryl-CoA synthase (HGMCS1) expression decreased continuously during the time 
course when treated with EFV while HMGCS1 expression in the control condition initially decreased but 
then appeared to recover. Fatty acid synthase (FASN) was significantly down-regulated at 24 and 72 
hours post treatment and followed a similar trend to the control condition. At 48 hours, the variation of 
FASN detected in the control was high and thus not statistically significant although still appeared to 
follow the same trend with decreased levels compared to the control (Figure 5.6). 
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Acetyl-CoA acetyltransferase (ACAT) and ATP citrate lyase (ACLY) were both significantly down-regulated 
in the treatment condition at 48 and 72 hours. Both genes followed the same trend as the control 
condition throughout the time course. Squalene epoxidase (SQLE) was significantly up-regulated at 48 
hours in the treatment condition and followed an upward trend throughout the time course. In the 
control condition, SQLE initially decreased and then appeared to recover by 72 hours (Figure 5.7). The 
variation in all time points was high, although the trend indicates that there was a higher expression of 
SQLE across all time points in the treated condition than in the control. 
Splicing factor subunits A1 and B1 (SF3A1 and SF3B1), as well as the U6 small nuclear RNA (snRNA)- 
associated protein (LSM4) followed the same trend in the treatment and control conditions. At 72 hours 
post treatment, all three genes were significantly down regulated in the treated samples (Figure 5.8). 
UBX domain protein (UBXN7) followed the same trend as the control but was significantly down- 
regulated at 48 hours post treatment. The cleavage and polyadenylation specificity factor subunit 1 
(CPSF1) increased significantly at each time point in the control samples, and was significantly higher 
than the treatment samples at T72 (Figure 5.9). 
Annexin 2 (ANXA2) decreased significantly across the time points in both the control and treatment 
conditions, as indicated by the green shading. At 72 hours, ANXA2 expression was significantly higher in 
the treated condition. Signal transducer and activator of transcription 3 (STAT3) had a significantly 
higher expression in the treatment condition at 24 hours. STAT3 decreased in the treatment condition at 
48 hours and then increased by 72 hours, remaining below the level of STAT3 in the control, although 
not significantly (Figure 5.10). P21 activated kinase 2 (PAK2) and Ras related GTPase binding protein 
(RAC1) followed the same trend in the control and treated conditions with lower expression levels at 24 
and 48 hours. PAK2 and RAC1 both showed a significant decrease at 72 hours in the treated condition 
(Figure 5.11). Glycogen synthase kinase 3β (GSK3B) and ß-catenin (CTNNB1) followed similar trends to 
the control samples, and were both significantly decreased in the treatment condition compared to the 
control at 72 hours (Figure 5.12). 
Peptidyl prolyl isomerase E (PPIE) and the cytoplasmic linker gene (CLIP2) were the two most 
respectively down or up-regulated genes in the dataset. PPIE expression in the treatment samples was 
opposite to that of the control, resulting in a significant down regulation at 72 hours. CLIP2 regulation 
followed the same trend in the treatment condition as the control, but was significantly up-regulated in 
the treatment samples after 72 hours (Figure 5.13).
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Figure 5.6: Time course graph of genes of interest significantly differentially regulated over 72 
hours of EFV treatment enriching the cholesterol biosynthesis pathway. The yellow graph 
represents the control condition. The blue graph represents the EFV treatment condition. FDFT1, 
HMGCS1, and FASN enriched the cholesterol biosynthesis pathway. All three genes were down-regulated 
in the treatment condition. FDFT1 and HMGCS1 were down-regulated compared to the control across all 
three time points. FASN was significantly down-regulated at 24 and 72 hours. 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: Time course graph of genes of interest significantly differentially regulated over 72 hours of 
EFV treatment enriching the cholesterol biosynthesis and fatty acid synthesis pathways. The yellow 
graph represents the control condition. The blue graph represents the EFV treatment condition. All 
three genes enriched the cholesterol biosynthesis pathways. ACAT2 and ACLY were down-regulated 
compared to the control across 72 hours. SQLE was up-regulated compared to the control across 72 
hours, but only significantly different at 48 hours post-EFV treatment.
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Figure 5.8: Time course graph of genes of interest significantly differentially regulated over 72 
hours of EFV treatment enriching the mRNA splicing pathway. The yellow graph represents the 
control condition. The blue graph represents the EFV treatment condition. All three genes enriched 
mRNA processing pathways and followed similar trends in the control and treated conditions up to 48 
hours post-treatment. At 72 hours, all three genes were down-regulated in the treated compared to the 
control condition. 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Time course graph of genes of interest significantly differentially regulated over 
72 hours of EFV treatment related to immune response. The yellow graph represents the control 
condition. The blue graph represents the EFV treatment condition. CPSF1 enriched the mRNA splicing 
pathway and is known to interact with UBXN7, which was significantly down-regulated at T48 in the 
treatment samples. The red shading indicated a significant increase in the intensity of CPSF1 in the 
control condition across the time points.
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Figure 5.10: Time course graph of genes of interest significantly differentially regulated over 
72 hours of EFV treatment enriching the JAK/STAT signaling pathway. The yellow graph 
represents the control condition. The blue graph represents the EFV treatment condition. ANXA2 
enriched the JAK/STAT signalling pathway and was up- regulated at 72 hours post-treatment compared 
to the control. STAT3 was significantly up-regulated at 24 hours and subsequently decreased to levels 
below the control, although not significantly. The green shading indicates a significant decrease in 
intensity between each time point in both the control and treated samples. 
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Figure 5.11: Time course graph of genes of interest significantly differentially regulated over 
72 hours of EFV treatment enriching the JAK/STAT and Wnt signaling pathways. The yellow 
graph represents the control condition. The blue graph represents the EFV treatment condition. PAK2 
and RAC1 enriched the JAK/STAT and Wnt signalling pathways respectively, and both were significantly 
down-regulated after 72 hours. The down-regulation of both genes appears to begin at 48 hours, 
although this is not significant. 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: Time course graph of genes of interest significantly differentially regulated over 72 
hours of EFV treatment enriching the Wnt signaling pathway. The yellow graph represents the 
control condition. The blue graph represents the EFV treatment condition. CTNNB1 and GSK3B both 
enriched the Wnt signalling pathway. In both cases, the gene regulation appeared to follow the same 
trend as the control until 72 hours, where both genes were significantly down regulated compared to the 
control. 
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Figure 5.13: Time course graph of genes of interest that were the most highly differentially 
regulated over 72 hours of EFV treatment. The yellow graph represents the control condition. The 
blue graph represents the EFV treatment condition. PPIE was the most highly down-regulated gene in 
the data set and enriched the mRNA splicing pathways. PPIE was initially up-regulated with EFV 
treatment compared to the control at 24 hours, and was subsequently down-regulated at 72 hours. 
CLIP2 was not found in any of the enriched pathways, but was the most highly up-regulated gene in the 
data set. CLIP2 initially followed the same trend as in the control, and was highly up-regulated at 72 
hours.
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5.3.4 Biological inference 
5.3.4.1 STRING-db and Reactome analysis 
The top five most significantly enriched Reactome pathways in each time point were selected for further 
analysis. The genes contained within each pathway were extracted from the differentially regulated gene 
list in order to assess significance and fold change values (Supplementary tables S1-S3). All differentially 
regulated genes from each time point were imported into STRING-db for further investigation. Genes 
found within the enriched pathways and their interactions with various other genes not within the 
enriched pathways were investigated. 
 
 
5.3.4.1.1 T24 
The top three most significantly enriched pathways were linked to cholesterol biosynthesis and related 
functions and contained the genes FDFT1, HMGCS1, and FASN. All three genes were down regulated in 
response to treatment (Table 5.2 and 5.3). The fourth most significantly enriched pathway, 
carboxyterminal post-translational modifications of tubulin, contained TUBA1B gene, which was down 
regulated in the EFV treatment group (Table 5.3). The fifth most significant pathway, HSP90 chaperone 
cycle for steroid hormone receptors (SHR), contained genes TUBA1B, DYNC1LI1, and DNAJA1, which were 
down, up, and down regulated respectively in the treatment group (Table 5.3). TUBA1B was linked to 
DYNC1LI1 and CAP2 (an unknown protein that appears to be able to interact with actin, GeneCards) in the 
interaction network (Figure 5.15). 
 
 
 
 
 
 
 
 
119 
 
 
Table 5.2: Reactome top five most significantly enriched pathways at T24 post EFV treatment 
 
Pathway p-value 
% entities 
found 
Activation of gene expression by SREBF (SREBP) 2.18E-08 8.57 
Regulation of cholesterol biosynthesis by SREBP (SREBF) 7.30E-08 6.98 
Metabolism of steroids 1.30E-04 1.87 
Carboxyterminal post-translational modifications of tubulin 3.03E-04 5.77 
HSP90 chaperone cycle for steroid hormone receptors (SHR) 7.17E-04 4.29 
 
 
Table 5.3: Genes enriching the top five most significantly enriched Reactome pathways at T24 post EFV 
treatment. 
Gene ID 
Fold Change 
(log2) 
p-value Pathway 
FASN -0.138 0.048 Activation of gene expression by SREBF (SREBP)/Regulation of 
cholesterol biosynthesis by SREBP (SREBF)/Metabolism of 
steroids 
FDFT1 -0.322 0.023 
HMGCS1 -0.362 0.001 
TUBA1B 
-0.064 0.038 
Carboxyterminal post-
translational 
modifications of tubulin HSP90 chaperone cycle for steroid 
hormone receptors (SHR) DNAJA1 0.14 0.041  
DYNC1LI1 -0.138 0.041 
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Figure 5.15: STRING-db interaction network of deregulated genes at T24 post EFV treatment. 
Genes contained in the cholesterol biosynthesis related pathways are indicated with a yellow box. FASN 
gene shows interactions with FADS2 and STAT3. Genes contained within the carboxyterminal post- 
translational modifications of tubulin and HSP90 chaperone cycle for SHR pathways are indicated with a 
red box. One of the genes in the SHR pathway (DNAJA1) is not found in the cluster. TUBA1B gene shows 
an interaction with CAP2 gene.
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5.3.4.1.2 T48 
The top four most significantly enriched pathways were linked to cholesterol biosynthesis and related 
functions and contained the genes FDFT1, HMGCS1, and SQLE. FDFT1 and HMGCS1 were down- regulated in 
response to treatment, and SQLE was up-regulated (Table 5.4 and 5.5). The genes clustered together in the 
STRING-db interaction network and showed interactions with genes involved in fatty acid biosynthesis (ACLY) 
and mitochondrial fatty acid beta-oxidation (ETFA) (Figure 5.16). The fifth most significantly enriched pathway 
was prefoldin mediated transfer of substrate to CCT/TriC (Table 5.4), enriched by CCT2 and TUBB4B, which 
were both down regulated in the EFV treatment group (Table 5.5). TUBB4B is a major constituent of 
microtubules, while CCT2 is involved in microtubule and actin protein folding (GeneCards). 
 
Table 5.4: Reactome top five most significantly enriched pathways at T48 post EFV treatment 
Pathway p-value % entities found 
Activation of gene expression by SREBF (SREBP) 1.56E-07 8.57 
Regulation of cholesterol biosynthesis by SREBP (SREBF) 5.16E-07 6.98 
Metabolism of steroids 1.05E-04 2.18 
Cholesterol biosynthesis 1.12E-04 5.56 
Prefoldin mediated transfer of substrate to CCT/TriC 1.42E-04 10.35 
 
 
Table 5.5: Genes enriching the top five most significantly enriched Reactome pathways at T48 post EFV treatment 
Gene ID 
Fold Change 
(log2) 
p-value Pathway 
ACAT2 -0.197 0.001 
Activation of gene expression by SREBF (SREBP)/Regulation of cholesterol 
biosynthesis by SREBP (SREBF)/Metabolism of steroids/Cholesterol 
biosynthesis 
FDFT1 -0.219 0.004 
HMGCS1 -0.261 0.011 
SQLE 0.313 0.022 
CCT2 -0.082 0.021 
Prefoldin mediated transfer of substrate to CCT/TriC 
TUBB4B -0.098 0.043 
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Figure 5.16: STRING-db interaction network of deregulated genes at T48 post EFV treatment. 
Clusters of genes contained within the four most significantly enriched pathways, all of which relate to 
cholesterol biosynthesis, are indicated with a yellow box. Genes contained in the fifth most enriched 
pathway, prefoldin mediated transfer of substrate to CCT/TriC, are indicated with a red box. Interactions 
between multiple genes in the cholesterol biosynthesis related pathways and ACLY, involved in fatty acid 
biosynthesis, can be observed. ACLY and SQLE both link the cholesterol biosynthesis pathways to the 
prefoldin transfer pathway highlighted in red.
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5.3.4.1.3 T72 
The top two most significantly enriched Reactome pathways were related to mRNA splicing and contained 
nine genes (Table 5.6 and 5.7). Of the nine genes in the enriched pathway, seven are part of a spliceosome 
complex (Figure 5.17). The second most significantly enriched pathway was activation of gene expression 
by SREBF (SREBP), containing FDFT1, HMGCS1, and FASN. The next most significantly enriched pathway 
was gene and protein expression by the Janus kinase (JAK)-STAT signaling after Interleukin-12 stimulation, 
containing ANXA2, PAK2, and SOD2, which were up, down, and up-regulated respectively. The fifth most 
significantly enriched pathway was signaling by Wnt, containing 11 genes (Table 5.6 and 5.7). Genes from 
the cholesterol biosynthesis pathway show interactions with ACLY, which in turn shows interactions with 
genes from the JAK/STAT (ANXA2) and Wnt (GSK3B) signaling pathways. GSK3B and CTNNB1 interact with 
multiple genes contained in the enriched Reactome pathways such as PAK2, SMARCA4, and SF3B1 (Figure 
5.17). 
 
Table 5.6: Reactome top five most significantly enriched pathways at T72 post EFV treatment 
Pathway p-value 
% entities 
found 
mRNA Splicing - Major Pathway 7.05E-06 4.86 
mRNA Splicing 1.11E-05 4.59 
Activation of gene expression by SREBF (SREBP) 1.15E-05 8.57 
Gene and protein expression by JAKSTAT signaling after Interleukin-12 stimulation 1.45E-05 8.22 
Signaling by WNT 2.25E-05 3.33 
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Table 5.7: Genes enriching the top five most significantly enriched Reactome pathways at T48 post EFV treatment 
Gene ID 
Fold 
Change 
(log2) 
p-value Pathway 
CPSF1 -0.538 0.014 
mRNA Splicing - Major Pathway/mRNA splicing 
LSM4 -0.333 0.038 
PPIE -1.354 0.029 
PRPF19 -0.134 0.022 
PRPF38A -0.258 0.035 
SF3A1 -0.173 0.011 
SF3B1 -0.109 0.004 
SNRPF 0.866 0.018 
SRRM1 -0.153 0.015 
FASN -0.233 0.001 
Activation of gene expression by SREBF (SREBP) FDFT1 -0.222 0.002 
HMGCS1 -0.396 0.005 
ANXA2 0.145 0.032 
Gene and protein expression by JAK/STAT signalling after Interleukin-12 
stimulation 
PAK2 -0.158 0.029 
SOD2 0.118 0.021 
AP2S1 0.323 0.004 
Signaling by WNT 
CALM2 -0.229 0.009 
CDC73 -0.319 0.049 
CTNNB1 -0.259 0.003 
GSK3B -0.331 0.049 
PSMB1 -0.118 0.025 
PSMB3 -0.174 0.035 
RAC1 -0.24 0.03 
RPN1 0.166 0.043 
SMARCA4 -0.133 0.003 
YWHAZ 0.122 0.008 
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Figure 5.17: STRING-db interaction network of deregulated genes at T72 post EFV treatment. 
Clusters of genes found within the enriched pathway, mRNA splicing, is indicated by a green box. Genes 
found within the cholesterol biosynthesis pathway are indicated by a yellow box. A portion of the 
clusters of genes in the JAK/STAT and Wnt signalling pathways are indicated by a blue box.
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5.4 Discussion 
5.4.1 MS runs 
 
Variations in TIC and LC should be minimised during MS analysis to allow for accurate comparison of 
samples. During sample analysis, the LC spray was disrupted, requiring repair and calibration prior to 
continuing sample analysis. The spray and the TIC intensity improved in subsequent runs, as seen in the 
reference sample after the experimental analysis when compared to the reference sample before 
experimental analysis (Figure 5.3). The improved TIC intensity may have been due to a more stable LC 
spray or the analysis continuing immediately after calibration. Due to limited instrument time, samples 
that had been analysed prior to LC failure but with poor spray were not re-analysed. Variations in data 
acquisition caused by unstable spray may have affected the detection of true differences between the 
treatment and control groups. 
The two samples discarded due to low peptide level were not analysed sequentially and thus it is unlikely 
that the low TIC was due to a technical MS error. Peptide loss may have occurred during sample 
processing, most likely due to experimenter error. 
 
 
5.4.2 MaxQuant 
 
The total number of protein groups identified across 35 samples (1663) is low compared to similar 
previous work performed in the Blackburn Laboratory with human neural cell lines. In NES cells, over 
3000 protein groups were identified and in SH-SY5Y and differentiated neural stem cells, between 
3000 to 4000 protein groups were detected across samples.262–264 The lower number of protein 
groups detected may have been due to using the GuHCl lysis method, as the previous work was 
prepared using filter aided sample preparation (FASP) methods. Upon inspection of reference 
samples of SH-SY5Y that was prepared with FASP methods and analysed after the experimental 
samples, 2028 total proteins groups were identified (data not shown). Identification of approximately 
3000 protein groups in the reference sample is expected with optimal instrument function. This 
indicated that the low protein group identification in the experimental samples was not due to the 
sample preparation methods, but more likely due to a lower level of instrument performance. The 
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digestion efficiency in this work was low, as it is common for up to 90% of peptides to have no missed 
cleavages using FASP methods (Blackburn Laboratory, unpublished). Prior to trypsin digestion, pre-
digestion with LysC was used to improve digestion efficiency. Therefore, the relatively low percentage 
of no missed cleavages may indicate that lysis with GuHCl causes disruption of effective  digestion 
(Supplementary Figure S2). GuHCl was diluted to 1 M before trypsin digestion, which was below the 
recommended maximum of 2 M, but it is possible that the concentration of GuHCl was still too high 
for efficient trypsin activity. 
Protein identification is also affected by the mass error, measured in parts per million (ppm), which can 
affect database searching. A lower ppm results in fewer candidate sequences, and thus results in a 
decreased risk of false positive matches. A ppm < 2 is considered a high mass accuracy. In this data set, 
the mass error remained close to 0.8 ppm across all samples (Supplementary Figure S4). This indicates 
that identification of the protein groups was accurate, even though the sensitivity was low. 
 
 
5.4.3 Statistical analysis 
 
5.4.3.1 Data visualisation 
A core proteome is generally conserved between eukaryotes, and even more so within the same cell 
line.265 A highly conserved proteome within a cell line would therefore not be expected to change 
dramatically with a low dosage treatment. Weak clustering of the treatment conditions indicate that 
changes in the proteome caused by EFV treatment are subtle, which would be expected (Figure 5.4). As 
the time course progressed, the control samples became more variable compared to the treatment 
samples (Figure 5.5). This may have been due to a common response caused by EFV treatment. It is 
unlikely that the variation in the control samples was caused by processing errors or a decrease in 
instrument performance over time with MS analysis, as subsequent to harvesting, all samples were 
processed and analysed in a randomised order. 
 
5.4.3.2 Differential statistics 
Protein groups identified by PSM were then subjected to statistical analysis. Of the 1663 identified 
protein groups, 131 were significantly different after filtering (described in section 5.2.3.1).  In a similar 
experimental design in our laboratory assessing the effect of HIV-tat on differentiated neurons over three 
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time points, from 4104 identified protein groups, 280 were significantly differentially regulated after 48 
hours. From this observation, it is not possible to conclude whether the low number of significant proteins 
was due to poor instrument performance and thus lower protein identifications, or due to EFV having a 
more subtle effect on the NES cells. The relatively low number of protein group identifications across all 
samples in this work may have restricted the sensitivity to detect changes in the proteome as well as the 
magnitude of those changes. This is an important factor to keep in mind during interpretation of the data, 
as well as for future work. 
When analysed separately, the number of identified protein groups is higher in each time point than in 
the total number of protein groups remaining within the three time points. This was due to the criteria 
of filtering which required that at least three replicates in each group (in both treatment and control 
groups for all three time points) were required to contain valid values. This may therefore have excluded 
protein groups which reached the criteria within a single time point, but not in others. 
 
 
5.4.3.2.1 Multiple testing corrections. 
Multiple testing corrections (MTCs) are performed when many statistical tests are used to determine 
true significance. As the number of tests performed increases, so does the possibility of an apparently 
significant result being returned by chance. The level of significance is adjusted based on the number of 
tests performed, decreasing the chance of a false positive (type I error) occurring with an increasing 
number of tests. An adjusted level of significance will cause fewer results to pass the significance 
threshold, but those values that do pass are more likely to be truly significant than chance occurrences.   
It has been suggested that in exploratory studies, which are designed to be followed by confirmatory 
studies, multiple testing corrections can be detrimental.266–268 A false positive result can be easily 
removed once deemed insignificant after more rigorous testing, but a false negative (type II error) 
cannot be recovered. The nature of a shotgun proteomic experiment is hypothesis generating, with 
validation studies designed based on rational biological inference. The removal of significant values 
below the adjusted threshold, although statistically robust, does not consider the biology behind the 
results, and thus may limit the scope of confirmatory studies. In general, protein expression in an 
organism is tightly regulated, and this conservation is even observed across different eukaryotes.265 
Small changes in the proteome may therefore not be directly proportional to the effect of the change; 
factors such as post-translational modifications also influence the function of proteins without affecting 
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protein expression. For this reason, many biologists are of the opinion that FDR and fold change cut off 
corrections, without taking the biology into account, are somewhat arbitrary and can lead to valuable 
data being lost.269–271  When using the adjusted Benjamini-Hochberg272 and Storey273 FDR control, no 
significant values between the time points in either condition and between the two conditions were 
observed. It is possible that at the estimated biologically relevant concentration of 1.05 µg/mL, EFV did 
not have a significant effect on proliferating NES cells. Another possible explanation is that the low level 
of protein identification may have decreased the sensitivity of the experiment, resulting in fewer 
detected differences. Based on the literature, EFV has been found to cause extensive alterations to 
cellular mechanisms in cell culture, and thus no significant alterations in the proteome did not coincide 
with the ubiquitous empirical findings.274 
Subsequently, the analysis was repeated without MTCs using the following rationale: Biological inference 
that focusses on protein interaction networks and pathway analysis applies additional stringency to 
proteins deemed significant (p < 0.05) as it ensures that proteins of interest are less likely to be significant 
by chance. A pathway enriched by multiple significantly different proteins is more likely to be a true result, 
as it contains evidence from multiple proteins.275 Here, pathways containing a minimum of three genes 
were further discussed. 
 
 
5.4.4 Biological inference 
 
At all three time points, pathways related to cholesterol biosynthesis and metabolism were enriched by 
the same set of genes, which were differentially regulated throughout the time course. As cholesterol 
biosynthesis related pathways were in the top three and four pathways enriched in T24 and T48, 
respectively, it will be the only pathway discussed for these time points and will be discussed as an 
overview for across all three time points. The pathways that were enriched in T72, excluding cholesterol 
biosynthesis, will be discussed separately. Within each pathway, the functions of genes of interest are 
discussed based on existing literature. The functions of individual genes as well as the pathway as a whole 
are then discussed in the context of the response of NES cells to EFV treatment. 
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5.4.5 Enriched pathways: 
 
5.4.5.1 Cholesterol Biosynthesis (activation of gene expression by SREBP) 
 
The most significantly enriched pathways across the time points listed in tables 5.2, 5.4, and 5.6 
contained FASN, HGMCS1, ACAT2, and FDFT1, which were all down-regulated throughout the 72 hours 
compared to the control, and followed a decreasing trend. SQLE was up-regulated significantly 48 hours 
post EFV treatment and increased throughout the time course (Figure 5.6 and 5.7).  Cholesterol and fatty 
acid biosynthesis are interconnected pathways containing genes that were differentially regulated 
throughout the data set, including ACLY and FADS (Figure 5.18). All genes discussed in the following 
section were related to cholesterol or fatty acid biosynthesis and were found to be differentially 
regulated in EFV treatment, the majority of which were down-regulated. 
 
Figure 5.18: Schematic overview of cholesterol, fatty acid, phosphoglyceride, eicosanoid, and 
sphingolipid synthesis. Genes that were down-regulated following EFV treatment are circled in green. 
Genes that were up-regulated following treatment are circled in red. ACLY converts citrate to Acetyl- 
CoA, which is needed for both cholesterol and fatty acid biosynthesis. ACAT and FASN direct acetyl-CoA 
to the cholesterol and fatty acid synthesis pathways respectively. Adapted from Baenke et al., 2013.276
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Cholesterol biosynthesis regulation is an essential component of healthy CNS function 
Cholesterol is a lipid molecule that is essential for a large range of functions in animal cells including 
membrane structure and signal transduction.277,278 Cholesterol also acts as a precursor for important 
molecules such as bile salts, vitamin D, and various steroid hormones. Acquisition of cholesterol is either 
through ingestion or can be synthesized de novo in the endoplasmic reticulum. Systemic cholesterol does 
not cross the BBB and therefore the cells in the CNS have to create cholesterol de novo.278,279 
Neurogenesis, and specifically synaptogenesis, is a cholesterol dependent process as neurite outgrowth 
requires plasma membrane growth.280 Once synapses are formed, cholesterol synthesis plays an 
important role in vesicle formation and transmitter receptors for signalling.281 Cholesterol is also an 
important component of myelin in the CNS that is required for efficient propagation of an action 
potential in axons and for general neuronal health.282 
 
 
Aberrant regulation of cholesterol biosynthesis can lead to changes in proliferation and 
differentiation in stem cells. 
Cholesterol biosynthesis is vital for embryonic development, and its aberrant synthesis can lead to 
serious malformation syndromes.283 Cholesterol has a positive effect on self-renewal of stem cells, 
protects cells from apoptosis, and is vital in retaining the “stemness” of the cells.284,285 Inhibition of 
cholesterol and fatty acid synthesis leads to spontaneous differentiation, and the level of synthesis 
continues to decline as differentiation progresses.284–287 FASN, a key enzyme in de novo lipogenesis, is 
vital for neurogenesis and maintains the proliferation of neural stem cells.288 Prolonged inhibition of 
FASN in murine neural stem cells resulted in a drastic reduction in cell proliferation, increased apoptosis 
within the cell population, and the altered expression of several stem cell markers,  highlighting its 
importance in the maintenance and survival of proliferating cells.288 ACLY links carbohydrate metabolism 
and fatty acid synthesis by converting citrate to acetyl CoA (Figure 5.18). ACLY has also been linked to 
the maintenance of pluripotency in stem cells, and was down- regulated significantly 48 hours post 
differentiation initiation following the removal of FGF in human embryonic stem cell culture.289 The 
specific inhibition of ACLY in embryonic stem cells caused a subsequent decrease in the expression of 
several pluripotency markers.289 
Stemness is a characteristic trait found in both stem cells and cancerous cells. The study of stemness in 
cancerous stem cells found in the CNS can give insight into non-cancerous neurogenesis. In glioma stem
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cells, several components of the cholesterol and fatty acid synthesis pathways including ACLY, ACAT, 
HMGCS1, FDFT1, and SQLE are implicated in the maintenance of stemness. Upon differentiation of 
the glioma stem cells, the expression of the above mentioned genes decreased.285,286 This further 
implicates cholesterol and fatty acid biosynthesis in the maintenance of a proliferating state in stem 
cells. 
 
 
Components of the cholesterol biosynthesis pathway play a role in embryonic neural 
development as well as in the maintenance of a healthy adult neural system. 
Cholesterol biosynthesis plays an important role in both the developing and adult CNS. FDFT1 is the first  
enzyme exclusively involved in the cholesterol biosynthesis pathway, and is therefore vital to many 
downstream processes.  FDFT1 synthesizes lanosterol, from which steroids and cholesterol are 
derived, and has been implicated in multiple CNS defects.280,290 The knockout of FDFT1 in mice 
resulted in reduction of the radial thickness of both the cortical wall and diencephalon,  as well as 
increased apoptosis in new-born neurons.280 Embryos also had smaller forebrains and an open neural 
plate, indicating incomplete neural tube closure.290 Mutations in humans resulting in decreased 
FDFT1 production presented with structural brain malformations, global developmental delay, 
generalized seizures, and facial dysmorphisms.291 
Lanosterol can be produced at low levels in adult neurons and has a neuroprotective effect by 
regulating mitochondrial uncoupling in response to reactive oxygen species (ROS) stress or 
neurotoxins.292 The effect of MTPT, a neurotoxic compound that can induce a Parkinson’s-like 
disease, was diminished when lanosterol was co-administered due to it mitochondrial uncoupling 
action.293 Lowered levels of lanosterol have been implicated in both Parkinson’s and Alzheimer’s 
diseases, and increased levels has been identified to have a neuroprotective effect.293,294 
 
 
Viral infection can regulate cholesterol biosynthesis to benefit its infection and replication. 
As viruses display highly varied life cycles, the cellular response to viral infection is appropriately 
diverse. For example, Kaposi’s sarcoma-associated herpesvirus (KSHV) produces micro RNAs (miRNA) 
that result in a down-regulation of HMGCS1 and FDFT1 transcripts, and subsequently protein levels, as 
a protective mechanism.295   A final product of the cholesterol biosynthesis pathway, cholesterol 25-
hydroxylase, converts cholesterol to 25-hydroxycholesterol and restricts replication of viruses such as 
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KSHV,295 as well as blocking HIV and other enveloped viruses entry into cells.296 Silencing cholesterol 
synthesis is therefore advantageous for the virus in order to establish latent infection,295 although 
cholesterol is necessary for the lytic cycle of the virus.295,297 
In contrast to this theory, upon infection with cytomegalovirus (CMV), primary bone marrow derived 
cells decreased cholesterol synthesis via a reduction in expression levels of HMGCS1 and SQLE 
(among others). The innate response to viral infection caused a reduction in sterol synthesis via the 
increased production of inteferons (IFN) IFN-γ or ß that act as transcriptional regulators to decrease 
sterol production, subsequently inhibiting viral infection.298 In most cases of viral infection, including 
HIV, sterol biosynthesis down regulation via the inflammatory response acts an innate immune 
response to limit infectivity.298,299 
The success of HIV can be partially attributed to its ability to hijack vital host processes, such as 
cholesterol and sterol synthesis. HIV up-regulates cholesterol biosynthesis, using lipid rafts to gain 
entry to cells and improve viral formation, budding, and infectivity.279,300    Upon infection with HIV, 
proteins involved in cholesterol biosynthesis such as HMGCS1, SQLE, and FDFT1,  among others, were 
up- regulated, improving viral infection in multiple different cell lines.279,300 Decreasing cholesterol 
biosynthesis was therefore recommended as an adjuvant therapy to ARVs and was considered a 
desirable side effect of ARV treatment; however, hyperlipidaemia, lipodystrophy, insulin resistance, 
accelerated atherosclerosis, and coronary heart disease have been reported as side effects of certain 
protease inhibitor ARV drugs.301,302 A reduction in cholesterol biosynthesis thus appears to be 
detrimental to both the host and the virus, indicating a need for more targeted treatment to mitigate 
these specific negative side effects in the host as a result of ARV treatment.
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EFV treatment causes a down-regulation in multiple components of cholesterol biosynthesis 
that is linked to deregulated proliferation, mitochondrial dysfunction, and CNS 
abnormalities. Treatment with EFV for 72 hours causes an overall down-regulation in genes relating 
to cholesterol biosynthesis in NES cells. Based on evidence from the literature, the down-regulation 
appears be a function of - or as a result of - a shift from proliferation towards differentiation, although 
this was not visibly apparent in the cells. Deregulated cholesterol biosynthesis may result in 
mitochondrial dysfunction via mitochondrial uncoupling. EFV has been well documented as a cause 
of disruption of mitochondrial function, causing mitochondrial depolarization, decreased membrane 
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potential, and increased ROS production in neuronal cells.120,122 Mitochondrial damage from NRTI 
treatment is generally as a result of the inhibition of mitochondrial DNA (mtDNA) polymerase, or by 
inducing mtDNA mutations.43,303 Although EFV does not inhibit mtDNA polymerase, mitochondrial 
toxicity is still common, indicating another mechanism of toxicity.304 Deregulated fatty acid and 
cholesterol biosynthesis affect the mitochondria through uncoupling, which occurs when cells are 
exposed to toxic ROS. Uncoupling agents such as lanosterol decrease the mitochondrial inner 
membrane potential by causing protons to bypass ATP synthase, limiting mitochondrial ROS 
production.305,306   The down-regulation of FDFT1 as a result of EFV treatment followed by a 
subsequent down-regulation of lanosterol synthesis would impact mitochondrial uncoupling, causing 
a subsequent increase in ROS production, which may indicate a mechanism by which EFV causes 
mitochondrial toxicity.304 Mitochondrial toxicity in neuronal cells has been linked to various 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS), and 
Huntington’s disease.43,293,305,307,308 
Although the cells used for this work were proliferating neural stem cells, the mode of mitochondrial 
dysfunction may give insights into the mechanism of persistent HAND in the ARV era, which mimic 
various neurodegenerative diseases. The similarities seen in HAND and non-HIV related 
neurodegenerative diseases may be due to mitochondrial dysfunction, albeit with different aetiology. 
 
 
Lowered cholesterol biosynthesis during embryonic development results in CNS malformations 
that are echoed in case studies implicating EFV as the cause of CNS abnormalities. 
FDFT1, a major component of cholesterol biosynthesis, was down-regulated across all time points in 
NES cells when treated with EFV (Figure 5.6). The malformations caused by depletion of FDFT1, and 
deregulated cholesterol synthesis in general, echo some of the concerns surrounding EFV treatment 
during pregnancy. Case studies report defects neural tube closure, cleft palate, myelomeningocele, 
encephalocoele, and seizures where EFV treatment was the only known risk factor, although this has 
not been recognised as an increased risk from EFV.78–81,117,119 FDFT1 depletion in mice models has 
similarly been linked to incomplete neural tube closure, cleft palate, craniofacial malformations, 
seizures and developmental delay.280,283,290,291,309 Reduced cholesterol synthesis as observed with EFV 
treatment may contribute to developmental CNS abnormalities and explain the seemingly low risk of 
EFV exposure in utero, as reduced cholesterol biosynthesis causes early embryonic lethality. 280,290,309 
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The embryonic and adult CNS requires cholesterol and fatty acid biosynthesis for optimal functioning. 
Although desirable for its adjuvant antiviral protection, the down-regulation of cholesterol biosynthesis 
with EFV treatment may offer a mechanistic explanation for some of the CNS side effects observed in 
adults with EFV treatment. Cholesterol deficiency in adults has been linked to Alzheimer’s, 
Huntington’s, Niemann Pick C disease, reduced synaptic activity, and neuronal loss.308,310 These 
neurodegenerative diseases have a host of symptoms which can present as psychiatric problems, loss 
of cognitive function, cerebellar ataxia, and progressive dementia, among others.308,310–312  Similarly, 
CNS side effects of EFV include confusion, lethargy, impaired concentration, amnesia, and 
depression.49,50 Many cases reporting neuropsychiatric events resolve within two months, but in up to 
50% of cases symptoms can persist for years, including a marked neuropsychological decline observed 
after three years of treatment that improved with treatment discontinuation.50,219,313  These findings, 
along with the significant prevalence of HAND when otherwise under virologic control, indicates that 
ARVs, and specifically EFV, may contribute to the milder forms of HAND.219 Based on the present work, 
one can speculate that the neurocognitive impairments associated with mild forms of HAND in the ARV 
era, specifically those associated with EFV treatment, may be caused by de-regulated cholesterol 
biosynthesis, which is linked to mitochondrial dysfunction and many neurocognitive disorders.89,307 
 
 
5.4.5.2 mRNA Splicing – Major Pathway 
 
mRNA splicing regulates and modulates gene expression. 
One of the fundamental processes in the of regulation and modulation of gene expression is that of 
messenger RNA (mRNA) splicing and degradation, which influences gene regulation through 
transcription elongation, mRNA splicing, degradation, and mRNA export.314,315 The spliceosome is made 
up of six small nuclear ribonucleoproteins (snRNPs) and polypeptides and is responsible for gene 
expression modulation through alternative splicing, which has been linked to specifying cell identity 
during neurogenesis,316,317   as well as implicated in diseases such as various cancers318,319 and ALS.320 
 
 
mRNA splicing controls proliferation, differentiation, and survival in neuronal stem cells. 
Splicing factors play an important role in proliferation or stemness maintenance.316 Aberrant regulation 
of mRNA splicing factor SF3B1 from the U2 snRNP is often associated with cancer formation, and its 
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inhibition results in a reduction of proliferation.318,321   SF3B1 and LSM4, a decapping protein from the U6 
snRNP, are expressed at high levels in proliferating stem cells in the sub-ventricular zone (SVZ) in adult 
mice brains. Another mRNA processing gene, CPSF1, has also been specifically linked to stem cell growth, 
proliferation, and survival.319  
Transcriptional profiling of adult brain stem cells revealed that RNA splicing and chromatin remodelling 
were prominent processes involved in adult neurogenesis and is vital for generating the complexity seen 
in the nervous system.316   Alternative splicing in embryonic and adult neural stem cells regulates 
processes such as transcription factor activity, cell fate, axon guidance, the development of 
neurotransmitter receptors, and the switch between proliferation and differentiation.316 
 
 
Deregulation of components of the spliceosome has been associated with weakened immune 
response. 
The SF3 complex is essential for splicing in human cells, and its complete inhibition results in mRNA build 
up, depleted protein expression, and eventual cell death.322 Protein depletion of the SF3A1 or SF3B1 
subunits did not cause cell death, but resulted in a decreased immune response in mouse and human 
cells.323 When challenged with gram negative bacterial lipopolysaccharide, inhibition of SF3A1 and SF3B1 
resulted in a decreased expression of inflammatory cytokines tumour necrosis factor α (TNF-α) and 
interleukin 6 (IL-6), indicating that the two subunits are specifically required for a robust innate immune 
response.323 
The SF3A and SF3B complexes also interact with PPIE, which was the most down-regulated gene 
expressed in response to EFV treatment (Supplementary table S1, Figure 5.13). PPIE is a nuclear 
localized cyclophillin, also termed spliceophillin or immunophillin,324   that is important for the 
regulation of pre-mRNA splicing, chromatin remodelling, transcription coupled DNA repair, and 
degradation of single stranded or super coiled DNA.324,325 Multiple genes in the deregulated mRNA 
pathway, including PPIE, CPSF1, and UBNX7, play a role in mRNA stability and degradation and have all 
been implicated in directly inhibiting transcription and replication of viruses such as influenza and 
HIV.319,326 Interestingly, previous work in our laboratory found UBXN7 and CPSF subunits to be down-
regulated in SH-SY5Y and differentiated neurons, respectively, in response to HIV-tat treatment.262,263 
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EFV treatment causes a down-regulation in components of spliceosomes, possibly affecting 
proliferation, differentiation, and immune response. 
The down-regulation of multiple components of the mRNA splicing pathway is directly linked to immune 
response and anti-viral activity.319,323,326 Following EFV treatment for 72 hours, multiple components of 
the mRNA splicing pathway were down-regulated. Splicing factors SF3A1 and SF3B1, implicated in a 
decreased inflammatory response, were both down regulated at 72 hours post treatment (Figure 
5.8).323 When exposed to a pathogen, the innate immune response initiates an increase in the 
production of inflammatory cytokines, which can be detrimental if not tightly controlled. HIV infection 
causes chronic inflammation, even in patients with virologic control, and has been suggested to 
contribute to the development of HAND.327 Previous work in our laboratory found that upon treatment 
with viral tat protein, SF3A1 and SF3B1 were both up-regulated in neural cell lines.328 Another study 
found that inflammatory cytokine IL-6 was significantly increased subsequent to cessation of ARV 
treatment in infected individuals.329    This indicates that one of the mechanisms by which HIV causes 
inflammation may be via an up-regulation of SF3A1 and SF3B1, which in turn aids in the production of IL- 
6,323 contributing to the inflammatory response caused upon HIV infection. 
In this work, treatment with EFV in the absence of HIV or HIV proteins resulted in a down regulation of 
SF3A1 and SF3B1 after 72 hours. It has been suggested that HIV infection and the subsequent 
inflammation associated with it during pregnancy may be a risk factor for neurodevelopmental 
disorders seen in HEU children, and that the ARV drugs have a protective effect by reducing 
inflammation via the reduction of viral load.97 The response to EFV seen in this work may support this 
whereby, aside from reducing the viral load, EFV also reduces an inflammatory response via signalling 
modulation and causes the subsequent reduction of expression of SF3A and SF3B subunits that are vital 
for an inflammatory immune response.  On the other hand, if this response is maintained throughout 
foetal development, it may cause HEU children to be more susceptible to infections, as depletion of 
SF3A1 and SF3B1 have 
been linked to a lowered immune response.323 Perinatal exposure to ARVs has been linked to an 
increased susceptibility to infections such as rubella, herpes simplex virus, CMV, toxoplasmosis, 
and influenza, which have been linked to neurodevelopmental problems when exposed during 
infancy.97,103,330 Neurodevelopmental delays suspected to be caused by in utero ARV exposure 
may therefore not be caused directly by the ARVs, but rather due to increased vulnerability to 
illness during early childhood. 
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CPSF1 and UBXN7, two components of the mRNA splicing pathway, were down-regulated in 
undifferentiated NES cells (Figure 5.9). Interestingly, previous work in the Blackburn Laboratory found 
the same trend, although to a higher degree, of down-regulation of both UBXN7 and CPSF1 in neural 
cells when exposed to HIV-tat.328,331 Investigating the effects of EFV and HIV-tat treatment 
concurrently would indicate whether the regulation of mRNA genes related to immune response and 
viral inhibition would result in a synergistic or antagonistic interaction between the innate immune 
response and the ARV drug action. 
 
 
5.4.5.3 Gene and protein expression by JAK-STAT signalling after Interleukin-12 stimulation 
 
JAK/STAT pathway regulates the expression of inflammatory responses 
The JAK/STAT pathway is activated via interferons and cytokines binding to cell surface receptors and 
phosphorylating the JAK proteins, which in turn phosphorylate the STAT proteins. Phosphorylated 
STAT translocates into the nucleus and activates transcription of various target genes. The JAK/STAT 
pathway can also be activated by ROS to increase transcription of protective proteins.332 In response 
to viral infection, interferons activate the JAK/STAT pathway, and the production of cytokines such as 
IL-6 and TNF-α is subsequently increased.333 Increased IL-6 and TNF-α levels in turn activate JAK, 
leading to chronic inflammation, which if not regulated can cause disruption of CNS function, including 
that of the BBB.333–336 ANXA2 interacts with STAT3 as a receptor that modulates cytokine production 
via the JAK/STAT pathway. The silencing of ANXA2 in human-derived macrophages resulted in a down 
regulation of TNF-α and IL-6 production when stimulated with a pro-inflammatory molecule that 
activates JAK/STAT.337 
 
 
The cell fate and proliferation of stem cells is modulated by components of the JAK/STAT 
pathway 
The JAK/STAT pathway is considered to be an essential attribute to the stemness of cells, promoting 
self-renewal.338,339   Transforming growth factor ß (TGF-ß), responsible for the epithelial to mesenchymal 
transition (EMT) switch, regulates the expression of STAT3 and ANXA2 and induces EMT, which is vital 
during neural tube formation and BBB development.340,341 In breast cancer cells, inhibition of STAT3 
resulted in lower levels of ANXA2 expression and decreased EMT, causing in a more epithelial 
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phenotype.342 Together this indicates that the JAK/STAT pathway via ANXA2 and STAT3 regulates the 
maintenance of stemness. 
 
 
Pathogenic viruses hijack the JAK/STAT machinery to gain entry into host cells. 
In murine brain endothelial cells, ANXA2 was up-regulated in response to fungal infection, which 
resulted in an increase in fugal invasion of the BBB. The subsequent knockdown of ANXA2 resulted in a 
weakened immune response when challenged and inhibited the transmigration of the fungus across 
the BBB.343  Both HIV and pathogenic Cryptococcus neoformans hijack ANXA2, the former using ANXA2 
to improve viral entry and infectivity, 344,345 and the latter using ANXA2 to traverse the BBB.343 HIV 
increases the production of IL-6 and TNF-α, and subsequently up-regulates expression of STAT 
proteins.346,347 The JAK/STAT response to HIV and EFV both result in the increase of STAT3 (although 
transient with EFV treatment) and ANXA2 protein levels (Figure 5.10). It appears that EFV may lower 
cytokine production while HIV increases it, based on the observed down-regulated genes involved in 
cytokine regulation (SF3A1 and SF3B1) in response to EFV treatment (section 5.4.5.2). Common genes 
deregulated in EFV and HIV treatment require further investigation in order to determine whether the 
response is synergistic or antagonistic, and how it affects the efficacy of EFV. 
Considering that HIV uses ANXA2 to gain entry into the host cell, it would be pertinent to investigate 
whether HIV uses ANXA2 to traverse the BBB, as C.neoformans does, to elucidate the mechanism by 
which HIV enters the CNS. HIV and IL-6 synergistically increase infected monocyte migration across 
in vitro models of the BBB, and STAT1 plays a role in HIV-induced BBB damage.346 It is possible that 
HIV uses the up-regulation of IL-6 and subsequent up-regulation of ANXA2 as a means to enter the 
CNS. If HIV uses the JAK/STAT pathway for BBB traversal, then the increase in expression in 
response to EFV treatment may implicate a weakened BBB, due to EFV and HIV, as a cause of the 
CNS side effects seen with EFV treatment. 
 
 
The down-regulation of JAK/STAT pathway genes may cause alterations to proliferation of NES 
cells. 
Based on the link between cytokine production, JAK/STAT signalling, and the response to EFV, it 
appears that EFV may be able to alter the innate inflammatory immune response in vitro as a signalling 
molecule. If EFV does indeed affect IL and cytokine signalling, then it may contribute to the 
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mechanistic causes of HEU children being more susceptible to childhood illnesses.97,103   Further 
investigation of the long-term effects of the deregulation of this pathway caused by EFV is also 
important, especially in the context of neurodevelopment. For example, a haploinsufficiency in mice of 
PAK2 resulted in abnormal synapse morphology and decreased synapse density. The mice also 
displayed characteristics of impaired social interactions.348 Synapse formation is critical for memory 
and learning, and aberrant formation during neurogenesis may cause long term effects into adulthood, 
as seen in mice models.348,349   Although behavioural deficits in humans are more complex, it is 
interesting to note that subtle behavioural differences have been detected in HEU children, including 
verbal IQ and language expression, which can have a major impact on social interactions.99,116 It is 
possible that deregulated JAK/STAT signalling may affect normal neurogenesis and CNS development. 
PAK2 has been implicated in the control of proliferation in stem cells, possibly resulting in the 
decreased synapse density observed in the haploinsufficiency mouse model.348 PAK2 expression is 
strongly associated downstream of phosphorylated STAT3 and its activation is further increased by 
RAC1.350,351 In this work, the overall lower levels STAT3, RAC1, and PAK2 compared to the control 
indicates that the EFV treatment may affect the efficiency or rate of proliferation, possibly acting as a 
signalling molecule and altering the signal transduction of the JAK/STAT pathway (Figure 5.10 and 
5.11).350  
Phosphoproteomic analysis would give insight into the effects of EFV as a potential signal transducer 
and elucidate how the JAK/STAT pathway and its target genes are affected by EFV, and how this in 
turn may affect CNS development. 
 
 
5.4.5.4 Wnt signalling 
 
Wnt signalling transcriptional regulation modulates embryogenesis and neurogenesis 
The Wnt signalling cascade is involved in many stages of embryonic development and plays an 
important role in both embryonic and adult neurogenesis.352,353 Wnt signalling via the canonical 
pathway generally results in transcriptional regulation of various genes by CTNNB1. Briefly, Wnt ligands 
bind to the frizzled receptor and low-density lipoprotein cell surface receptors on target cells and 
initiate the transduction of signals to inhibit the cytoplasmic destruction complex. This complex consists 
of axin, adenomatous polyposis coli tumour suppressor protein, GSK3B, casein kinase 1, and protein 
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phosphatase 2A. Cytoplasmic CTNNB1 levels are normally low due to phosphorylation by the 
destruction complex, marking it for proteosomal degradation. In the presence of Wnt signalling, the 
destruction complex is destabilized and is thus unable to phosphorylate CTNNB1, which subsequently 
accumulates in the cytoplasm, translocates into the nucleus, and induces the expression of various Wnt 
target genes.354 
 
 
The proliferative state of neural stem cells is maintained by the Wnt signalling pathway 
Wnt signalling via CTNNB1, the transcriptional activator of the Wnt pathway, is required for the 
maintenance of neural stem cells; a loss of signalling induces neural, glial, and oligodendral 
differentiation. 355–357 GSK3B constitutes part of the destruction complex that phosphorylates CTNNB1 
in the absence of Wnt signalling, and its inhibition results in the stabilization of cytoplasmic CTNNB1, 
which promotes self-renewal in stem cells and protection from premature differentiation.353,358,359 By 
knocking out CTNNB1, the differentiation blockade caused by GSK3B inhibition is alleviated and cells 
begin to differentiate.358,359 Ablation of CTNNB1 also decreased the rate of proliferation and increases 
the number of cells exiting the proliferation cycle and differentiating, controlling the size of the 
precursor pool and, by extension, the size of the nervous system is thus partially controlled by 
CTNNB1.357 
 
 
Mutations affecting Wnt signalling result in aberrant craniofacial patterning and 
neurogenesis 
During embryogenesis, GSK3B and CTNNB1 have multiple functions, including participating in skeletal 
patterning. In mouse knockout models, all homozygous null GSK3B mice had a cleft palate, as well as 
other skeletal dysmorphism. The cleft palate phenotype could only be rescued early in foetal 
development, indicating the importance of GSK3B for craniofacial patterning during early embryonic 
development.360 CTNNB1 null mice die in early embryonic development with brain and craniofacial 
malformations, and conditional knockout of CTNNB1 results in severe dendrite malformation followed 
by neuronal death.361,362    In humans, mutations of CTNNB1 present with “dose sensitive” 
developmental delay, postnatal microcephaly, progressive ataxia, and spasticity.363,364 
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Viral replication can be modulated by Wnt signalling 
The activated Wnt pathway and its constituents have been implicated in HIV positive long-term non- 
progressors (LTNP), whereby viral control is achieved without the help of ARVs.303 The activated Wnt 
pathway is suggested to improve cell survival in LTNPs and contribute to a stronger antiviral response 
by regulation of cytokine activity.303 Inhibition of GSK3B, mimicking Wnt signalling, causes an increase 
in CTNNB1 and a decrease in viral replication.365–367    When treated with HIV, an up-regulation of 
GSK3B was detected in neuronal cells leading to a decrease in CTNNB1 and an increase in viral 
replication.365–367 This occurs due to the HIV gp120 envelope protein blocking Wnt signalling and 
preventing CTNNB1 from entering the nucleus, where it is able to repress HIV replication by binding to 
the HIV promoter region.367,368 
 
 
EFV treatment in proliferating NES cells may cause a shift towards differentiation and points to 
a possible mechanism of CNS side effects with EFV treatment. 
Of the 11 genes enriching the Wnt signalling pathway in response to EFV treatment, eight were down- 
regulated, including the transcriptional regulator CTNNB1, which would likely cause a decrease in the 
transcription of Wnt target genes of the canonical pathway.353,354   In both the control and treated 
conditions, GSK3B expression initially increased, which correlates to a decrease in CTNNB1 (Figure 
5.12), as increased GSK3B expression would result in more CTNNB1 being phosphorylated and marked 
for degradation.353,354   After 72 hours of exposure, both GSK3B and CTNNB1 expression increased in the 
control, which was unexpected as GSK3B expression results in CTNNB1 degradation. This may be 
explained by phosphoproteomic analysis, as more CTNNB1 may be phosphorylated and marked for 
degradation at this particular point in time, as opposed to lowered expression levels due to 
degradation.353,354 
Both GSK3B and CTNNB1 were down regulated in the treatment group compared to the control group 
(Figure 5.12). The inhibition or knockdown of both of these genes results in differentiation of 
embryonic or neural stem cells, 356–359    indicating that the EFV treated NES cells may be progressing 
towards differentiation or are proliferating less efficiently. EFV has been implicated as potentially 
causing risk to foetal neural development as seen in animal studies and case studies where neural 
tube defect is reported with EFV as the only known risk factor.78–81 Interestingly, a cleft palate has 
been observed in monkeys and humans after exposure to EFV during foetal development,82,249,254,369 as 
seen with GSK3B knockout mice.360 EFV toxicity in children has also resulted in progressive ataxia,118 
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as seen with mutated CTNNB1 genes.363,364 The down-regulation of expression of GSK3B and CTNNB1, 
both of which are involved in early brain and craniofacial development, may indicate the mechanism 
by which EFV can cause the above-mentioned malformations. 
CTNNB1 also plays a role in BBB maintenance, as well as inhibits viral replication as part of an innate 
antiviral response. If EFV causes a down-regulation of CTNNB1 in CNS tissue, the BBB may be 
weakened and the viral replication inhibition by CTNNB1 would be decreased in the CNS. This would 
be a concerning outcome, as that would imply that EFV treatment makes the CNS more vulnerable to 
HIV infection via a damaged BBB, reduced innate replication inhibition, and increased vulnerability to 
a peripheral inflammatory response.  If this were the case, persistent HAND with undetectable plasma 
viral load or EFV-related CNS side effects may be due to a continuous neuroinflammatory response or 
a temporarily higher CNS viral load, caused by a weakened BBB.370 
 
 
5.4.5.5 Themes in enriched pathways briefly summarised and discussed. 
 
Multiple deregulated pathways point to a shift towards differentiation of proliferating NES 
cells. 
Each enriched pathway contained multiple genes that participate in the maintenance of stem cells. 
Down-regulation of the various genes discussed was consistently linked to a shift from proliferation 
to differentiation. The NES cells used in this work were treated with EGF and FGF in order to 
maintain a proliferating state and no morphological changes that indicated differentiation were 
visually observed during the treatment period.123 
One of the most highly up-regulated genes in the data set was CLIP2. Although not present in any of 
the enriched pathways, CLIP2 is associated with microtubules and cytoskeleton formation, and is an 
important regulator of neurite, axon, and dendrite formation during differentiation.317 Initially, CLIP2 
expression in the control and treated conditions was equivalent, but 72 hours post-treatment, CLIP2 
expression increased compared to the control. The up-regulation of CLIP2 in the treated condition 
further supports the hypothesis that NES cells shift towards differentiation with increased length of 
exposure to EFV (Figure 5.13). 
In the treatment condition, many of the down-regulated proteins follow similar trends to the control 
condition with slightly lowered expression (Figure 5.7, 5.8, and 5.11). Multiple genes involved in 
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cholesterol biosynthesis decreased in expression over time in both conditions, which may possibly 
indicate that the shift towards differentiation was caused in part by the drug-delivery vehicle, DMSO. 
A depletion of ANXA2 was observed in both the treated and control samples and has been linked to 
causing the inhibition of STAT3 activation by EGF, 342 one of the factors used to maintain proliferation 
in NES cells. Based on this evidence, it is possible that the vehicle, DMSO, acts as a signalling 
molecule, which ultimately causes EGF signal to be weakened and ineffective at maintaining 
proliferation. 
DMSO is widely used as a vehicle for drug delivery as it is considered to be genetically inactive. 
Recently, subtle gene expression modulation was observed with concentrations as low as 0.05% 
DMSO.371 High concentrations of DMSO administered at 0.5% has also been shown to decrease 
pluripotency markers and cause stem cells to be more susceptible to differentiation signals.372–374 In 
this work, DMSO was administered at a final concentration of 0.05% and was not found to impact cell 
viability significantly at 
0.125%. DMSO above 1% resulted in 80% survival compared to the control, although this trend was 
not statistically significant (Chapter 4, section 4.3.2). No visual morphological changes were observed 
in cells treated with 0.01 and 0.1% of DMSO373 or in the current work with 0.05%. The down-regulation 
of various genes related to differentiation in both conditions indicates that an assessment of the 
proteome of DMSO treated NES cells is necessary in order to determine whether DMSO is an 
appropriate vehicle when working with this cell line. The effects of EFV treatment may also need to be 
re-evaluated using a different drug-delivery vehicle, but it is still possible to interpret the effects of 
EFV on the NES cells due 
to differential regulation. A significant difference between the conditions, even if following the 
same trend, indicates that EFV caused a response in the cells. Even so, conclusions must be drawn 
with caution, as effects of the EFV treatment may be inflated due to DMSO increasing membrane 
permeability.373 
 
 
EFV treatment may cause a disruption in normal inflammatory response in NES cells 
One of the outcomes of down-regulation of cholesterol biosynthesis in the context of HIV infection is 
the subsequent decrease in viral replication, due to viral dependence on cholesterol for replication and 
infectivity. A decrease in cholesterol biosynthesis is therefore a desired side effect of ARV treatment. 
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The inflammatory response system and regulation of cholesterol synthesis are tightly linked functions, 
both of which were down-regulated in response to EFV treatment. A decreased inflammatory response 
is another desired side effect of ARV treatment, and possibly occurs with EFV treatment caused by a 
down regulation of SF3A1 and SF3B1. In the context of foetal development, this would contribute to 
protection from the increased inflammation caused by maternal HIV infection.327 On the other hand, a 
decreased immune response during foetal development may cause increased susceptibility to 
infection at during early childhood development.97 
Based on the findings in this work, it appears that EFV reduces an innate immune response through 
the reduction of cytokine production. EFV caused a reduction in SF3A1 and SF3B1 protein levels after 
72 hours, which is known to cause a reduction in IL-6 and TNF-α cytokines.323 Inhibition or down-
regulation of components of the cholesterol biosynthesis pathway, as seen during the 72 hour time-
course, further decrease IL-6 and TNF-α expression,336 which results in limited activation of the 
JAK/STAT pathway and subsequently limits the JAK/STAT inflammatory immune response. A reduced 
immune response caused by EFV may offer an important avenue for future research, as HEU children 
are more susceptible to various infections which can affect neurodevelopment when contracted 
during childhood.97,103,330 Negative neurodevelopmental outcomes in HEU children due to childhood 
infections can be easily minimised by early intervention strategies to boost immune function in HEU 
children immediately postnatally. 
 
 
Malformations caused by deregulated genes mirror malformations suspected to be caused by 
EFV exposure in utero 
Various differentially regulated genes in the enriched pathways were associated with CNS 
malformations or disorders. A reduction in cholesterol biosynthesis and depletion of certain genes 
such as PAK2 are both linked to synapse malformation which is a vital component in memory and 
learning.349 When depleted in mouse models, multiple deregulated genes in this work such as FDFT1, 
GSK3B, and CTNNB1 cause embryonic lethality or malformations that echo those seen in cases where 
EFV is the sole risk factor. For example, the cleft palate phenotype, which has been implicated in 
exposure to EFV and the depletion of GSK3B during embryo development, is also a phenotype of 
cholesterol deficiencies.283,309,360,375 Given that cholesterol depletion is commonly seen during ARV 
treatment, the link between EFV, cholesterol deficiency, and birth defects is one that requires further 
investigation. These observations indicate a possible molecular mechanism for the potential 
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dangerous effects of in utero exposure to EFV that have yet to be confirmed or denied. In order to 
detect even a small increase in the incidence of rare disorders, such as incomplete neural tube 
formation, a very large sample size is required. There is a paucity of data regarding the effects of EFV 
when used during pregnancy, with most studies consisting of few participants and poorly matched 
control groups. Although EFV is generally considered safe for use during pregnancy, it is still classed as 
a category D drug and thus needs further investigation. 
Based on the observation that EFV treatment may cause cells to cease proliferation prematurely, and 
that the expression of essential proteins for craniofacial and brain development were decreased, it 
would be pertinent to assess whether the altered protein levels persist over a longer period of time, 
as well as during differentiation and maturation. Diffusion tensor imaging (DTI) neuroimaging studies 
in HEU children found abnormalities in the CNS which may represent microscopic deficits in axonal 
structure, which are suggested to be as a result of abnormal cell proliferation or aberrant pruning.252 
This supports the hypothesis that EFV treatment may cause a premature exit from proliferation and 
promote differentiation in NES cells. The abnormal axonal structure observed in HEU children DTI 
results correlated to subtle neurological defects in the HEU children,252 which further indicates the 
need for a deeper understanding of the safety profile of EFV for HEU children, and how exposure 
may affect them throughout development. 
 
 
A comparison of the response to EFV and HIV-tat treatment shows similarities and differences 
that necessitate further investigation. 
This work and previous work in our laboratory highlight differences and similarities in the response of 
neural cells to HIV and EFV. In some cases, down-regulation occurred in response to EFV treatment, and 
up-regulation in response to HIV-tat treatment as seen with SF3A1, SF3B1, and GSK3B. In other cases, 
the regulation of the gene was in the same direction but of a different magnitude, as seen with a small 
decrease in UBXN7 in response to EFV, and a large decrease in response to HIV-tat. Further research to 
elucidate the potentially synergistic effects of EFV and the innate immune response when challenged 
with HIV may improve our understanding of the aetiology of persistent HAND and CNS side effects in 
the ARV treatment era. 
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Proteome changes observed subsequent to predicted initiation of EFV metabolism may be 
caused by EFV metabolites 
The majority of differentially regulated genes occurred between 48 and 72 hours post EFV treatment. 
Based on the findings from previous chapters that indicate that NES cells begin to metabolise EFV more 
rapidly between 48 and 72 hours, the changes seen in the proteome may be caused as a result of the 
up-regulation of EFV metabolism. The major metabolite of EFV, 8-hydroxy-EFV, is metabolised by the 
CYP2B6 cytochrome and has been implicated in causing various CNS side effects seen with EFV 
treatment.274,376 It is thus plausible that the alterations in the proteome seen after 72 hours, which 
correlates to the hypothesised initiation of EFV metabolism (Chapter 4, section 4.4.4), may be due to a 
response to the increase in the 8-hydroxy-EFV metabolite as opposed to un-metabolised EFV.
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5.5 Conclusion 
The benefits of ARV usage are undeniable and have changed HIV from a death sentence to a 
chronic, manageable illness.  HIV-infected patients on ARV treatment live longer, relatively healthy 
lives. ARV treatment has also resulted in a substantial decrease the in incidence of HIV transmission 
in utero, allowing HIV-positive mothers to give birth to HIV-negative children. Thus, ARV treatment 
for HIV- positive pregnant women is a top priority in order to protect both the mother and the child. 
As the population of children born with HIV infection decreases, the population of those exposed to 
ARVs in utero increases, highlighting the need to address the potential long-term effects of 
exposure to often toxic drugs during a critical developmental period. 
EFV is a first line treatment in South Africa that is administered as part of an FDC, with pregnant 
women being priority patients regardless of the stage of pregnancy. Although the overarching opinion 
is that EFV is safe for use in pregnancy, the fact that EFV causes CNS toxicity in adults makes its safety 
profile in vulnerable foetuses questionable. This study, among others, has shown that EFV can cause 
global cellular changes with negative side effects that may persist throughout the life on an HEU child 
if not sufficiently recognized and mitigated as early as possible. 
EFV appears to cause proliferating NES cells either to become less efficient at proliferating, or to begin 
to prepare for differentiation. The potential differentiation initiation was found to be a function of all 
four enriched pathways, indicating that it is highly probable that this was a true effect. EFV treatment 
caused deregulation in multiple signalling pathways, possibly disrupting Wnt and JAK/STAT signalling, 
both of which are vital for embryonic development. Treatment with EFV caused a major overall down- 
regulation of the cholesterol biosynthesis pathway, which is important for not only embryonic 
development but also general CNS health. EFV was also implicated in affecting the activation of the 
inflammatory response through multiple pathways, which could have both positive and negative 
effects in terms of foetal development. 
Although this study was performed in proliferating NES cells, thus making it a model specifically for 
early neural development, many of the effects caused by aberrant expression of the genes in the 
deregulated pathways echo the effects of EFV not only in foetal neurogenesis and development, but 
also in the CNS of adult HIV positive people suffering from HAND. This work can therefore be 
extrapolated to some degree to explain the effect of EFV on the adult CNS, which also contains a 
population of neuronal stem cells. By analysing EFV in isolation, it may be possible to tease apart the 
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effects of HIV and EFV, as well as to elucidate potential synergistic effects that may occur due to the 
ability of HIV to hijack many vital cellular processes. This work has elucidated multiple pathways of 
interest for further analysis involving not only neurogenesis but also mature neurons in the presence of 
EFV, which may lead to vital pre-clinical data to improve the protection of both the foetal and adult 
CNS in the ARV era.
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5.6 Limitations 
5.6.1 Electing to not use MTC subsequent to initial statistical analysis 
There are many opinions that posit that discovery work followed by pathway analysis and validation 
mitigates the need for MTC, which can result in the loss of valuable information. Not using MTC in this 
work is considered a limitation as the decision was made subsequent to observing that MTCs 
recommended for proteomic data were too stringent for this work. Low protein identification, possibly 
due to poor instrument performance or poor protein extraction and digestion by GuHCl lysis protocol, 
limits the present work, since significantly dysregulated but lower abundant proteins may have been 
missed. This study would need to be repeated in order to determine the cause of low numbers of 
statistically significant results. 
5.6.2 The EFV vehicle, DMSO, may have caused a proteomic response 
Based on observations in both the treatment and control conditions, it is suspected that DMSO might 
have an effect on NES cell proliferation and signalling. This may have caused the effect of DMSO and EFV 
on the cells to be conflated. At higher concentrations, DMSO is also known to increase membrane 
permeability, and thus may have exaggerated the effects of EFV in vitro. 
5.6.3 Inaccurate modelling of in vivo EFV concentration in vitro. 
Prior to performing a proteomic analysis of NES cells exposed to EFV, the concentration of EFV in cell 
culture conditions over time was analysed. Although it was attempted to make the dosage and the 
treatment schedule as biologically relevant as possible, the conditions used for NES cell culture 
effectively resulted in the highly lipophilic EFV molecule being absorbed into the plastic tissue culture 
plates, creating a reservoir. EFV accumulates in the CNS but it is not known to what extent, and 
therefore the final concentration of EFV that the cells were exposed to may not be as biologically 
relevant as intended. 
5.6.4 Poor MS quality and protein extraction 
Based on previous reports from the Blackburn Laboratory, the Q-Exactive instrument was not operating 
optimally, resulting in relatively low peptide and protein group identification. During sample analysis, 
the LC spray was inconsistent, but due to time limitations on the instrument, it was not possible to re- 
analyse samples analysed during a period of poor chromatographic spray. Together, these factors may 
have caused the sensitivity of the experiment decrease.
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5.7 Future Research 
 
5.7.1 Investigating the effects of EFV during neuronal differentiation and in 
mature neurons.  
This work focused on investigating the effects of EFV on NES cells during proliferation. In order to create 
a broader overview of the effects of EFV on neural development, it would be pertinent to assess the 
effects of EFV on the NES cells during differentiation as well as once matured in the presence of EFV. 
Work assessing the effects of EFV on mature neurons not exposed during maturation would offer 
insights into the potential effects of EFV in the adult CNS, as suggested in this work. Based on findings in 
chapter 4 (section 4.4.4), EFV may only initiate its own metabolism after reaching a threshold 
concentration. This indicates that studies of EFV should extend for more than 72 hours, as this would 
allow for insight into the effect of EFV and its metabolites on the neural system. Further investigation of 
the metabolites and the upstream processes involved in EFV metabolism in the neural system would 
further improve our understanding of how EFV affects the CNS.  
 
5.7.2 Phosphoproteomic analysis to assess signalling pathways 
Based on the findings elucidated by pathway analysis, EFV can affect transcriptional regulation of genes 
within immune response and signalling pathways, as well as potentially acting as a signalling molecule 
that modulates signal transduction. Phosphoproteomic analysis would offer insight into the signal 
transduction networks that are affected by EFV in NES cells and mature neurons. 
 
5.7.3 Assessing synergy or antagonistic effects caused by co-treatment with 
HIV-tat and EFV. 
EFV treatment resulted in the deregulated expression of several genes that were also deregulated with 
HIV-tat treatment. The next investigation would thus be to establish how these responses change when 
exposed to both EFV and HIV or HIV-tat. This work would be vital in gaining a deeper understanding of 
the persistent presence of HAND, even in patients with undetectable viral loads, as well as the 
synergistic and/or antagonistic effects of HIV and EFV in the CNS. 
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5.7.4 Comparing the effects of metabolised and unmetabolised EFV 
Polymorphisms of the primary metaboliser of EFV, CYP2B6, cause slow drug metabolism, resulting in 
higher EFV plasma levels. Slow metabolisers have an increased risk of experiencing CNS side effects and 
are more likely to discontinue EFV treatment.377 An assessment of the molecular effects of EFV in slow 
metabolisers, as well as the molecular effects of pure 8-hydroxy-EFV would help to improve the current 
knowledge of the safety profile of EFV and its metabolites in order to optimise the efficacy and toxicity 
profile of EFV.
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Supplementary Data 
 
 
 
 
 
 
 
Figure S1: Cell count over 72 hours when treated with EFV. Cells were treated according to the 
two treatment schedules. Each condition had a total of nine replicates that were harvested every 24 
hours and manually counted with the Trypan Blue cell counting assay. The differences in cell counts 
between the two conditions were not significantly different, although there appeared to be a slight but 
insignificantly lower count after 72 hours in the re-treatment condition.
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Gene ID              Fold change (Log2)                                      p-value 
ATP5C1                              0.157                                                    0.011 
CAP2                                  -0.174                                                   0.016 
CCAR1                               -0.154                                                   0.016 
DNAJA1                             0.140                                                    0.041 
DYNC1LI1                          -0.138                                                   0.041 
FADS2                                -0.265                                                   0.006 
FASN                                  -0.138                                                   0.048 
FDFT1                                -0.322                                                   0.023 
HMGCS1                           -0.362                                                   0.001 
IDH1                                  -0.151                                                   0.039 
IPO4                                   0.444                                                    0.021 
KIAA0368                          0.256                                                    0.007 
LIN28B                               0.160                                                    0.023 
LRRC59                              -0.324                                                   0.024 
MSH2                                 0.119                                                    0.042 
PSME2                               0.128                                                    0.031 
RAB10                               -0.270                                                   0.010 
RAB2A                                0.128                                                    0.047 
RPS5                                  -0.198                                                   0.020 
SEC61B                               0.611                                                    0.040 
SMARCC1                          0.212                                                    0.033 
STAT3                                 0.147                                                    0.018 
TLN2                                   0.344                                                    0.016 
TMSB15B                          -0.857                                                   0.027 
TUBA1B                             -0.064                                                   0.038 
APOA1BP                          -0.292                                                   0.050 
 
Table S1: Significantly differentially regulated genes in T24 with EFV treatment
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Gene ID            Fold change (Log2)                                        p-value 
ACAT2                           -0.197                                                     0.001 
ACLY                              -0.081                                                     0.018 
APOA1BP                     -0.398                                                     0.026 
CALR                               0.168                                                     0.003 
CCT2                              -0.082                                                     0.021 
CTNNB1                        -0.102                                                     0.044 
DDX1                             -0.107                                                     0.046 
DNM2                           -0.093                                                     0.016 
EIF3M                            0.139                                                     0.006 
ETFA                              -0.197                                                     0.043 
FAM98B                        -0.278                                                     0.023 
FDFT1                            -0.219                                                     0.004 
GART                             -0.163                                                     0.034 
HMGCS1                       -0.261                                                     0.011 
LAMTOR5                     -0.288                                                     0.020 
LARS                              -0.147                                                     0.038 
METAP2                        -0.322                                                     0.017 
MSH6                            -0.251                                                     0.046 
NDUFS1                        -0.259                                                     0.008 
NPEPPS                         -0.129                                                     0.021 
PIN1                               -0.249                                                     0.005 
PLD3                              -0.178                                                     0.014 
POR                               -0.156                                                     0.003 
PPP2R4                          0.347                                                     0.018 
PRCC                              0.178                                                     0.004 
PRPF19                          -0.119                                                     0.019 
RUVBL1                         -0.064                                                     0.029 
SAR1A                            0.147                                                     0.042 
SBDS                              -0.208                                                     0.049 
SF1                                  0.080                                                     0.033 
SLC2A1                          -0.573                                                     0.030 
SQLE                               0.313                                                     0.022 
SRSF5                            -0.349                                                     0.039 
TFRC                               0.472                                                     0.026 
TUBB4B                         -0.098                                                     0.043 
TXNDC17                      -0.172                                                     0.001 
UBXN7                          -0.196                                                     0.018 
USP5                              0.056                                                     0.031 
VCP                                -0.073                                                     0.049 
 
Table S2: Significantly differentially regulated genes in T48 with EFV treatment
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Gene ID              Fold change (Log2)                                        p-value 
AASS                                0.226                                                     0.007 
ACAT2                             -0.155                                                     0.007 
ACLY                                -0.066                                                     0.045 
ACTC1                              0.319                                                     0.040 
ACTR2                              0.179                                                     0.038 
ANKFY1                           0.376                                                     0.007 
ANXA2                             0.145                                                     0.032 
AP2S1                              0.323                                                     0.004 
APOA1BP                       -0.349                                                     0.036 
APOE                                0.168                                                     0.040 
BDH2                               -0.455                                                     0.020 
CALM2                            -0.229                                                     0.009 
CAP1                                -0.188                                                     0.004 
CCT2                                -0.056                                                     0.031 
CDC73                             -0.319                                                     0.049 
CDK11A                           0.152                                                     0.026 
CLIP2                                1.117                                                     0.049 
COPA                               0.102                                                     0.030 
CORO1B                          -0.445                                                     0.032 
CPSF1                              -0.538                                                     0.014 
CTNNB1                          -0.259                                                     0.003 
CYB5B                             -0.265                                                     0.028 
DBI                                   -0.156                                                     0.050 
DCXR                               -0.264                                                     0.012 
DDX1                               -0.180                                                     0.015 
DNMT3A                         0.136                                                     0.024 
EIF3E                               -0.193                                                     0.016 
EIF4G2                            -0.084                                                     0.049 
EIF5                                  -0.367                                                     0.040 
FASN                               -0.233                                                     0.001 
FDFT1                              -0.222                                                     0.002 
FSCN1                              0.242                                                     0.019 
G6PD                                0.250                                                     0.036 
GSK3B                             -0.331                                                     0.049 
GTF2I                               -0.098                                                     0.049 
HMGCS1                         -0.396                                                     0.005 
HP1BP3                           -0.134                                                     0.016 
HSP90B1                         0.065                                                     0.043 
KHDRBS1                        -0.230                                                     0.042 
LSM4                               -0.333                                                     0.038 
LUC7L                              -0.437                                                     0.046 
 
 
Table S3: Significantly differentially regulated genes in T72 with EFV treatment
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LUC7L3 -0.383 0.019 
MAPRE1 -0.225 0.042 
MCM4 -0.072 0.029 
NDUFB11 -0.307 0.009 
NPEPPS -0.111 0.009 
NRAS 0.123 0.002 
PAK2 -0.158 0.029 
PCMT1 0.240 0.037 
PGAM1 0.135 0.011 
PPIE -1.354 0.029 
PRPF19 -0.134 0.022 
PRPF38A -0.258 0.035 
PSAP -0.270 0.049 
PSMB1 -0.118 0.025 
PSMB3 -0.174 0.035 
RAB5C -0.105 0.031 
RAC1 -0.240 0.030 
RPL7 -0.185 0.047 
RPN1 0.166 0.043 
RPS13 -0.128 0.016 
RPS8 0.141 0.016 
SARS -0.227 0.048 
SART3 -0.225 0.037 
SERPINH1 0.130 0.033 
SF3A1 -0.173 0.011 
SF3B1 -0.109 0.004 
SHMT2 0.160 0.018 
SMARCA4 -0.133 0.003 
SNRPF 0.866 0.018 
SOD2 0.118 0.021 
SPARC 0.158 0.035 
SRI -0.122 0.019 
SRRM1 -0.153 0.015 
SSRP1 -0.096 0.047 
TWF1 -0.199 0.037 
UBE2L3 -0.390 0.050 
UHRF1 -0.271 0.039 
UQCRQ 0.585 0.025 
YWHAZ 0.122 0.008 
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Gene ID        EFV_24                      EFV_48                         EFV_72 
AASS                                                                                       0.226051985 
ACAT2                                             -0.197335632              -0.155244843 
ACLY                                                -0.081066736              -0.065701131 
ACTC1                                                                                     0.319075036 
ACTR2                                                                                     0.179065109 
ANKFY1                                                                                  0.376258304 
ANXA2                                                                                    0.145280186 
AP2S1                                                                                     0.323101758 
APOA1BP    -0.292019861          -0.398311366              -0.349498123 
APOE                                                                                      0.1683741 
ATP5C1        0.156601932 
BDH2                                                                                      -0.454698704 
CALM2                                                                                    -0.229432766 
CALR                                                0.168240919 
CAP1                                                                                       -0.187581016 
CAP2             -0.174103534 
CCAR1          -0.154105444 
CCT2                                                -0.082012302              -0.056048559 
CDC73                                                                                     -0.318998605 
CDK11A                                                                                  0.151562687 
CLIP2                                                                                       1.117413907 
COPA                                                                                      0.102147937 
CORO1B                                                                                 -0.444615409 
CPSF1                                                                                      -0.537768338 
CTNNB1                                          -0.10180373                -0.259199393 
CYB5B                                                                                     -0.265496434 
DBI                                                                                          -0.155945485 
DCXR                                                                                       -0.26435659 
DDX1                                               -0.107166206              -0.180080323 
 
 
Table S4: The log2 fold change of significantly differentially regulated (p < 0.05) 
 
genes in the EFV treatment condition compared to the control over 72 hours.
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DNAJA1 0.13993827 
DNM2 -0.092746525 
DNMT3A 0.135759725 
DYNC1LI1 -0.138355186 
EIF3E -0.19299421 
EIF3M 0.139349909 
EIF4G2 -0.083618832 
EIF5 -0.366597851 
ETFA -0.196723636 
FADS2 -0.265345043 
FAM98B -0.278464695 
FASN -0.137777574                                                 -0.232712644 
FDFT1 -0.321702705          -0.218780143              -0.221640884 
FSCN1 0.241824984 
G6PD 0.250131711 
GART -0.16348609 
GSK3B -0.330965738 
GTF2I -0.097651269 
HMGCS1 -0.362220449          -0.260686886              -0.395591236 
HP1BP3 -0.133686846 
HSP90B1 0.06494082 
IDH1 -0.150721799 
IPO4 0.444272561 
KHDRBS1 -0.230279521 
KIAA0368 0.255843629 
LAMTOR5 -0.288057976 
LARS -0.146560599 
LIN28B 0.160403616 
LRRC59 -0.324030828 
LSM4 -0.333162882 
LUC7L -0.437158687 
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MAPRE1 -0.225374795 
MCM4 -0.071720181 
METAP2 -0.321904969 
MSH2 0.119388084 
MSH6 -0.251419032 
NDUFB11 -0.306676274 
NDUFS1 -0.259212128 
NPEPPS -0.129434585              -0.110551767 
NRAS 0.122985745 
PAK2 -0.158471253 
PCMT1 0.239640951 
PGAM1 0.135335936 
PIN1 -0.248838539 
PLD3 -0.178277578 
POR -0.155635268 
PPIE -1.354399645 
PPP2R4 0.346841337 
PRCC 0.178044921 
PRPF19 -0.119265927              -0.133575327 
PRPF38A -0.258222858 
PSAP -0.269540545 
PSMB1 -0.117819553 
PSMB3 -0.174354001 
PSME2 0.127549351 
RAB10 -0.269609422 
RAB2A 0.127834658 
RAB5C -0.105111257 
RAC1 -0.240205549 
RPL7 -0.185108562 
RPN1 0.166123957 
RPS13 -0.128457268 
RPS8 0.141379339 
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RUVBL1 -0.064492353 
SAR1A 0.147260183 
SARS -0.227025669 
SART3 -0.225111154 
SBDS -0.207532417 
SEC61B 0.610764539 
SERPINH1 0.129712985 
SF1 0.079859447 
SF3A1 -0.172811858 
SF3B1 -0.109148744 
SHMT2 0.160241531 
SLC2A1 -0.573487884 
SMARCA4 -0.133435068 
SMARCC1 0.212019598 
SNRPF 0.866089834 
SOD2 0.118300502 
SPARC 0.158418024 
SQLE 0.312757545 
SRI -0.122350996 
SRRM1 -0.15306555 
SRSF5 -0.349192207 
SSRP1 -0.095695216 
STAT3 0.146624578 
TFRC 0.471813357 
TLN2 0.344359789 
TMSB15B -0.857042084 
TUBA1B -0.064395233 
TUBB4B -0.098069445 
TWF1 -0.199145087 
TXNDC17 -0.172060836 
UBE2L3 -0.389743257 
UBXN7 -0.196118545 
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UHRF1 -0.270599342 
UQCRQ 0.585083921 
USP5 0.055862943 
VCP -0.073076308 
YWHAZ 0.122406091 
  
 
Figure S2: Assessment of digestion efficiency based on missed cleavages. 
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Figure S3: MS/MS identification rate per raw file. A 20% or higher identification rate was 
achieved in all raw files. 
 
Figure S4: The average mass error of the MS instrument in each sample, measured in parts per 
million.The mass error across all samples was 0.8 +-0.5 ppm 
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Figure S5: A multi-scatter plot containing replicates from control and treated samples in T72. 
LQF intensity values from each replicate are plotted against each other replicate in order to assess 
variation. Pearson’s correlation scores   indicate the amount of variation between two samples. Scores > 
0.95 indicate low variation between samples. 
 
